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CHAPTER-I 
NANOTECHNOLOGY: A BOON TO DRUG DELIVERY 
 
1.1 Introduction  
 
Size reduction is a fundamental unit operation having important applications in pharmacy. It 
helps in improving solubility and bioavailability, reducing toxicity, enhancing release and 
providing better formulation opportunities for drugs. In most of the cases, size reduction is 
limited to micron size range, for example, various pharmaceutical dosage forms like powder, 
emulsion, suspension etc. Drugs in the nanometer size range enhance performance in a 
variety of dosage forms. Major advantages of nanosizing include (i) increased surface area 
(ii) enhanced solubility (iii) increased rate of dissolution (iv) increased oral bioavailability  
(v) more rapid onset of therapeutic action  (vi) less amount of dose required (vii) decreased 
fed/fasted variability and (viii) decreased patient-to-patient variability.  
The word ‘nano’ is derived from Latin word, which means dwarf. Nano size refers to one 
thousand millionth of a particular unit thus nanometer is one thousand millionth of a meter     
(i.e. 1nm = 10
-9 
m).  
Nanotechnology is the science that deals with the processes that occur at molecular level and 
of nanolength scale size. There are numerous examples from nature like DNA, water 
molecules, virus, red blood corpuscles (RBC) etc., which are of nanodimensions; even our 
history has numerous examples which prove that we have exploited the advantages of 
technology in one or other form. Figure 1 depicts various examples from nature and 
pharmaceuticals which are operated at various dimensions of nanolength scale. The term 
nanotechnology has been most commonly used in other fields of science like electronic, 
physics and engineering since many decades. Nanotechnology has shown tremendous 
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progress in these fields. However, biomedical and pharmaceutical fields remain yet to be 
explored.  
Nanotechnology is a multidisciplinary field, convergence of basic sciences and applied 
disciplines like biophysics, molecular biology, and bioengineering. It has created powerful 
impact in various fields of medicine including cardiology, ophthalmology, endocrinology, 
oncology, immunology etc., and to highly specialized areas like gene delivery, brain 
targeting, tumor targeting, and oral vaccine formulations. Nanotechnology provides 
intelligent systems, devices and materials for better pharmaceutical applications. 
 
Figure 1 Dimensions of Nanotechnology 
1.2 Nano-Definitions  
 
Important nano-definitions are described below:  
 
•  ‘Nanoscience’ can be defined as study of phenomenon and manipulation of materials 
at atomic and molecular scales.  
•  ‘Nanotechnology’ is related to design characterization, production and applications 
of structures, devices and systems by controlling shape and size at nanometer scale.  
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•  ‘Pharmaceutical nanotechnology’ embraces applications of nanoscience to 
pharmacy as nanomaterials, and as devices like drug delivery, diagnostic, imaging and 
biosensor.  
•  ‘Nanomedicine’ is defined as submicron size (<1um) modules, used for treatment, 
diagnosis, monitoring, and control of biological system.  
Pharmaceutical nanotechnology has provided more fine-tuned diagnosis and focused 
treatment of disease at a molecular level. Pharmaceutical nanotechnology is most innovative 
and highly specialized field, which will revolutionize the pharmaceutical industry in near 
future. Pharmaceutical nanotechnology presents revolutionary opportunities to fight against 
many diseases. It helps in detecting the antigen associated with diseases such as cancer, 
diabetes mellitus, neurodegenerative diseases, as well as detecting the microorganisms and 
viruses associated with infections. It is expected that in next 10 years market will be flooded 
with nanotechnology-devised medicine.  
1.3 Opportunities and Scope  
 
In view of post GATT (General Agreement of Trade and Tariff) scenario pharmaceutical 
industries are focusing towards their research on nanotechnology because developing new 
chemical entity (NCE) is very time consuming and expensive affair and most of drugs will be 
off patent very soon causing huge revenue loss. Applications of nanotechnology to pharmacy 
that provide intelligent and smart drug delivery systems is expected to emerge as most 
important and powerful tool as alternate to conventional dosage form. These nano-intelligent 
drug delivery systems need little investment while expected to be a high profit making deal 
due to new patent-protection for current or soon-to-be off-patent drugs. A recent report 
claimed that 23 major pharmaceutical patents would expire by 2008 leading to revenue loss 
of US $ 46 billion and by 2011, US $ 70-80 billion loss is expected as various drugs go off-
patent (Baba, 2007). Therefore most of industrial research interest lies in fact to exploit the 
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newer technology to develop drug delivery system of available drugs in order to reduce or 
overcome their shortcoming like high toxicity, instability in biological environment, poor 
bioavailability, and low therapeutic concentration at site of action, which rendered them poor 
candidates in currently available dosage forms.  
Now days most of the industries have realized the potential applications of nanotechnology in 
pharmacy and are making their efforts in research and development in this area. Recent data 
depicts that global investment on nanotechnology reached US $ 12.4 billion in 2006. The data 
presented below suggests the global interest over nanotechnology investment and related 
issue (Figure 2).  
 
 
Figure 2 Global investment on nanotechnology (9 billion US $, 2005) 
Novel drug delivery comprises of a number of features of nanotechnology, which make it a 
suitable tool to address major issues. The scope of pharmaceutical nanotechnology is very 
wide from smart material for tissue engineering to intelligent tools for delivery of drugs and 
diagnostics, and more recently, artificial RBC etc. Current applications of nanotechnology in 
pharmacy are development of nanomedicine, tissue engineering, nanorobots, advance 
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diagnostic, as carrier of diagnostic and therapeutic modalities and as biosensor, biomarker, 
image enhancement device, implant technology, bioactive surfaces etc. A large number of 
nanosystems, which have been investigated in pharmacy to date, are liposomes, dendrimers, 
metallic nanoparticles, polymeric nanoparticles, carbon nanotubes, quantum dots, nanofibres 
etc.  
1.4 Pharmaceutical Nanotechnology Based Systems  
 
Pharmaceutical nanotechnology provides two basic types of nanotools viz. nanomaterials and 
nanodevices, which play a key role in realm of pharmaceutical nanotechnology and related 
fields. 
1.4.1 Nanomaterials are biomaterials used, for example, in orthopedic or dental implants or 
as scaffolds for tissue-engineered products. Their surface modifications or coatings might 
greatly enhance the biocompatibility by favoring the interaction of living cells with the 
biomaterial. These materials can be sub classified into nanocrystalline and nanostructured 
materials.  
1.4.2 Nanocrystalline materials are readily manufactured and can substitute the less 
performing bulk materials. Raw nanomaterials can be used in drug encapsulation, bone 
replacements, prostheses (artificial mechanical devices to replace body parts lost in injury 
and or by birth e.g. artificial limbs, facial prosthetics and neuroprosthetics etc.), and implants.  
1.4.3 Nanostructured materials are processed forms of raw nanomaterials that provide 
special shapes or functionality, for example quantum dots, dendrimers, fullerenes and carbon 
nanotubes.  
1.4.4 Nanodevices are miniature devices in the nanoscale and some of which include nano- 
and micro-electromechanical systems (NEMS/ MEMS), microfluidics (control and 
manipulation of micro or nanolitre of fluids), and microarrays (different kind of biological 
assay e.g. DNA, protein, cell, and antibody). Examples include biosensors and detectors to 
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detect trace quantities of bacteria, airborne pathogens, biological hazards, and disease 
signatures and some intelligent machines like respirocytes (Figure 3). 
 
Figure 3 Schematic diagram of various types of pharmaceutical nanosystems 
A brief discussion of various types of pharmaceutical nanosystems is presented below:  
1.4.4.1   Carbon nanotubes: Carbon nanotubes are hexagonal networks of carbon atoms, 1 
nm in diameter and 1–100 nm in length, as a layer of graphite rolled up into a cylinder. There 
are two types of nanotubes: single-walled nanotubes (SWNTs) and multi-walled nanotubes 
(MWNTs), which differ in the arrangement of their graphene cylinders (Figure 4). 
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                 (a) Single walled (SWNTs)                                           (b) Multi walled (MWNTs) 
Figure 4 Structure of Carbon nanotubes 
These are small macromolecules that are unique for their size, shape, and have remarkable 
physical properties. Nanotubes offer some distinct advantages over other drug delivery and 
diagnostic systems due to very interesting physicochemical properties such as ordered 
structure with high aspect ratio, ultra-light weight, high mechanical strength, high electrical 
conductivity, high thermal conductivity, metallic or semi-metallic behavior and high surface 
area (Sinha and Yeow, 2005).  
1.4.4.2 Quantum dots: Quantum dots (QDs) are semiconducting materials consisting of a 
semiconductor core (CdSe), coated by a shell (e.g., ZnS) to improve optical properties, and a 
cap enabling improved solubility in aqueous buffers. They are neither atomic nor bulk 
semiconductors. Their properties originate from their physical size, which ranges from 10–
100 Å in radius. Due to their bright fluorescence, narrow emission, broad UV excitation and 
high photo stability QDs have been adopted for in vitro bioimaging for real time monitoring 
or tracking of intracellular process for longer time (Figure 5). Quantum-dots have a large 
impact on some important development in different medical areas like diagnostic tools 
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(magnetic resonance imaging, MRI), in vitro and in vivo detection and analysis of 
biomolecules, immunoassays, DNA hybridization, development of non-viral vectors for gene 
therapy, transport vehicles for DNA, protein, drugs or cells, time graded fluorescence 
imaging of tissue, labeling of cells and as therapeutic tools for cancer treatment.  
 
Figure 5 Size dependent representation of a quantum dots 
1.4.4.3 Dendrimers: Dendrimers are hyper branched, tree-like structures and have 
compartmentalized chemical polymer. Dendrimers contain three different regions: core, 
branches, and surface (Figure 6). The macromolecule constituents radiate in branching form 
from the central core, creating an internal cavity as well as a sphere of end groups that can be 
tailored according to requirements (Khopde et al., 2001). They can be tailored or modified 
into biocompatible compounds with low cytotoxicity and high biopermeability. They bear 
promising properties for delivery of bioactive ranging from drugs, vaccines, metal, and genes 
to desired sites. Their hollow interior provides space to incorporate drugs and other bioactive 
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physically or by various interactions to act as drug delivery vehicles. Most important 
applications of dendrimers are solubilization, gene therapy, dendrimers based drug delivery, 
immunoassay and MRI contrast agent. Dendrimers is ideal carrier for drug delivery due to 
advantages like very low size (1-5 nm), feasibility to develop with defined molecular weight, 
very low polydispersity index (ratio of weight average molecular weight (Mw) to number 
average molecular weight (Mn) of polymer), good entrapment efficiency and offering surface 
for functionalization. They can be modulated for target-specific drug delivery but their 
toxicity profile renders them not very popular system for use as delivery means.  
Figure 6 Schematic representation of a dendrimer showing core, branches, and surface 
 
1.4.4.4 Polymeric nanoparticles: Polymeric nanoparticles (Figure 7) provide an alternative 
to above-mentioned nanosystems due to some inherent properties like biocompatibility, 
nonimmunogenicity, nontoxicity and biodegradability. These are colloidal carrier, 10 nm -
1µm in size, consisting of synthetic or natural polymers. Polymeric nanoparticles are a broad 
class comprised of both vesicular systems (nanocapsules) and matrix systems (nanospheres). 
Nanocapsules are systems in which the drug is confined to a cavity surrounded by unique 
polymeric membrane whereas Nanospheres are systems in which the drug is dispersed 
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throughout the polymer matrix. The various natural polymers like gelatin, albumin and 
alginate are used to prepare the nanoparticles; however they have some inherent 
disadvantages like poor batch-to-batch reproducibility, prone to degradation and potential 
antigenicity. 
 
Figure 7 Scanning electron microscopy image of polymer nanoparticles 
(Adopted from Senthilkumar et al., 2007) 
Synthetic polymers used for nanoparticles preparation may be in the form of preformed 
polymer e.g. polyesters like polycaprolactone (PCL), poly lactic acid (PLA) or monomers 
that can be polymerized in situ e.g. polyalkyl cyanoacrylate. The candidate drug is dissolved, 
entrapped, attached or encapsulated throughout or within the polymeric shell/matrix. 
Depending on the method of preparation, the release characteristic of the incorporated drug 
can be controlled. Polymeric nanoparticulate systems are attractive modules for intracellular 
and site specific delivery. Nanoparticles can be made to reach a target site by virtue of their 
size and surface modification with a specific recognition ligand. Their surface can be easily 
modified and functionalized.  
 
1.4.4.5   Metallic nanoparticles: Metallic nanoparticles are emerging as good delivery 
carrier for drug and biosensor. Although nanoparticles of various metals have been made yet 
silver and gold nanoparticles are of prime importance for biomedical use (Figure 8). Their 
surface functionalization is very easy and various ligands have been decorated onto the 
surface. A large numbers of ligands have been linked to nanoparticles including sugars, 
peptide, protein and DNA. They have been used for active delivery of bioactive, drug 
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discovery, bioassays, detection, imaging and many other applications due to surface 
functionalization ability, as an alternative to quantum-dots.  
 
Figure 8 Surface functionalized gold nanoparticles 
 
 
1.4.4.6 Liposomes: Liposomes have been extensively explored and most developed 
nanocarriers for novel and targeted drug delivery. These closed vesicles are formed when dry 
phospholipids are hydrated (Figure 9). Liposomes are classified into three basic types based 
on their size and number of bilayers. Multilamellar vesicles (MLVs) consist of several lipid 
bilayers separated from one another by aqueous spaces. These entities are heterogeneous in 
size, often ranging from a few hundreds to thousands of nanometers in diameter. On the other 
hand, both small unilamellar vesicles (SUVs) and large unilamellar vesicles (LUVs) consist 
of a single bilayer surrounding the entrapped aqueous space. SUVs are less than 100 nm in 
size whereas LUVs have diameters larger than 100 nm. 
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Figure 9 Structure of Liposomes 
Drug molecules can be either entrapped in the aqueous space or intercalated into the lipid 
bilayer of liposomes, depending on the physicochemical characteristics of the drug. 
Liposomes can be prepared with enormous diversity in structure, composition, size, 
flexibility, and a variety of surface modification approaches proving most intelligent carrier 
system for both active and passive delivery of bioactives. They have been successfully 
exploited in cancer therapy, carrier for antigens, pulmonary delivery, leishmaniasis, 
ophthalmic drug delivery etc. Some of liposome-based formulations are already in market 
(Table I). 
Table I Liposomal formulation in market 
 
PRODUCT 
 
 
STATUS 
 
 
PAYLOAD 
 
 
INDICATION 
 
 
Daunoxome® 
 
 
Market 
 
Daunorubicin 
 
Cancer 
 
 
Doxil®/caelyx® 
 
Market 
 
Doxorubicin 
 
 
Cancer 
 
 
Moet® 
 
Market 
 
Doxorubicin 
 
 
Cancer 
 
 
Ambisome® 
 
Market 
 
Amphotericin B 
 
Fungal infections 
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1.4.4.7 Polymeric micelles: Amphiphilic block copolymers assemble into nanoscopic 
supramolecular core-shell structures known as ‘polymeric micelles’. Polymeric micelles are 
usually of <100 nm and their hydrophilic surface protects their nonspecific uptake by 
reticuloendothelial system. Micelles are formed in solution as aggregates in which the 
component molecules (e.g., amphiphilic AB-type or ABA-type block copolymers, where A 
and B are hydrophobic and hydrophilic components, respectively) are generally arranged in a 
spheroidal structure with hydrophobic cores shielded from water by a mantle of hydrophilic 
groups (Figure 10).  
 
Figure 10 Structure of block copolymer micelles 
These dynamic systems are used for the systemic delivery of water-insoluble drugs.  
1.4.4.8 Polymer drug conjugate: The conjugation of low molecular weight drugs with 
polymer causes drastic change in pharmacokinetic disposition of drug in whole body and at 
cellular level. Polymer-drug conjugates are thus designed to increase the overall molecular 
weight, which facilitates their retention in cancer cells through enhanced permeation and 
retention (EPR) effect using passive delivery approach.  
1.4.4.9 Polyplexes/Lipopolyplexes: These are assemblies, which form spontaneously 
between nucleic acids and polycations or cationic liposomes (or polycations conjugated to 
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targeting ligands or hydrophilic polymers), and are used in transfection protocols. The shape, 
size distribution, and transfection capability of these complexes depends on their composition 
and charge ratio of nucleic acid to that of cationic lipid/polymer. Examples of polycations 
that have been used in gene transfer/therapy protocols include poly-L-lysine, linear- and 
branched-poly (ethyleneimine), poly (amidoamine), poly-amino esters, and cationic 
cyclodextrin.  
Table II Brief descriptions of nanosystems (Nahar et al., 2006) 
 
Types of 
Nanosystems 
 
 
Size 
 
Characteristics 
 
Applications 
 
 
 
 
 
 
Polymeric 
nanoparticles 
 
 
 
 
 
10-1000 
nm 
 
 
 
 
 
Biocompatible, biodegradable, 
offer complete drug protection 
Excellent carrier for 
controlled and 
sustained delivery 
of drugs. Stealth 
and surface 
modified 
nanoparticles can 
be used for active 
and passive 
delivery of 
bioactives 
 
 
 
 
 
Nanocrystal  
Quantum dots 
 
 
 
 
 
2–9.5 nm  
 
 
 
 
 
Semi conducting material 
synthesized with II-VI and III-V 
column element; Size between 10-
100 Å; Bright fluorescence, narrow 
emission, Broad UV excitation and 
high photo stability  
 
Long term multiple 
color imaging of 
liver cell; DNA 
hybridization, 
immunoassay; 
receptor mediated 
endocytosis; 
labeling of breast 
cancer marker 
HeR
2 
surface of 
cancer cells  
 
 
 
 
Carbon nanotubes  
 
 
0.5–3 nm 
diameter 
and 20–
1000 nm 
length 
Third allotropic crystalline form of 
carbon sheets either single layer 
(single walled nanotube, SWNT) or 
multiple layer (multi-walled 
nanotube, MWNT). These crystals 
have remarkable strength and 
unique electrical properties  
(conducting, semi  
conducting, or insulating)  
Functionalization 
enhanced solubility, 
penetration to cell 
cytoplasm and to 
nucleus, as carrier 
for gene delivery, 
peptide delivery  
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Dendrimer  
 
 
 
 
<10 nm  
 
 
 
Highly branched, nearly 
monodisperse polymer system 
produced by controlled 
polymerization; three main parts 
core, branch and surface  
 
Long circulatory, 
controlled delivery 
of bioactives, 
targeted delivery of 
bioactives to 
macrophages, liver 
targeting  
 
 
 
 
 
Metallic 
nanoparticles  
 
 
 
 
<100 nm  
 
 
 
 
Gold and silver colloids, very small 
size resulting in high surface area 
available for functionalization, 
stable  
 
Drug and gene 
delivery, highly 
sensitive diagnostic 
assays, thermal 
ablation and 
radiotherapy 
enhancement  
 
 
 
Polymeric 
micelles  
 
 
 
10-100nm  
 
 
 
Block amphiphilic copolymer 
micelles, high drug entrapment, 
payload, biostability  
 
Long circulatory, 
target specific 
active and passive 
drug delivery, 
diagnostic value  
 
 
 
 
 
Liposome  
 
 
 
 
 
50-100 nm  
 
 
 
 
Phospholipid vesicles, 
biocompatible, versatile, good 
entrapment efficiency, offer easy  
surface functionalization  
 
 
Long circulatory, 
offer passive and 
active delivery of 
gene, protein, 
peptide and various 
other  
bioactives  
 
 
 
 
Silica 
Nanoparticles  
 
10nm–50 
µm  
 
Silanised and coated with 
oligonucleotide. Observable by 
fluorescence method.  
Efficient nucleic 
acid hybridization  
Detection of DNA  
Nanobiosensor for 
trace analysis  
 
 
 
Nanoshells 
  
 
Nanoshells typically have a silicon 
core that is sealed in an outer 
metallic core. By manipulating the 
ratio of wall to core, the shells can 
be precisely tuned to scatter or 
absorb very specific wavelengths of 
light  
 
 
Gold encased 
nanoshells have 
been used to 
convert light into 
heat, enabling the 
destruction of 
tumors by selective 
binding to 
malignant cells.  
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1.5 Characterization of Pharmaceutical Nanotools  
1.5.1 Structural characterization: Structural characterization is a parameter that plays 
important role in determining various attributes of a nanosystem like shape, size, surface 
morphology, structural arrangement spatial distribution, density, geometric feature etc. 
Development of electron microscopy tool improves accessibility and feasibility to determine 
these attributes at nanometer scale. Scanning electron microscopy (SEM) produces the image 
down to length scales of 10 nm and provides valuable information regarding structural 
arrangement, spatial distribution as well as surface morphology of nanoparticles. 
Transmission electron microscopy (TEM) and high resolution TEM are more powerful 
imaging tools than SEM and give more detailed geometrical features and information like 
crystal structure, quality, and orientation of nanoparticles. Moreover, scanning tunneling 
probe such as scanning tunneling microscope (STM), electrical field gradient microscopy 
(EFM), and scanning thermal microscopy, combined with atomic force microscopy(AFM) 
have been employed to illustrate structural, electronic, magnetic and thermal properties 
besides topographical properties of nanosystems.  
1.5.2 Particle Size Distribution: Particle size distribution (also known as polydispersity 
index) being an important aspect during the formulations of nanosystems, efforts are made to 
achieve a system with lowest polydispersity index. Some techniques to determine the particle 
size distribution are dynamic light scattering, which is used to measure particles ranging from 
a few nanometers to about 3 µm, while laser diffraction is used to detect microparticles or 
possible aggregates of drug nanoparticles.  
1.5.3 Particle Charge / Zeta Potential: Zeta potential is used to determine the charge at 
particle surface. Zeta potential measurement is made to optimize formulation parameters and 
to make predictions regarding the storage stability of the colloidal dispersion. Currently 
principal technique involved in zeta potential determination is laser Doppler anemometry.  
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1.5.4 Crystalline Status: Differential scanning Calorimetry, X ray diffraction and other 
analytical methods are used to assess any possible changes brought about in the physical form 
of the drug during processing.  
1.5.5 Toxicity Evaluation: Some important types of acute toxicities caused by nanosystems 
are enhanced endocytosis (cause inflammation, granuloma formation); oxidative stress (cause 
cell death due to free radical generation) and alter/modify protein/gene structure (resulting 
immune response causes autoimmune effect) while long-term toxicities are bioaccumulation, 
poor biodistribution and ultimate fate of nanosystems in body. These toxicities of 
nanosystems are evaluated using well defined and established protocols available in 
literature. Ex vivo toxicity evaluation generally carried out in various cell lines and MTT 
assay is used to determine the cell viability. In vivo acute and chronic toxicities are 
determined in various animal models.  
1.6 Engineering of Pharmaceutical Nanosystems  
Most of the nanosystems discussed above are not very efficient in biomedical and 
pharmaceutical applications due to non-specific uptake by reticulo endothelial system (RES); 
opsonization, aggregation and poor biocompatibility associated with them. However, 
manipulations in their size and surface by biocompatible polymers, hydrophilic polymers and 
some site-specific ligands render them efficient delivery vehicle for various drugs and 
utilized for various biomedical applications. Some examples of such manipulations are 
discussed below.  
1.6.1 Functional nanosystems: Modification in properties by incorporation, adsorption or 
covalent coupling by moieties like polymers and/or ligands to nanoparticles surface is known 
as surface functionalization. Some commonly used tools for surface modification are 
polymers, carbohydrates, endogenous substances/ligands, peptide, protein, nucleic acid and 
polysaccharides. These tools make the nanosystems an intelligent tool and confer a large 
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variety of properties like higher biostability, lower aggregation and high target specificity in 
comparison to conventional nanosystems. Various nanosystems like polymeric nanoparticles, 
liposomes, dendrimers, carbon nanotubes, quantum dots etc. have been successfully 
functionalized for efficient use in biomedical area. Functional polymer nanoparticles, their 
methods of surface modifications and their pharmaceutical applications have been 
excessively reviewed by our group (Nahar et al., 2006)  
1.6.2 Multifunctional nanosystems: Multifunctional nanosystems could be developed in 
following ways:  
a) Multifunctionality imparted to core:  
• Simultaneous delivery of two or more therapeutic active moieties,  
• Containing contrast enhancer; and  
• Containing permeation enhancer  
b) Multifunctionality imparted to surface:  
• Steric stabilization by PEG(poly ethylene glycol) in order to modify circulation 
time, and  
• Use of targeting moiety  
c) Multifunctionality imparted to material:  
• By use of thermal sensitive, pH and stimuli sensitive biomaterials.  
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1.7 Applications of Pharmaceutical Nanotools  
Miniaturization is often beneficial in pharmaceutical technology. Although it has increased 
complexicity yet it imparts large number of benefits in drug delivery and diagnostic               
(Reisch et al., 2007). Miniaturization is helpful in overcoming various physiological, 
biochemical and pharmaceutical barriers. Pharmaceutical nanotechnology provides wide 
array of systems or device of nanosize, which offer numerous benefits. Some major 
advantages are (i) improved bioavailability (ii) reduced toxicity (iii) sustained and controlled 
release (iv) ability to target (v) do not occlude blood capillaries and traverse easily to most 
physiological biobarrier and provide effective delivery to brain and intracellular compartment 
(vi) protects fragile drugs/proteins from harsh biological environment (vii) faster, safer and 
more accurate disease diagnosis (viii) more accurate, less invasive surgery (ix) inexpensive 
and (x) large-scale production is feasible. However some shortcomings in pharmaceutical 
applications of nanotechnology are (i) high aggregation in biological system due to high 
surface energy (ii) poor solubility and poor biocompatibility in case of carbon nanotubes (iii) 
quickly scavenged by RES system of body resulting in low biological half life (iv) poor target 
and site specificity (v) high immunogenicity or foreignness (vi) undefined and unpredictable 
safety issue and (vii) acute and chronic toxicity.  
In spite of the above shortcomings, there are various pharmaceutical and biomedical areas 
where pharmaceutical nanosystems have achieved remarkable breakthrough and realized 
their market applications. Some important applications areas are discussed here:  
1.7.1 As nanomaterials for tissue engineering: Nanotechnology offered numerous smart 
materials that are used for tissue repair and replacement, implant coatings, tissue regeneration 
scaffolds, structural implant materials, bone repair, bioresorbable materials, some implantable 
devices (sensory aids, retina implants etc.), surgical aids, operating tools, and smart 
instruments.  
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Table III Applications of nanosystems in tissue regeneration, growth and repair 
 
Nanosystems 
 
 
Property 
 
Applications 
 
Nanoengineered 
prosthetics  
 
 
Increased miniaturization; increased 
prosthetic strength & weight reduction; 
improved biocompatibility  
 
 
Retinal, auditory, spinal 
and cranial implants  
 
Cellular 
manipulation  
 
 
Manipulation of cellular systems 
 
Persuasion of lost nerve 
tissue to grow; growth of 
body parts  
 
1.7.2 As drug carrier system: Conventional drug delivery systems or dosage forms suffer 
from many limitations such as lack of target specificity, high rate of drug metabolism, 
cytotoxicity, high dose requirement, poor patient compliance etc. Nanotechnology enabled 
drug delivery system with optimized physical, chemical and biological properties can serve 
as effective delivery tools for currently available bioactives. Some nanobased drug delivery 
tools are polymeric nanoparticles, liposome, dendrimers, polymeric micelles, polymer-drug 
conjugates, antibody- drug conjugates, which can broadly be classify as (i) sustained and 
controlled delivery system (ii) stimuli sensitive delivery system (iii) functional system for 
delivery of bioactives     (iii) multifunctional system for combined delivery of therapeutics, 
biosensing and diagnostic and (iv) site specific targeting (intracellular, cellular, tissue)            
(Vasir et al., 2005). 
1.7.2.1   Cancer treatment: Nanotechnology can have a revolutionary impact on cancer 
diagnosis and therapy. Available therapies commonly employed in cancer treatment include 
surgery, chemotherapy, immunotherapy and radiotherapy. Nanotechnology offers tremendous 
opportunities to aid and improve these conventional therapies by virtue of its nanotools. 
Some nanotools that have played key role in cancer therapy are listed below (Table IV).  
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Table IV Applications of various nanosystems in cancer therapy 
 
Nanosystem 
 
 
Applications in cancer therapeutics 
Carbon nanotubes  DNA mutation detection, disease protein 
biomarker detection  
 
Dendrimers  Controlled release drug delivery, image 
contrast agents  
 
Nanocrystals  Improved formulation for poorly-soluble 
drugs  
 
Nanoparticles  MRI and ultrasound image contrast 
agents, targeted drug delivery, permeation 
enhancers, reporters of apoptosis, 
angiogenesis, etc.  
 
Nanoshells  Tumor-specific imaging, deep tissue 
thermal ablation  
 
Nanowires  Disease protein biomarker detection, 
DNA mutation detection, gene expression 
detection  
 
Quantum dots  Optical detection of genes and proteins in 
animal models and cell assays, tumor and 
lymph node visualization.  
 
 
Targeting and localized delivery are the key challenges in cancer therapy. These challenges 
can be overcome by virtue of development of functional and multifunctional system for 
passive and active delivery. The approaches are basically attributed to the pathophysiology of 
diseased sites like leaky vasculature of the cancer tissues (Ferrari, 2005). The nanocarriers 
can alter the biodistribution and pharmacokinetic parameters of the anticancer drug 
significantly compared to free drug due to nano size of the carrier. These nanotools identify 
biomarker or detect mutation in cancer cell and treat the abnormal cells by (i) thermotherapy 
by photo-thermal ablation therapy using silica nanoshells, carbon nanotubes; magnetic field-
induced thermotherapy using magnetic nanoparticles; photodynamic therapy by quantum dots 
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as photosensitizes and carriers, (ii) chemotherapy by nano-structured polymer nanoparticles, 
dendrimers and nanoshells and (iii) radiotherapy by carbon nanotubes, dendrimers for boron 
neutron capture therapy.  
1.7.2.2 Implantable delivery systems: Nanotechnology is opening up new opportunities in 
implantable delivery systems by virtue of its size, controlled and approximately zero order 
release which otherwise may cause toxicity when compared to intravenous administration 
(due to first order drug kinetics). Some pharmaceutical novel nano drug vascular carriers like 
liposome, ethosome and transferosome and some implant chips have been envisaged recently, 
which may help in minimizing peak plasma levels and reduce the risk of adverse reactions, 
allow for more predictable and extended duration of action, reduce the frequency of re-dosing 
and improve patient acceptance and compliance.  
1.7.2.3  Site specific drug delivery: Several approaches are now being tested for better site-
specific delivery using liposomes, polymeric micelles, dendrimers, iron oxide, proteins using 
manipulation in passive and active uptake of drug. The tumor targeting of drugs with passive 
delivery using enhanced permeation and retention (EPR) effect is thought to be one 
intelligent approach using these carrier system taking the advantages of leaky vasculature of 
tumor. Some surface modification approaches using various site-specific ligands via covalent 
binding or adsorption with carrier system enhanced their site specificity and make them 
intelligent tools for active delivery. The conjugations of these carriers with ligands provide 
them site specificity at various levels. In the chemotherapy of tuberculosis with active 
delivery to lung cells is reported to have improved drug bioavailability, reduction in dose 
frequency and overcoming the non-adherence problem encountered in the control of TB.  
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1.7.2.4 Gene therapy: In gene therapy, a normal gene is inserted in place of an abnormal 
disease-causing gene using a carrier molecule. Conventional uses of viral vectors are 
associated with adverse immunologic, inflammatory reactions and diseases in the host. 
Nanotechnology enabled delivery systems have currently emerged as potential vector and are 
shown to be effective and promising tool in systemic gene treatment. Various polymer based 
nanoparticles like chitosan, gelatin and poly-l-lysine and modified silica nanoparticles have 
been reported to have increased transfection efficiency and decreased cytotoxicity. It is well 
established that nanotechnology provides viable option as ideal vector in gene delivery.  
1.7.3 Molecular Diagnostics: Molecular imaging is the nanoscience of representing, 
characterizing, and quantifying sub cellular biological processes in intact organisms. These 
processes include gene expression, protein-protein interaction, signal transduction, cellular 
metabolism, and both intracellular and intercellular trafficking. Some nanoparticles, which 
have inherent diagnostic properties, are quantum dots, iron oxide nanocrystal and metallic 
nanoparticles. They have been successfully utilized in various magnetic resonance imaging, 
optical imaging, ultrasonic imaging and nuclear imaging (Wickline and Lanza, 2002). Some 
other applications of nanoparticles in diagnostics are as specific labeling of cells and tissues, 
useful for long-term imaging, useful for multi-color multiplexing, suitable for dynamic 
imaging of sub-cellular structures and may be used for fluorescence resonance energy 
transfer (FRET)-based analysis and magnetic resonance imaging (MRI). FRET-based 
analysis and MRI are two main diagnostic techniques developed for molecular level 
diagnostics. Traditional MRI contrast agents (paramagnetic and super paramagnetic 
materials) are now being replaced by various novel nanosystems like dendrimers, quantum 
dots, carbon nanotubes and magnetic nanoparticles. They are proved very efficient contrast 
agent in providing stable, intense, clearer image of object due to high intensity photo 
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stability, resolution, resistance to photo bleaching. Some approved nanoparticles used as 
imaging and as drug carriers are listed below (Table V).  
Table V Approved nanoparticles as imaging agents and drug carriers 
 
Modality 
 
 
Compound 
 
Status 
 
Use 
 
Imaging Agents  
Endorem®  
 
 
 
Gadomer®  
 
 
Super paramagnetic 
iron oxide 
nanoparticle. 
 
Dendrimers-based 
MRI agents  
 
 
 
Market  
 
 
 
Phase III clinical trial  
 
 
MRI agent  
 
 
 
MRI agent-
cardiovascular  
 
Drug delivery  
Abraxane®  
 
 
 
Albumin 
nanoparticle 
containing paclitaxel  
 
 
 
Market  
 
 
Breast cancer  
 
1.7.4. Biosensor and biolabels: A number of analytical tools have been developed with 
application of this smart and potential technology. These tools are employed for 
determination of various pathological proteins and physiological-biochemical indicator 
associated with disease or disrupted metabolic conditions of body. Various nanoenabled 
technologies, techniques and their analytical applications are listed below (Table VI).  
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Table VI Nanoenabled technologies, techniques and their analytical applications 
 
Technology 
 
 
Technique 
 
Application 
Bioarrays and Biosensors  
 
Nanofabrication  Nano-Objects Detection  
DNA Chips  Lab on Chip Nanotubes  
 
Electrochemical Detection  
Protein-Chips  Pill on Chip Nanowires  
 
Optical Detection  
Glyco-Chips  Nanofluidics Nanoparticles  
 
Mechanical Detection  
Cell-Chips  Nanostructured Surfaces  
 
Electrical Detection  
 
A biosensor is generally defined as a measurement system that consists of a probe with a 
sensitive biological recognition element, or bioreceptor, a physicochemical detector 
component, and a transducer in between to amplify and transduce these signals in to 
measurable form. A nanobiosensor or nanosensor is a biosensor that has dimensions on the 
nanometre size scale. Applications of various nanosystems as biosensor and biolabels are 
given below (Table VII).  
Table VII Applications of various nanosystems as biosensor and biolabels                       
(Kubik et al., 2005) 
Nanosystem  
Applications  
Gold Nanoparticles 
For ssDNA detection; in immune 
histochemistry to identify protein-
protein interaction  
Iron oxide nanocrystal 
Monitor gene expression; detect the 
pathogens such as cancer, brain 
inflammation, arthritis and 
atherosclerosis  
Nanopores 
Sensing single DNA molecules by 
nanopores  
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Cantilever array 
Diagnosis of diabetes mellitus, for 
detection of bacteria, fungi, viruses; for 
cancer diagnosis  
Carbon nanotube 
Blood glucose monitoring; sensors for 
DNA detection  
Nanowire 
Electrical detection of single viruses and 
biomolecules  
Nanoparticle-based biodetection 
Detection of pathogenic biomarkers, 
Ultra-sensitive detection of single 
bacteria  
 
Nanosensors could provide the tools to investigate important biological processes at the 
cellular level in vivo. The basic functions of nanosensors are to understand living cell, to 
monitor cell as biomarker, as sensor and fluorescent biological labels (Kubik et al., 2005). 
Biosensors are currently used in the areas of target identification, validation, assay 
development, and absorption, distribution, metabolism, excretion and toxicity determination 
(Jain, 2005). 
1.7.5  Drug discovery: Pharmaceutical nanotechnology is playing crucial role in drug 
discovery that rely on better understanding of mechanism of the drug action and 
identification of biomarker associated with specific disease. Nanotechnology help 
identification and validation of target by identifying the protein present on the cell surface or 
target surface. Nanotechnology will enhance the drug discovery process, through 
miniaturization, automation, speed and reliability of assays. For example single walled 
nanotubes are successfully used to identity surface protein of pathogen. QDs are used to track 
individual glycine receptors and to analyze their dynamics in the neuronal membrane of 
living cells, for periods ranging from milliseconds to minutes. Similarly, gold nanoparticles, 
nanobodies (smallest, available, intact, antigen-binding fragments) produced by Ablynx 
(Ghent, Belgium,) are some commonly used nanomaterials in diagnostics (Jain, 2005).  
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1.7.6 Miscellaneous Applications: Various other applications of nanosystems in biomedical 
and pharmaceutical fields are (i) biodetection of pathogens in humans, (ii) separation and 
purification of molecules and cells, (iii) detoxifying agents etc. One of future proposed 
nanomachine known as respirocytes is the nano-on-board minicomputer which can be used to 
simultaneous detection of disease causing marker/antigen/marker, to view the diseased site 
and to deliver the therapeutic agent to that site.  
1.8 Challenges to Pharmaceutical Nanotechnology  
 
Pharmaceutical nanotechnology has provided fine-tuned diagnosis and focused treatment of 
disease. However some ethical, scientific, social and regulatory issues posing various 
challenges in practical realization of pharmaceutical nanotechnology. Some major health risk 
associated with such devices includes cytotoxicity, translocation to undesired cells, acute and 
chronic toxicity; some unknown, unpredictable and undefined safety issues, environmental 
impacts of nanomaterials and non-biocompatibility. Some ethical issues are altered gene 
expression, ultimate fate and altered or permanent anomaly in cell behavior/ response on 
short/long term exposure. There are no specific FDA directives to regulate pharmaceutical 
nanotechnology based products and related issues. Altogether these challenges cause urgent 
need to regulate these nanotechnology based products and delivery devices. The 
characterization, safety and environment impact are three main elements that need to be 
regulated. Though regulatory agencies like FDA, EPA (Environment Protection Agency) and 
nuclear protection agency etc. are regulating the major health risk associated with 
nanomaterials, yet lack of adequate and conclusive research on the health risks of nano-based 
substances demand the need for a dialogue on regulatory adequacy, inadequacy, or possible 
alternatives more urgent. US-FDA kept nanotechnology as an element under evaluation in its 
critical path initiative.  
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FDA regulates most pharmaceutical nanotechnology based products as “combination 
products” (i.e., drug-device, drug-biologic, and device-biologic products). Some FDA 
approved nanotechnology based products, which have entered the market are liposome, 
nanoparticles, monoclonal antibody based product, polymer drug conjugate, polymer–protein 
conjugate and some polymeric drugs. Well-tuned, coordinated and sincere effort of 
government, industries, academia and researchers over guidelines for regulation must be 
drawn in order to utilize the benefit of nano-based technology without hampering its 
development. 
1.8.1 Future Prospects of Pharmaceutical Nanotechnology  
 
Pharmaceutical nanotechnology is an emerging field that could potentially make a major 
impact on human health. Nanomaterials promise to revolutionize medicine and are 
increasingly used in drug delivery or tissue engineering applications. Newly developed 
hybrid systems seem promising for future applications in human. Functional and 
multifunctional approaches have tremendous potential in temporal and spatial controlled 
delivery of bioactives. A modular approach to construct delivery systems that combine 
targeting, imaging and therapeutic functionalities into nanoplate forms is emerging as 
intelligent concept. These multifunctional nanoplate forms would localize to target cells, 
enable diagnostics and subsequently deliver therapeutics with great precision. But such 
approaches to nano devices construction are inherently complex. One very interesting and 
novel future strategy is to devise a nano machine, which can detect and attack pathogen 
simultaneously, detect the change in molecular event during diseased state, and also monitor 
the efficacy of treatment. However such intelligent machine (also known as nanorobots 
which can serves as mini onboard computer in human body) is very far reaching concept.  
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In short, recent development, market realization of various pharmaceutical nanotools and 
global interest shown by scientists, governments and industries ensure that there is 
tremendous potential and scope of nanobased drug delivery system in near future. There is no 
doubt to presume that in next ten years market will be flooded with nano-enabled delivery 
devices and materials. 
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CHAPTER-II 
A REVIEW ON POLYMERIC NANOPARTICLES  
 
2.1. Introduction 
Nanoparticles have become one of the most active areas of research in the field of drug 
delivery due to their ability to deliver drugs to the right place, at appropriate times and in the 
right dosage (Desai et al., 1997).  They have received considerable attention over the past 20 
years due to their advantages compared to other drug delivery systems. These advantages 
include: targeted delivery of drugs to the specific site to minimize toxicity; improved 
bioavailability by reducing fluctuations in therapeutic ranges; improved stability of drugs 
against enzymatic degradation; sustained and controlled release effect that reduces dosing 
frequency with improved patience compliance; and the ease of administering through various 
routes including oral, nasal, pulmonary, intraocular, parenteral and transdermal                   
(Kreuter J et al., 1994).  
Nanotechnology focuses on synthesizing biocompatible nanocomposites such as 
nanoparticles, nanocapsule, micellar systems (Bae Y et al., 2007) and nanoconjugates 
(Ljubimova J.Y et al., 2008) for delivering small molecular weight drug as well as 
macromolecular therapeutic agents. Nanoparticles  can be defined as solid, sub-micron, 
colloidal particles ranging in size from 10 nm to 1000 nm in diameter, generally but not 
necessarily made of natural or synthetic polymers, in which drugs can be adsorbed, 
entrapped, encapsulated or covalently attached and are produced by mechanical or chemical 
means (Kreuter J et al., 1983).  The term “Nanoparticles” includes –Nanocapsule (Reservoir 
device) in which the drug is confined to an aqueous or oily core surrounded by a shell-like 
wall and Nanospheres (Monolithic/matrix device) in which the drug is adsorbed, dissolved, or 
dispersed throughout the matrix (Kreuter J et al., 2004)  as seen in Figure 11.               
31 
 
Depending on the type of material or carrier used, four broad classes of nanoparticles are 
recognized: Polymeric nanoparticles, Lipid based nanoparticles (Wissing S.A et al., 2004), 
Metal based nanoparticles (Bhattacharya R et al., 2008) and Biological nanoparticles                   
(Manchester M et al., 2006) 
 
Figure 11 Structure of the polymeric nanospheres and nanocapsules (Vauthier et al., 2009)  
2.1.1 Advantages over Microparticles 
• They have higher intracellular uptake compared to micro particles (Desai et al., 1996)  
• They are better suited for I.V. delivery since the smallest blood capillaries in the body 
is about 5-6 µm. 
2.1.2 Advantages over Liposomes (Soppimath K.S et al., 2001)  
They have better stability in biological fluids and during storage. 
• Their preparation is more amenable to scale up. 
• They have the unique ability to create a controlled release product. 
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2.1.3 Materials used for preparation of nanoparticles 
Nanoparticles can be prepared from a variety of materials such as metals (silver, gold, 
platinum, silicon) as well as polymers and lipids. Researchers have developed virus based 
nanoparticles for tissue-specific targeting and imaging agents in vivo. Potential improvements 
in the field of polymer chemistry have made polymers the most suitable carrier for delivering 
small and macromolecules. Polymeric materials can be classified broadly as natural polymers 
and synthetic polymers (Table VIII). 
The selection of materials for preparing nanoparticles depends upon consideration of the 
following factors:  
• Size and surface characteristics of the particle desired. 
• Aqueous solubility and stability of drugs or active ingredients. 
• Degree of biodegradability, biocompatibility and toxicity. 
• Drug release profile desired. 
• Antigenicity of the polymers. 
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Table VIII Most widely used polymers for preparing nanoparticles in drug delivery 
(Vauthier  et al., 2009)  
 
MATERIAL 
 
FULL NAME 
 
ABBREVIATION OR 
COMMERCIAL NAMES* 
 
 
 
 
Synthetic 
homopolymers 
 
Poly (lactide) 
Poly (lactide-co-glycolide) 
Poly (epsilon-caprolactone) 
Poly (isobutylcyanoacrylate) 
Poly (isohexylcyanoacrylate) 
Poly (n-butylcyanoacrylate) 
Poly (acrylate) and 
Poly(methacrylate) 
 
 
PLA 
PLGA 
PCL 
PICBA 
PIHCA 
PBCA 
 
Eudragit* 
 
 
Natural polymers 
 
Chitosan 
Alginate 
Gelatin 
Albumin 
 
 
 
 
 
 
 
 
 
Copolymers 
 
Poly ( lactide)- poly  
(ethylene glycol) 
 
Poly (lactide-co-glycolide)- 
poly (ethylene glycol) 
 
Poly (epsilon-caprolactone)- 
poly (ethylene glycol) 
 
Poly 
(hexadecylcyanoacrylate-co-
poly (ethylene glycol) 
cyanoacrylate) 
 
 
PLA- PEG 
 
 
PLGA-PEG 
 
 
PCL-PEG 
 
 
Poly (HDCA-PEGCA) 
 
 
Colloid stabilizers 
 
Dextran 
Pluronic F68 
Poly (vinyl alcohol) 
Co polymers (see above) 
Tween®20 and Tween® 80 
 
 
 
F68 
PVA 
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2.2. Methods for the preparation of nanoparticles 
 
Figure 12 Schematic representation of various techniques for the preparation of 
polymer nanoparticles. SCF: supercritical fluid technology, C/LR: controlled/living 
radical 
2.2.1 Dispersion of preformed polymers 
2.2.1.1. Emulsification-solvent evaporation 
The emulsification-solvent evaporation method was the first method used to prepare 
biodegradable and injectable lattices by Gurny et al., 1981. Briefly, both the drug and 
polymer are dissolved in a volatile, water immiscible organic solvent such as 
dichloromethane, chloroform or ethyl acetate. The organic phase is then emulsified as 
nanodroplets in an aqueous surfactant (such as Polyvinyl alcohol, Pluronic etc.) solution 
using high energy homogenizer or sonicator (Tice et al., 1985). The polymer precipitates as 
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nanospheres and subsequently the organic phase is evaporated using a rotary evaporator or by 
continuous stirring (Soppinath et al., 2001) as represented in Figure13. 
 
Figure 13 Schematic representation of the emulsification-solvent evaporation method 
 
The parameters which affect particle size are the stirring rate, type and amount of dispersing 
agent, viscosity of the organic and aqueous phases, and temperature. The method can also be 
applied to prepare amphiphilic copolymers including PEG-PLA, PEG-PLGA, PEG-PCL, 
PEGPACA and polysaccharide-PCL without the need of any surfactant                  
(Avgoustakis  K et al., 2004; Brigger et al., 2004). Various lipophilic and hydrophilic drugs 
such as indomethacin (Bodmeier R et al., 1990), cyclosporine A (san chez et al., 1993), 
loperamide (Ueda H et al., 1997), praziquantel (Mainardes R.M et al., 2005) tetanus toxoid 
(Ya-Ping L et al., 2001) and testosterone (Gurny R et al., 1981) have been encapsulated in 
polymeric nanoparticles using this method. 
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2.2.1.2 Solvent displacement and interfacial deposition method 
 
One of the easiest and reproducible techniques for preparing nanospheres was the solvent 
displacement (also called nanoprecipitation) method developed by Fessi et al., 1989 and has 
been widely used to prepare nanoparticles (Molpeceres J et al., 1996; Guterres S.S et al., 
1995; Chacon M et al., 1996). The method is based on the precipitation of reformed polymer 
following displacement of a semipolar solvent miscible with water in the presence or absence 
of surfactant . The basic principle of this technique is similar to spontaneous emulsification of 
the organic phase containing drug and polymer into the external aqueous phase. Three basic 
ingredients are needed for this method: polymer, polymer solvent and non-solvent for the 
polymer. In brief, both the polymer and drug are dissolved in a water miscible organic 
solvent (polymer solvent phase) of intermediate polarity (e.g. acetone and ethanol). The 
resulting organic phase is injected into a stirred aqueous phase (non-solvent phase) containing 
a surfactant as stabilizer. The nanoparticles are formed instantaneously during the rapid 
diffusion of the organic phase into the aqueous phase as shown in Figure 14. Two important 
parameters affecting the physicochemical properties of the prepared nanoparticles include 
(Legrand P et al., 2007)  
• Miscibility of the organic solvent with the nonsolvent. 
• Nature of the polymer solvent interactions. 
• Concentration of the polymer in the organic phase. 
Interfacial deposition is an emulsification/solidification technique which allows production of 
nanocapsule when nontoxic oil (such as benzyl benzoate) is incorporated into the organic 
phase (Quintanar-Guerrero D et al., 1998). The polymer deposition occurs at the interface 
between the water and finely dispersed oil phase forming nanocapsule with a shell-like wall 
(Ammoury N  et al., 1991; Seijo B et al., 1990) The method has been adapted to various 
polymeric materials such as PLA (Ugo Bilati et al., 2005),  PLGA (Barichello J. M et al., 
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1999), PCL (Molpeceres J et al., 1996), peptides (Duclairoir C et al., 1998), cyclodextrins 
(Skiba M et al., 1996) and various drugs (Skiba M et al., 1995; Némati F et al., 1996). 
 
Figure 14 Schematic representation of the solvent displacement technique 
2.2.1.3 Emulsification–solvent diffusion 
 
The emulsification solvent diffusion or emulsification-solvent displacement method is the 
widely used method for preparing nanoparticles due to several advantages. These include 
high drug entrapment efficiency for poorly water soluble drugs, narrow particle size 
distribution, high batch-to-batch reproducibility, no homogenization required, simplicity, ease 
of scale up and rapid organic solvent extraction (Moinard-Chécot D et al., 2006). The drug 
and polymer usually PLA, PLGA, PCL or Eudragit are dissolved in a partially water soluble 
solvent. Commonly used solvents are propylene carbonate, benzyl alcohol, ethyl acetate, 
isopropyl acetate, methyl acetate, methyl ethyl ketone, butyl lactate or isovaleric acid 
(Battaglia L et al., 2007). The organic phase is saturated with water to ensure the initial 
thermodynamic equilibrium. It is then diluted with an extensive amount of pure water to 
facilitate diffusion of the organic solvent from the organic phase droplets leading to the 
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precipitation of the polymer as presented in Figure 15. The aqueous phase may contain 
surfactants such as Pluronic, PVA and sodium taurocholate while the organic phase 
sometimes contains soy lecithin as the emulsifier. Finally, the solvent is eliminated by 
evaporation or filtration, depending upon the boiling point. Several parameters can affect the 
size of the nanoparticles such as miscibility of the water with the organic solvent (Quintanar-
Guerrero D et al., 1996) stirring rate, concentration of the surfactant(s) and concentration of 
the polymer is the organic phase (Quintanar-Guerrero D et al., 1998). Nanocapsules are 
successfully prepared by this method when a small amount of oil is incorporated into the 
organic phase (Quintanar-Guerrero D et al., 1998). The disadvantages of this method include: 
long time required to remove the high volume of water and leakage of water soluble drugs 
during processing. 
 
Figure 15 Schematic representation of the emulsification-solvent diffusion method 
2.2.1.4 Salting out method 
 
The salting-out procedure can be considered as a modification of the emulsification/solvent 
diffusion method. The separation of a water miscible solvent from aqueous solution is 
achieved via a salting-out effect (Figure 16). Briefly, a water miscible organic solvent, 
usually acetone, containing polymer and drug is added drop wise to an aqueous phase 
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saturated with an electrolyte or non-electrolyte (such as magnesium chloride, calcium 
chloride or sucrose) with a colloidal stabilizer (such as polyvinyl pyrrolidone) under agitation 
to form an o/w emulsion. A sufficient volume of water is added to enhance the diffusion of 
acetone to the water phase and nanospheres are thus obtained. The technique offers 
advantages such as the avoidance of chlorinated solvents and surfactants, minimization of 
stress for protein encapsulates (Jung T et al., 2005) useful for heat-sensitive substances 
(Lambert G et al., 2001), high encapsulation efficiency and easy scaling up. The method is 
not popular because of the extensive washing steps required to achieve purity of the 
nanoparticles (Couvreur P et al., 1995) and the possibility of incompatibility between drugs 
and salts. 
 
Figure 16 Schematic presentation of salting out method of preparing nanospheres 
 
2.2.2 Polymerization method 
 
In the polymerization method, monomers are polymerized to form nanoparticles in aqueous 
solution. The polymerization method can be classified into emulsion and interfacial 
polymerization. The emulsion polymerization method is the fastest and scalable method of 
producing nanoparticles (Kreuter J et al., 1990). It can be classified into two categories; 
continuous organic phase or continuous aqueous phase methodology depending on the use of 
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the continuous phase. In general, the monomer is dissolved into an organic or aqueous 
continuous phase. Additional monomer molecules are then emulsified into the emulsion 
droplets that are stabilized by surfactant. The polymerization is started by chemical initiation, 
pH shift or by irradiation of gamma, ultraviolet or visible rays. In the continuous phase, chain 
growth starts when the initiated monomer ion or monomer radical collide with each other and 
forms aggregates which are stabilized by polymeric emulsifier particles. This mechanism is 
known as anionic polymerization (Vauthier C et al., 2003). Several materials are used to 
produce nanoparticles such as polyacrylamide (Ekman B et al., 1978), poly 
(methylmethacrylate), polybutylcyanoacrylate (Li V.H.K et al., 1986), poly 
(hexylcyanoacrylate) (Maincent P et al., 1986) and poly (dialkylmethylidene melonate) 
(Mbela T.K.M et al., 1992). The interfacial polymerization method is generally used to 
prepare nanocapsule using oily components such as benzyl benzoate or migliol (Alle´mann E 
et al., 1998) along with an organic solvent. In this case, polymerization occurs at the interface 
between the oily and aqueous phase to produce nanocapsule spontaneously. The 
nanocapsules are stabilized with the help of surfactant added in the aqueous phase. The 
technique is advantageous from the standpoint of producing nanocapsule with high drug 
entrapment efficiency with hydrophilic insulin (Couvreur P et al., 2002). This process was 
used to produce nanoparticles of polyethylcyanoacrylate (Watnasirichaikul S et al., 2000), 
poly (isobutylcyanoacrylate) (Lambert G et al., 2000) and poly (isohexylcyanoacrylate) 
(Lenaerts V et al., 1995). 
Interfacial polycondensation is another method by which lipophilic monomer, such as 
phtaloyldichloride, and hydrophilic monomer, such as diethylenetriamine, is condensed to 
prepare nanocapsule in the presence or absence of surfactant. It is a spontaneous 
emulsification technique in which the organic phase contains a water miscible solvent, 
lipophilic polymer and the oil, whereas the aqueous phase contains hydrophilic monomer and 
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surfactant. The polycondensation reaction occurs at the interface of the oil droplets to form an 
oil-in water emulsion and subsequently nanocapsule (Bouchemal K et al., 2006). By using the 
modified interfacial polycondensation method, encapsulation and stability of an oily drug, 
alpha-tocopherol, was improved by the use of polyurethane and poly (ether urethane) 
(Bouchemal K   et al., 2004). 
2.2.3 Coacervation and ionic gelation method 
 
Much research has been focused on preparing nanoparticles from natural hydrophilic 
polymers such as chitosan (Mansouri S et al., 2004: Mao H-Q et al., 2001; Illum L et al., 
1994), albumin (Kreuter J et al., 2007), gelatin (Yoshioka T et al., 1981), sodium alginate 
(Aslani P et al., 1996), agarose (Wang N et al., 1995) and gliadin (Duclairoir C et al., 2002). 
Coacervation is a process during which is a homogenous solution of charged macromolecules 
undergo liquid-liquid phase separation producing a separated phase of polymer rich particles 
(Mohantya B et al., 2005). In the ionic gelation method, the positive or negative charge of the 
hydrophilic polymer is complexed with a multivalent cationic (calcium chloride) or 
polyanionic (sodium tripolyphosphate) to form highly viscous gel particles with a size in the 
range of a nanometer. Calvo et al developed a method for preparing chitosan nanoparticles by 
this method (Calvo P et al., 1998). 
2.2.4 Production of nanoparticles using supercritical fluid technology 
 
Recently, supercritical or compressed fluids have been utilized as an alternative way to 
prepare biodegradable nanoparticles (Wang Y et al., 2004). This new technique obviates the 
use of toxic organic solvents associated with conventional methods. Two techniques are most 
commonly used for preparing nanoparticles – Supercritical anti-solvent (SAS) and Rapid 
Expansion of Critical Solution (RESS). In the SAS method, solutes are dissolved in methanol 
which is completely miscible with supercritical fluids. The extraction of methanol by the 
supercritical fluids leads to an instantaneous precipitation of the nanoparticles                  
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(Thote A J et al., 2005). Dexamethasone phosphate nanoparticles were prepared by this 
method. In the RESS method, solutes are dissolved in the supercritical fluid and the solution 
is expanded through a small nozzle into a region of lower pressure. The solutes eventually 
precipitate as nanoparticles. Insulin loaded PEG/PLA nanoparticles were prepared by this 
method (Elvassore N et al., 2001). The technique is very expensive and requires elaborate 
recycling measures. 
2.3. Separation and purification techniques of nanoparticles 
 
Depending on the method of preparation, potentially toxic impurities can be present in the 
nanoparticulate suspensions. These impurities are organic solvents, surfactants, residual 
monomers, polymerization initiators and large polymer aggregates (Limayem I et al., 2004). 
Separation of the drug entrapped nanoparticles from free polymer and unentrapped drugs is a 
very critical step in producing pure nanoparticles. The separation can be achieved by using 
Ultracentrifugation, crossflow microfiltration (Allémann E et al., 1993), Gel filtration, 
Dialysis and Diafiltration. 
2.4. Stability of nanoparticles 
 
There are several physical and chemical factors that play a major role in the instability of 
prepared nanoparticles. The overall stability can be classified into two types: Physical and 
chemical stability. 

2.4.1. Physical Stability 
 
The colloidal submicron particles in homogenous suspension do not sediment due to the 
continuous thermal motion of the particles known as Brownian motion. Gravitational forces 
which cause the particles to sediment are opposed by Brownian motion. At colloidal size 
range, the particles tend to remain suspended since Brownian motion dominates over 
gravitational forces. Random collision of suspended particles of various surface charge 
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content and shape often lead to agglomeration and subsequent settling of the particles. In 
order to avoid this phenomenon, a suitable stabilizer such as PVA, DMAB, Pluronic or 
phospholipids is used. Magneheim et al investigated the PLA particle aggregation due to the 
absorption of nifedipine molecules which displaces a part of the steric stabilized surface layer 
(Magneheim B., Benita S 1991). Charged stabilized particles are often reported to coagulate 
when counter ions are absorbed within the electrical double layer (Jiang J et al., 2009). 
2.4.2. Chemical Stability 
 
There are several factors which contribute to chemical instability of nanoparticles such as 
storage conditions including temperature and pH, chemical stability of entrapped drugs as 
well as the type and molecular weight of the polymer used. Biodegradable polymeric 
nanoparticles are generally stored at 4-50C for improving stability (Coffin M.D.,               
McGinity J.W 1992). Polymer degradation by hydrolysis was observed at extreme conditions 
of pH and temperature which the best stability was observed when the aqueous medium pH 
was adjusted to physiological pH (Belbella A et al., 1996). The overall stability of a 
nanoparticle formulation also depends on the chemical stability of the entrapped drugs. Most 
of the drugs have a pH dependent degradation profile and sometimes show photo 
degradation. Therefore, to reduce drug degradation and improve the stability of the 
nanoparticle formulation, freeze drying is most commonly used. 
2.5. Freeze drying of nanoparticles 
 
In order to remove the water from the nanoparticle system, freeze drying, also known as 
lyophilization is most commonly used. The basic principle of freeze drying is to remove 
water from a frozen sample by sublimation and desorption under vacuum (Williams N.A., 
Polli G.P 1984; Pikal M.J et al., 1990). However, the process could generate various stresses 
which could cause instability of particles. In order to protect the particles from freezing and 
dessication stresses, cryoprotectants and lyoprotectants are incorporated into the formulation 
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before freeze drying. Besides using these agents, other several excipients are commonly 
incorporated into the formulation for various purposes, as shown in Table IX. 
 Most commonly used cryoprotectants include sugars such as trehalose, sucrose, glucose, 
fructose, lactose and maltose (Abdelwahed W et al., 2006; Auvillain M et al., 1989; 
Zimmermann E et al., 2000). These saccharides act as a spacing matrix to prevent particle 
agglomeration. Freeze drying is generally carried out below the Tg´ temperature or Teu 
temperature (eutectic crystallization temperature) so that nanoparticles can be immobilized 
within the glassy matrix of the cryoprotectants (Tang X et al., 2004). 
Table IX Excipients used in freeze drying of nanoparticle suspension 
 
TYPE 
 
 
FUNCTION 
 
SUBSTANCE 
 
 
Bulking 
agents 

Provide bulk to the 
formulation especially when 
the concentration of the 
product to freeze dry is very 
low. 
 
 
Hydroxymethyl starch, 
trehalose, mannitol, lactose 
and glycine. 
 
Buffers 
 
Adjust pH changes during 
freezing. 
 

Phosphate, Tris HCl, citrate 
and histidine. 
 
 
Stabilizers 
 
Protect the product during 
freeze drying against the 
freezing and the drying 
stresses. 
 
 
Sucrose, lactose, glucose, 
trehalose, glycerol, mannitol, 
sorbitol, glycine, alanine, 
lysine, poly ethylene glycol, 
dextran and PVP. 
 
Tonicity 
adjusters 
Yield an isotonic solution 
and 
control osmotic pressure. 
 
Mannitol, sucrose, glycine, 
glycerol and sodium chloride. 
 
Collapse 
temperature 
modifiers 
 
Increase collapse temperature 
of the product to get higher 
drying temperature 
 

Dextran, hydroxypropyl-β- 
cyclodextrins, PEG, poly 
(vinyl pyrrolidone).
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2.6. Physicochemical properties of nanoparticles 
 
2.6.1. Particle size 
 
Nanoparticles have relatively higher intracellular uptake as compared to microparticles 
(Desai M.P et al., 1997). They were able to penetrate throughout the sub mucosal layers 
while the larger size microparticles localized in the epithelial lining (Desai M.P et al., 1996). 
Nanoparticles are also reported to cross the blood brain barrier following the opening of the 
tight junctions by hyper osmotic barrier (Kreuter J et al., 2003). Drug release and polymer 
degradation are also affected by the size distribution of nanoparticles. Larger particles allow 
more drugs to encapsulate inside the hyper osmotic mannitol for sustained delivery of drugs 
to brain tumors. Polysorbate 80 coated nanoparticles were also reported to enhance drug 
delivery across blood-brain core and slowly diffuse the drug molecules (Redhead H.M et al., 
2001). The rate of polymer degradation of PLGA nanoparticles was increased with increasing 
the particles size (Dunne M et al., 2000). 
2.6.2. Surface charge 
 
An important characteristic of nanoparticles is the surface charge which determines the 
physical stability in the formulation, in vivo distribution and targeting ability of 
nanoparticles. The zeta potential is the measure of the amount of charge on the particle and 
represents an index of particle stability. A physically stable nanosuspension stabilized by 
electrostatic repulsion should have a minimum zeta potential value of ± 30 Mv              
(Muller R.H et al., 2001). The stability is increased when negative zeta potential is lowered 
by the addition of PEG (Vila A., Sanchez A et al., 2002). The zeta potential also indicates 
whether the charged active material is encapsulated within the center or adsorbed onto the 
surface of the nanoparticles. Thus consideration of the zeta potential is important in 
preventing aggregation of the particles. 
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2.6.3. Surface hydrophobicity 
 
Following intravenous administration, hydrophobic nanoparticles are easily recognized by the 
mononuclear phagocytic system. Thus, they are rapidly opsonized and massively cleared by 
macrophages of the liver, spleen, lungs and bone marrow (Grislain L et al., 1983). Thus in 
order to minimize opsonization and prolong blood circulation of nanoparticles in vivo, the 
surface of the hydrophilic nanoparticles must be modified. There are two general approaches 
employed for this purpose. One is the surface coating of nanoparticles with hydrophilic 
polymers such as polyethylene glycol (PEG), chitosan (Janes K.A et al., 2001) or surfactants 
such as Poloxamer or poloxamines. The second approach is the use of biodegradable 
copolymers having hydrophilic segments such as PLA-PEG (Avgoustakis K et al., 2002). 
PEG functionalized nanoparticles are not taken up by the body and often called as “stealth 
nanoparticles” (Peracchia M.T et al., 1999). 
2.6.4. Drug loading 
 
Loading of the drug inside nanoparticles can be achieved by two methods: the incorporation 
method and the adsorption/absorption method. There are several factors which can affect 
drug loading and entrapment efficiency of nanoparticles such as drug solubility in the 
polymer matrix, molecular weight, drug polymer interaction and presence of end carboxylic 
groups. Ideally a nanoparticulate system should have high drug loading capacity in order to 
reduce the quantity of polymer required. 
2.6.5. Drug release 
 
One of the most important applications of polymeric nanoparticles is the sustained and 
controlled delivery of drugs. Various factors such as solubility of drug, desorption, drug 
diffusion, particle matrix degradation or erosion can affect drug release. Smaller particles 
have higher initial burst release caused by poorly entrapped drug or drug adsorbed onto the 
surface of the nanoparticles. Larger particles have longer sustained release with smaller initial 
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burst release. It is also possible to alter the release rate from PLA-PEGPLA copolymer by 
changing the amount of PEG or the molecular weight of the polymer (Matsumoto J et al., 
1999). Various methods can be used to study the in vitro release of drug from nanoparticles 
such as diffusion cell, dialysis bag diffusion, agitation followed by ultracentrifugation or ultra 
filtration. 
2.7. Application of Nanoparticles in Drug Delivery Systems 
i) Tumor targeting using nanoparticulate delivery systems  
The rationale of using nanoparticles for tumor targeting is based on 1) nanoparticles will be 
able to deliver a concentrate dose of drug in the vicinity of the tumor targets via the enhanced 
permeability and retention effect or active targeting by ligands on the surface of 
nanoparticles; 2) nanoparticles will reduce the drug exposure of health tissues by limiting 
drug distribution to target organ. Verdun et al demonstrated in mice treated with doxorubicin 
incorporated into poly (Isohexylcyanoacrylate) nanospheres that higher concentrations of 
doxorubicin manifested in the liver, spleen and lungs than in mice treated with free 
doxorubicin. Studies show that the polymeric composition of nanoparticles such as type, 
hydrophobicity and biodegradation profile of the polymer along with the associated drug’s 
molecular weight, its localization in the nanospheres and mode of incorporation technique, 
adsorption or incorporation, have a great influence on the drug distribution pattern in vivo. 
The exact underlying mechanism is not fully understood but the biodistribution of 
nanoparticles is rapid, within ½ hour to 3 hours, and it likely involves MPS and 
endocytosis/phagocytosis process. Recently Bibby et al reported the biodistribution and 
pharmacokinetics (PK) of a cyclic RGD doxorubicin- nanoparticle formulation in tumor 
bearing mice. Their biodistribution studies revealed decreasing drug concentrations over time 
in the heart, lung, kidney and plasma and accumulating drug concentrations in the liver, 
spleen and tumor. The majority injected dose appeared in the liver (56%) and only 1.6% in 
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the tumor at 48 hrs post injection, confirming that nanoparticles have a great tendency to be 
captured by liver. This indicates the greatest challenge of using nanoparticles for tumor 
targeting is to avoid particle uptake by mononuclear phagocytic system (MPS) in liver and 
spleen. Such propensity of MPS for endocytosis/phagocytosis of nanoparticles provides an 
opportunity to effectively deliver therapeutic agents to these cells. This biodistribution can be 
of benefit for the chemotherapeutic treatment of MPS- rich organs/tissues localized tumors 
like hepatocarcinoma, hepatic metastasis arising from digestive tract or gynecological 
cancers, brochopulmonary tumors, primitive tumors and metastasis, small cell tumors, 
myeloma and leukemia. It has been proved that using doxorubicin loaded conventional 
nanoparticles was effective against hepatic metastasis model in mice. It was found there was 
greater reduction in the degree of metastasis than when free drug was used. The underlying 
mechanism responsible for the increased therapeutic efficacy of the formulation was transfer 
of Doxorubicin from healthy tissue, acting as a drug reservoir to the malignant tissues. 
Histological examination showed a considerable accumulation of nanoparticles in the 
lysosomal vesicles of Kupffer cells, whereas nanoparticles could not be clearly identified in 
tumoral cells. Thus Kupffer cells, after a massive uptake of nanoparticles by phagocytosis, 
were able to induce the release of doxorubicin, leading to a gradient of drug concentration, 
favorable for a prolonged diffusion of the free and still active drug towards the neighboring 
metastatic cells. When conventional nanoparticles are used as carriers in chemotherapy, some 
cytotoxicity against the Kupffer cells can be expected, which would result in deficiency of 
Kupffer cells and naturally lead to reduced liver uptake and decreased therapeutic effect with 
intervals of less than 2 weeks administration. Moreover, conventional nanoparticles can also 
target bone marrow (MPS tissue), which is an important but unfavorable site of action for 
most anticancer drugs because chemotherapy with such carriers may increase 
myelosuppresive effect. Therefore, the ability of conventional nanoparticles to enhance 
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anticancer drugs efficacy is limited to targeting tumors at the level of MPS-rich organs. Also, 
directing anticancer drug-loaded nanoparticles to other tumoral sites is not feasible if a rapid 
clearance of nanoparticles occurs shortly after intravenous administration. 
ii) Long circulating nanoparticles 
To be successful as a drug delivery system, nanoparticles must be able to target tumors which 
are localized outside MPS-rich organs. In the past decade, a great deal of work has been 
devoted to developing so-called “stealth” particles or PEGylated nanoparticles, which are 
invisible to macrophages or phagocytes. A major breakthrough in the field came when the 
use of hydrophilic polymers (such as polyethylene glycol, poloxamines, poloxamers, and 
polysaccharides) to efficiently coat conventional nanoparticle surface produced an opposing 
effect to the uptake by the MPS. These coatings provide a dynamic “cloud” of hydrophilic 
and neutral chains at the particle surface which repel plasma proteins. As a result, those 
coated nanoparticles become invisible to MPS, therefore, remained in the circulation for a 
longer period of time. Hydrophilic polymers can be introduced at the surface in two ways, 
either by adsorption of surfactants or by use of block or branched copolymers for production 
of nanoparticles. Studies show nanoparticles containing a coat of PEG not only have a 
prolonged half-life in the blood compartment but also be able to selectively extravasate in 
pathological sites such as tumors or inflamed regions with a leaky vasculature. As a result, 
such long-circulating nanoparticles have increased the potential to directly target tumors 
located outside MPS-rich regions. The size of the colloidal carriers as well as their surface 
characteristics are the critical to the biological fate of nanoparticles. A size less than 100 nm 
and a hydrophilic surface are essential in achieving the reduction of opsonization reactions 
and subsequent clearance by macrophages. Coating conventional nanoparticles with 
surfactants or PEG to obtain a long-circulating carrier has now been used as a standard 
strategy for drug targeting in vivo. 
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Extensive efforts have been devoted to achieving “active targeting” of nanoparticles in order 
to deliver drugs to the right targets, based on molecular recognition processes such as ligand-
receptor or antigen-antibody interaction. Considering that fact that folate receptors are over 
expressed on the surface of some human malignant cells and the cell adhesion molecules such 
as selectins and integrins are involved in metastatic events, nanoparticles bearing specific 
ligands such as folate may be used to target ovarian carcinoma while specific peptides or 
carbohydrates may be used to target integrins and selectins. Oyewumi et al demonstrated that 
the benefits of folate ligand coating were to facilitate tumor cell internalization and retention 
of Gd-nanoparticles in the tumor tissue. 
Targeting with small ligands appears more likely to succeed since they are easier to handle 
and manufacture. Furthermore, it could be advantageous when the active targeting ligands are 
used in combination with the long-circulating nanoparticles to maximize the likelihood of the 
success in active targeting of nanoparticles.  
iii) Reversion of multidrug resistance in tumor cells 
 Anticancer drugs, even if they are located in the tumor interstitium, can turn out to be of 
limited efficacy against numerous solid tumor types, because cancer cells are able to develop 
mechanisms of resistance. These mechanisms allow tumors to evade chemotherapy. 
Multidrug resistance (MDR) is one of the most serious problems in chemotherapy. MDR 
occurs mainly due to the over expression of the plasma membrane p-glycoprotein (Pgp), 
which is capable of extruding various positively charged xenobiotics, including some 
anticancer drugs, out of cells. In order to restore the tumoral cells’ sensitivity to anticancer 
drugs by circumventing Pgp-mediated MDR, several strategies including the use of colloidal 
carriers have been applied. The rationale behind the association of drugs with colloidal 
carriers, such as nanoparticles, against drug resistance derives from the fact that Pgp probably 
recognizes the drug to be effluxed out of the tumoral cells only when this drug is present in 
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the plasma membrane, and not when it is located in the cytoplasm or lysosomes after 
endocytosis one of the most serious problems in chemotherapy. MDR occurs mainly due to 
the over expression of the plasma membrane p-glycoprotein (Pgp), which is capable of 
extruding various positively charged xenobiotics, including some anticancer drugs, out of 
cells . In order to restore the tumoral cells’ sensitivity to anticancer drugs by circumventing 
Pgp-mediated MDR, several strategies including the use of colloidal carriers have been 
applied. The rationale behind the association of drugs with colloidal carriers, such as 
nanoparticles, against drug resistance derives from the fact that Pgp probably recognizes the 
drug to be effluxed out of the tumoral cells only when this drug is present in the plasma 
membrane, and not when it is located in the cytoplasm or lysosomes after endocytosis. 
iv) Nanoparticles for oral delivery of peptides and proteins 
 
Significant advances in biotechnology and biochemistry have led to the discovery of a large 
number of bioactive molecules and vaccines based on peptides and proteins. Development of 
suitable carriers remains a challenge due to the fact that bioavailability of these molecules is 
limited by the epithelial barriers of the gastrointestinal tract and their susceptibility to 
gastrointestinal degradation by digestive enzymes. Polymeric nanoparticles allow 
encapsulation of bioactive molecules and protect them against enzymatic and hydrolytic 
degradation. For instance, it has been found that insulin-loaded nanoparticles have preserved 
insulin activity and produced blood glucose reduction in diabetic rats for up to 14 days 
following the oral administration. 
The surface area of human mucosa extends to 200 times that of skin. The gastrointestinal 
tract provides a variety of physiological and morphological barriers against protein or peptide 
delivery, e.g., (a) proteolytic enzymes in the gut lumen like pepsin, trypsin and chymotrypsin;   
(b) proteolytic enzymes at the brush border membrane (endopeptidases); (c) bacterial gut 
flora; and (d) mucus layer and epithelial cell lining itself. The histological architecture of the 
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mucosa is designed to efficiently prevent uptake of particulate matter from the environment. 
One important strategy to overcome the gastrointestinal barrier is to deliver the drug in a 
colloidal carrier system, such as nanoparticles, which is capable of enhancing the interaction 
mechanisms of the drug delivery system and the epithelia cells in the GI tract.  
v) Targeting of nanoparticles to epithelial cells in the GI tract using ligands 
 Targeting strategies to improve the interaction of nanoparticles with adsorptive enterocytes 
and M-cells of Peyer’s patches in the GI tract can be classified into those utilizing specific 
binding to ligands or receptors and those based on nonspecific adsorptive mechanism. The 
surface of enterocytes and M cells display cell-specific carbohydrates, which may serve as 
binding sites to colloidal drug carriers containing appropriate ligands. Certain glycoprotein’s 
and lectins bind selectively to this type of surface structure by specific receptor-mediated 
mechanism. Different lectins, such as bean lectin and tomato lectin, have been studied to 
enhance oral peptide adsorption. Vitamin B-12 absorption from the gut under physiological 
conditions occurs via receptor-mediated endocytosis. The ability to increase oral 
bioavailability of various peptides (e.g., granulocyte colony stimulating factor, 
erythropoietin) and particles by covalent coupling to vitamin B-12 has been studied. For this 
intrinsic process, mucoprotein is required, which is prepared by the mucus membrane in the 
stomach and binds specifically to cobalamin. The mucoprotein completely reaches the ileum 
where resorption is mediated by specific receptors.  
vi )Absorption enhancement using non-specific interactions  
In general, the gastrointestinal absorption of macromolecules and particulate materials 
involves either paracellular route or endocytotic pathway. The paracellular route of 
absorption of nanoparticles utilizes less than 1% of mucosal surface area. Using polymers 
such as chitosan, starch or poly (acrylate) can increase the paracellular permeability of 
macromolecules. Endocytotic pathway for absorption of nanoparticles is either by receptor-
53 
 
mediated endocytosis, that is, active targeting, or adsorptive endocytosis which does not need 
any ligands. This process is initiated by an unspecific physical adsorption of material to the 
cell surface by electrostatic forces such as hydrogen bonding or hydrophobic interactions. 
Adsorptive endocytosis depends primarily on the size and surface properties of the material. 
If the surface charge of the nanoparticles is positive or uncharged, it will provide an affinity 
to adsorptive enterocytes though hydrophobic, whereas if it is negatively charged and 
hydrophilic, it shows greater affinity to adsorptive enterocytes and M cells. This shows that a 
combination of size, surface charge and hydrophilicity play a major role in affinity. This is 
demonstrated with poly (styrene) nanoparticles and when it is carboxylated. Nanoparticles for 
gene delivery polynucleotide vaccines work by delivering genes encoding relevant antigens 
to host cells where they are expressed, producing the antigenic protein within the vicinity of 
professional antigen presenting cells to initiate immune response. Such vaccines produce both 
humoral and cell-mediated immunity because intracellular production of protein, as opposed 
to extracellular deposition, stimulates both arms of the immune system. The key ingredient of 
polynucleotide vaccines, DNA, can be produced cheaply and has much better storage and 
handling properties than the ingredients of the majority of protein-based vaccines. Hence, 
polynucleotide vaccines are set to supersede many conventional vaccines particularly for 
immunotherapy. However, there are several issues related to the delivery of polynucleotides 
which limit their application. These issues include efficient delivery of the polynucleotide to 
the target cell population and its localization to the nucleus of these cells, and ensuring that 
the integrity of the polynucleotide is maintained during delivery to the target site. 
Nanoparticles loaded with plasmid DNA could also serve as an efficient sustained release 
gene delivery system due to their rapid escape from the degradative endo-lysosomal 
compartment to the cytoplasmic compartment. Hedley et al.  reported that following their 
intracellular uptake and endolysosomal escape, nanoparticles could release DNA at a 
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sustained rate resulting in sustained gene expression. This gene delivery strategy could be 
applied to facilitate bone healing by using PLGA nanoparticles containing therapeutic genes 
such as bone morphogenic protein. 
vii) Nanoparticles for drug delivery into the brain 
The blood-brain barrier (BBB) is the most important factor limiting the development of new 
drugs for the central nervous system. The BBB is characterized by relatively impermeable 
endothelial cells with tight junctions, enzymatic activity and active efflux transport systems. 
It effectively prevents the passage of water-soluble molecules from the blood circulation into 
the CNS, and can also reduce the brain concentration of lipid-soluble molecules by the 
function of enzymes or efflux pumps. Consequently, the BBB only permits selective transport 
of molecules that are essential for brain function. Strategies for nanoparticle targeting to the 
brain rely on the presence of and nanoparticle interaction with specific receptor-mediated 
transport systems in the BBB. For example polysorbate 80/LDL, transferrin receptor binding 
antibody (such as OX26), lactoferrin, cell penetrating peptides and melanotransferrin have 
been shown capable of delivery of a self non transportable drug into the brain via the 
chimeric construct that can undergo receptor-mediated transcytosis . It has been reported poly 
(butylcyanoacrylate) nanoparticles was able to deliver hexapeptide dalargin, doxorubicin and 
other agents into the brain which is significant because of the great difficulty for drugs to 
cross the BBB. Despite some reported success with polysorbate 80 coated NPs, this system 
does have many shortcomings including desorption of polysorbate coating, rapid NP 
degradation and toxicity caused by presence of high concentration of polysorbate. OX26 
MAbs (anti-transferrin receptor MAbs), the most studied BBB targeting antibody, have been 
used to enhance the BBB penetration of liposomes.   
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CHAPTER-III 
LITERATURE REVIEW 
Mukesh S Patil et al., 2011, reported on preparation and optimization of simvastatin 
nanoparticle for solubility enhancement and in- vivo study. Simvastatin nanoparticles 
prepared by nanoprecipitation method using a partially water-miscible solvents and the 
mutual saturation of the aqueous and organic phases prior to form a nano suspension in order 
to reduce the initial thermodynamic instability of the nanoparticles. Because of the self-
emulsifying properties of the methacrylic acid co-polymers, it was possible to prepare 
aqueous dispersions of colloidal size containing up to 30% w/v of Eudragit L100 using 
methanol as a water-miscible solvent with surfactant. Nanoparticles have become an 
important area of research in the field of drug delivery, because they have the ability to 
deliver a wide range of drugs to varying areas of the body for sustained periods of time. The 
nanoparticles have a higher surface-to-volume ratio as compared with bulk material, and 
therefore the dose and frequency of administration would be reduced hence increasing patient 
compliance. 
Ji Jingou et al., 2011, reported on preparation, characterization of hydrophilic and 
hydrophobic drug in combine loaded chitosan/cyclodextrin nanoparticles and in vitro release 
study. The prepared nanoparticles were characterized by FT-IR spectroscopy to confirm the 
cross-linking reaction between CS and cross-linking agent. X-ray diffraction (XRD) was 
performed to reveal the form of the drug after encapsulation. The average size of 
nanoparticles ranged from 308.4±15.22 to 369.3±30.01 nm. The nanoparticles formed were 
spherical in shape with high zeta potentials (higher than +30 mV). In vitro release studies in 
phosphate buffer saline (pH 7.4) showed an initial burst effect and followed by a slow drug 
release. Cumulative release data were fitted to an empirical equation to compute diffusional 
exponent (n), which indicated the non-Fickian trend for drug release. 
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Akbari et al., 2011, reported on development and evaluation of orodispersible tablets of 
Rosuvastatin calcium-HP-β-CD inclusion complex by using different superdisintegrants 
rosuvastatin Calcium (RST), a poorly water-soluble 3-hydroxy3-methyl glut aryl CoA 
(HMG-CoA) Reductase inhibitor through inclusion complexation with hydroxy propyl  β-
cyclodextrin (HP-β-CD). The aim of this work was to develop Rosuvastatin Orodispersible 
tablets by exploiting the solubilizing effect of hydroxy propyl β-cyclodextrin (HP-β-CD). 
Drug–CD complex systems, prepared by different techniques, were characterized by 
differential scanning Calorimetry (DSC), X-ray diffractometry, and Fourier transform 
infrared (FT-IR) spectroscopy. The inclusion complex containing RST: HP-β-CD (1:1) was 
formulated into tablets using super disintegrants like sodium starch glycolate, crospovidone 
and croscarmellose. Tablets containing RST-HP- β-CD inclusion complex were prepared by 
direct compression and evaluated for various post compression parameters like hardness, 
friability, weight variation, thickness, drug content and in-vitro dissolution. A significant 
improvement of the drug dissolution profile was achieved from tablets containing drug-CD 
systems (Kneaded products showed the best dissolution profiles, reaching more than 97.46% 
drug release in 20 min.). The stability of tablets was studied and no significant changes were 
detected in the dissolution profile of tablets after 1 month. 
Peng Lium et al., 2011, studied the nanosuspensions of poorly soluble drugs: Preparation 
and development by wet milling. Nanosizing techniques are important tools for improving 
the bioavailability of water insoluble drugs. Here, a rapid wet milling method was employed 
to prepare nanosuspensions: 4 types of stabilizers at 4 different concentrations were tested on 
2 structurally different drug compounds: indomethacin and itraconazole. Photon correlation 
spectroscopy (PCS) results showed that the finest nanosuspensions were obtained when 80 
wt% (to drug amount) pluronic F68 was the stabilizer for indomethacin and 60 wt% pluronic 
F127 for itraconazole. Compared to physical mixtures, dissolution rates of the 
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nanosuspensions showed significant increases. The morphology of nanoparticles was 
observed by transmission electron microscopy (TEM). Crystalline state of the drugs before 
and after milling was confirmed using differential scanning calorimetry (DSC) and X-ray 
powder diffraction (XRPD). The physical and chemical stabilities of the nanosuspensions 
after storage for 2 months at room temperature and at 4°C were investigated using PCS, TEM 
and HPLC. No obvious changes in particle size and morphology and no chemical degradation 
of the drug ingredients were seen. 
Liang Fang et al., 2011, reported on preparation and in vitro/in vivo evaluation of 
revaprazan hydrochloride nanosuspension. To investigate the particle size reduction effect of 
RH on dissolution and absorption, three suspensions that containing different sized particles 
were prepared by high pressure homogenization and in vitro/in vivo evaluations were carried 
out. DSC and powder X-ray diffraction were used to study crystalline state of freeze dried 
powder of RH suspensions and the results showed that particles of RH micro suspension and 
nanosuspension remained in the same crystalline state as coarse suspension, but had lower 
lattice energy. In the in vitro dissolution test, both micro suspension and nanosuspension 
showed increased dissolution rate. In the in vivo evaluation, compared to coarse suspension, 
RH nanosuspension exhibited significant increase in AUC0–t, Cmax and decrease in Tmax, 
MRT. Nevertheless, RH micro suspension did not display any significant differences in these 
pharmacokinetic parameters compared to the coarse suspension. The findings revealed that 
particle size reduction can influence RH absorption in gastrointestinal tract and 
nanosuspension can enhance oral bioavailability of RH in rats. 
Khosro Adibkia et al., 2011, developed the naproxen–Eudragit® RS100 nanoparticles and 
characterized. The nanoparticles of naproxen with Eudragit® RS100 were formulated using 
the solvent evaporation/extraction technique (the single emulsion technique). The effect of 
several process parameters, i.e., drug/polymer ratio, aqueous phase volume and speed of 
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homogenization were considered on the size of the nano formulations. The physicochemical 
characteristics of nanoparticles were studied applying particle size analysis, differential 
scanning calorimetry, X-ray crystallography, Fourier transform infrared spectroscopy and 
scanning electron microscopy. The release rate of naproxen from various drug/polymer 
nanoparticles was investigated as well. All the prepared formulations using Eudragit® RS100 
resulted in nano-range size particles with relative spherical smooth morphology. The 
nanoparticles of naproxen–Eudragit® RS100 displayed lower crystallinity. The 
intermolecular interaction between naproxen and Eudragit® RS100 was detected in the        
FT-IR spectrum of the nanoparticles. All the nanoparticles displayed a slow release pattern 
with the reduced burst release in comparison with the intact drug powder and physical 
mixtures of drug and polymer. According of these findings, formulation of the naproxen–
Eudragit® RS100 nanoparticles was able to improve the physicochemical characteristics of 
the drug and possibly will increase the anti-inflammatory effects of drug following its ocular 
or intra-joint administration. 
Mohammed Anwar et al., 2011, evaluated the bioavailability of nano-sized chitosan-
atorvastatin conjugate after oral administration to rats. Nano-sized conjugate with a mean size 
of 215.3 ± 14.2 nm was prepared by the process of high pressure homogenization (HPH). 
Scanning electron microscopy (SEM) revealed that CH-AT nano-conjugate possess smooth 
surface whereas X-ray diffraction (XRD) spectra demonstrated amorphous nature of nano-
conjugate. Further, CH-AT nano-conjugate showed solubility enhancement of nearly 4-fold 
and 100-fold compared to CH-AT conjugate and pure AT, respectively. In vitro drug release 
studies in simulated gastric fluid and simulated intestinal fluid suggested sustained release of 
AT from the conjugate. Additionally, the nano-conjugate significantly reduced the acidic 
degradation of AT. The plasma-concentration time profile of AT after oral administration of 
CH-AT nano-conjugate (2574 ± 95.4 ng/mL) to rat exhibited nearly 5-fold increase in 
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bioavailability compared with AT suspension (583 ± 55.5 ng/mL). Finally, variable 
bioavailability, as observed for AT suspension was also reduced when AT was administered 
in form of CH-AT nano-conjugate. Taken together these data demonstrate that chitosan 
conjugate nano-prodrugs may be used as sustained polymeric prodrugs for enhancing 
bioavailability. 
Avadi et al., 2011, performed the ex vivo studies for insulin nanoparticles using chitosan and 
arabic gum. The nanoparticles were prepared by the ion gelation method. Particle size 
distribution, zeta potential, and polydispersity index of the nanoparticles were determined. It 
was found that the nanoparticles carried positive charges and showed a size distribution in the 
range of 170–200 nm. The electrostatic interactions between the positively charged group of 
chitosan and negatively charged groups of Arabic gum play an important role in the 
association efficiency of insulin in nanoparticles. In vitro insulin release studies showed an 
initial burst followed by a slow release of insulin. The muco adhesion of the nanosystem was 
evaluated using excised rat jejunum. Ex vivo studies have shown a significant increase in 
absorption of insulin in the presence of chitosan nanoparticles in comparison with free 
insulin. 
Chi H. Lee et al., 2011, developed the pH-sensitive Eudragit nanoparticles for mucosal drug 
delivery. The biocompatible pH-sensitive nanoparticles composed of Eudragit S-100 (ES) 
were developed to protect loaded compounds from being degraded under the rigorous vaginal 
conditions and achieve their therapeutically effective concentrations in the mucosal 
epithelium. ES nanoparticles containing a model compound (sodium fluorescein (FNa) or nile 
red (NR)) were prepared by the modified quasi-emulsion solvent diffusion method. Loading 
efficiencies were found to be 26% and 71% for a hydrophilic and a hydrophobic compound, 
respectively. Both hydrophilic and hydrophobic model drugs remained stable in nanoparticles 
at acidic pH, whereas they are quickly released from nanoparticles upon exposure at 
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physiological pH. The confocal study revealed that ES nanoparticles were taken up by 
vaginal cells, followed by pH-responsive drug release, with no cytotoxic activities. The pH-
sensitive nanoparticles would be a promising carrier for the vaginal-specific delivery of 
various therapeutic drugs including microbicides and peptides/proteins. 
Qiang Zhang et al., 2011, studied the bioavailability and pharmacokinetics of sorafenib 
suspension, nanoparticles and nanomatrix for oral administration to rat. The formulations 
were optimized by orthogonal design (L9 (34)) and their bioavailability were evaluated in rat 
and compared to pH-sensitive Eudragit nanoparticles and suspension of sorafenib. In the 
formulations, the ratio of sorafenib to Eudragit® S100 was found to be more important 
determinant of the sorafenib bioavailability than the ratio of sorafenib to Sylysia® 350. As 
for the bioavailability, the AUC0–36 h of sorafenib nanomatrix was 13–33 times to that of 
sorafenib suspension, but only 16.8% to 40.8% that of Eudragit® S100 nanoparticles. This 
may be resulted from the different drug dispersion degree, release character and bioadhesion 
activity. However, because all the materials used in the nanomatrix formulation are 
commonly adjuvant, safe, easy to get and cheap, above all, the nanomatrix formulation can 
solve the stability and scaling up problems in the nanoparticles, it had potential to develop 
into a product in the future. 
Javed Ali et al., 2011, developed the nanocarrier for the enhancement of bioavailability of a 
cardiovascular agent: In vitro, pharmacodynamic, pharmacokinetic and stability assessment. 
The goals of the current study were to develop and characterize a nanoemulsion of ezetimibe, 
evaluate its stability, lipid lowering and pharmacokinetic profile. Solubility of the drug was 
estimated in various oils and surfactants. Existence of nanoemulsion region was confirmed by 
plotting phase diagrams. Various thermodynamic stability and dispersibility tests were 
performed on the formulations chosen from phase diagram. Percentage transmittance, 
refractive index, viscosity, droplet size and zeta potential of the optimized formulations were 
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determined. Dialysis bag method was employed to study the release rate. The formulation 
selected for bioavailability estimation contained Capryol 90 (10%, v/v), Crempophor EL 
(11.25%, v/v), Transcutol® P (33.75%, v/v), and double distilled water (45%, v/v). The 
release rate from the nanoemulsion was highly significant (p < 0.001) in contrast to the drug 
suspension. The level of total cholesterol in the group receiving nanoemulsion CF1 was 
found to be highly significant (p < 0.001) in comparison to the group receiving drug 
suspension. Bioavailability studies in rats revealed superior absorption of ezetimibe from 
nanoemulsion as compared to the marketed formulation and drug suspension. The shelf life 
of the nanoemulsion was estimated to be 18.53 months. The present study corroborated 
nanoemulsion to be a promising choice to improve the bioavailability of ezetimibe. 
Xuenong Zhang et al., 2011, studied the pharmacokinetic profile of freeze-dried 
cyclosporine A- Eudragit S100 nanoparticle formulation in dogs. The pharmacokinetic 
profile of freeze-dried cyclosporine A-Eudragit S100 nanoparticles (CyA-S100-NP) was 
studied with a random two-way crossover study in dogs. The drug blood concentration was 
determined by internal standard HPLC method after oral administration of CyA-S100- NP 
and Neoral. Pharmacokinetics parameters were calculated by 3P97 program. The 
concentration-time data were fitted as a two-compartment open model. The AUC of CyA-
S100-NP was higher than that of neoral (P<0.05), while the CL significantly decreased 
(P<0.05). The relative bioavailability of CyA-S100-NP was 135.9% compared with Neoral. 
The bioavailability of CyA was significantly improved. CyA-S100-NP was a potential drug 
for developing a new CyA nanoparticles solid formulation. 
Vijaykumar et al., 2010, developed oral tablet dosage form incorporating drug 
nanoparticles. To enhance oral bioavailability and reduce variability in systemic exposure, 
nanoparticle formulation of these drugs were developed using a wet bead milling technique. 
The solid-state transitions of drug nanoparticles were evaluated before and after milling using 
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differential scanning calorimetry (DSC) and powder X-ray diffraction (XRPD). The 
nanosuspensions were converted into solid intermediate or granules by layering on to a 
water-soluble carrier lactose using a spray granulation processes. The granules were blended 
with excipients for tabletting. The saturation solubility and dissolution characteristics of 
nanoparticle formulations were investigated and compared with commercial tablet 
formulations in a discriminating dissolution media. The result indicated that there was no 
solid-state transition upon milling. A significant enhancement in dissolution rate for tablet 
dosage form incorporating drug nanoparticles was observed compared to the marketed 
products. The manufacturing process used is relatively simple and scalable indicating 
viability of the approach for commercial manufacture of drug product. 
Pieter Annaert et al., 2010, performed the ex vivo permeability experiments in excised rat 
intestinal tissue and in vitro solubility measurements in aspirated human intestinal fluids 
support age-dependent oral drug absorption. The possible influence of advanced age on 
intestinal drug absorption was investigated by determining the effects of aging on (i) 
solubility of model drugs in human intestinal fluids (HIF) obtained from two age groups (18–
25 years; 62–72 years); and (ii) transepithelial permeation of model drugs across intestinal 
tissue excised from young, adult and old rats. Average equilibrium solubility values for 10 
poorly soluble compounds in HIF aspirated from both age groups showed high inter 
individual variability, but did not reveal significant differences. Characterization of the HIF 
from both age groups demonstrated comparable pH profiles, while concentrations of 
individual bile salts showed pronounced variability between individuals, however without 
statistical differences between age groups. Trans epithelial permeation of the transcellular 
probe metoprolol was significantly increased in old rats (38 weeks) compared to the younger 
age groups, while the modulatory role of P-glycoprotein in transepithelial talinolol transport 
was observed in adult and old rats but not in young rats. In conclusion, age-dependent 
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permeability of intestinal tissue (rather than age-dependent luminal drug solubility) may 
contribute to altered intestinal drug absorption in older patients compared to young adults. 
Bivash Mandal et al., 2010, developed sulfacetamide loaded Eudragit L100 nanosuspension 
with potential for ocular delivery. Nanosuspensions were prepared by the solvent 
displacement method using acetone and Pluronic F108 solution. Drug to polymer ratio was 
selected as formulation variable. Characterization of the nanosupension was performed by 
measuring particle size, zeta potential, Fourier Transform infrared spectroscopy (FTIR), 
Differential Scanning Calorimetry (DSC), Powder X-Ray Diffraction (PXRD), drug 
entrapment efficiency and in vitro release. In addition, freeze drying, redispersibility and 
short term stability study at room temperature and at 40°C were performed.  Spherical, 
uniform particles (size range below 500 nm) with positive zeta potential were obtained. No 
significant chemical interaction between drug and polymer were observed in the solid state 
characterization of the freeze dried nanosuspension (FDN). Drug entrapment efficiency of the 
selected batch was increased by pH alteration and addition of polymethyl methacrylate in the 
formulation. The prepared nanosuspension exhibited good stability after storage at room 
temperature and at 40°C. Sucrose and mannitol were used as cryoprotectants and exhibited 
good water redispersibility of the FDN. The results indicate that the formulation of 
sulfacetamide in Eudragit RL100 nanosuspension could be utilized as potential delivery 
system for treating ocular bacterial infections. 
Syam Potnuru et al., 2010, designed biodegradable polymer nanoparticles for oral drug 
delivery of stavudine: in- vitro dissolution studies and characterization. The aim of present 
investigation was to describe formulation and characterization of novel biodegradable 
nanoparticles based on chitosan for encapsulation of Stavudine. To achieve this objective 
solvent evaporation method, in- situ nanoemulsion polymer cross linking method were used. 
Drug containing nanoparticles were prepared with different drug polymer ratio at ambient 
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temperature and freeze dried. The resulting nanoparticles loading efficiency is 55.19% to 
90.60% , loading capacity is 25.16% to 42.27%, particle size of nanoparticles is 65.5-176nm 
and dissolution studies were done by dialysis bag method with ph 7.4 (phosphate buffer)as a 
dissolution medium. It followed zero order release kinetics. 
Mishra et al., 2010, investigated the formulation variables affecting the properties of 
lamotrigine nanosuspension using fractional factorial design. Nanosuspension was prepared 
using emulsification-solvent diffusion method. All the formulations were subjected to in-vitro 
evaluation and the statistically optimized one was used for stability, scanning electron 
microscopic and differential scanning calorimetric studies. Nanoparticles were spherical with 
little surface adsorbed drug. Formulation characteristics in terms of size, zeta potential, 
polydispersity index (PDI), entrapment efficiency (EE), drug content and in vitro drug release 
were consistent and within their acceptable range. All the batches provided a burst release 
profile during first 1 hr, followed by a controlled release extending up to 24 hrs. The values 
of n in Peppas model ranged between 0.2-0.4 for all the formulations indicative of Fickian 
release mechanism. The formulation remained reasonably stable up to 3 months. No 
interaction was observed among the drug and polymers.  Results of in vitro drug release 
studies suggested that nanosuspension might be used as a sustained delivery vehicle for 
LMG. Statistical analysis revealed that size of the nanoparticles was most strongly affected 
by stabilizer type while EE was influenced by the drug-to-polymer ratio. 
Shishu et al., 2010, reported on comparative bioavailability of curcumin, turmeric and 
Biocurcumax in traditional vehicles using non-everted rat intestinal sac model. The 
bioavailability of curcumin from turmeric, Biocurcumax and as plain curcumin was 
investigated using conventional vehicles by a non-everted rat intestinal model. Results of ex 
vivo intestinal permeability studies showed an enhancement in the permeability of curcumin 
with increase in lipophilicity of the vehicle used. Maximum permeability of curcumin was 
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obtained from corn oil (13.4%) followed by clarified butter (9.82%), milk (4.24%) and 
aqueous suspension (1.66%) in 8 h. Another very interesting and important observation was 
that the permeation of curcumin was more from turmeric and Biocurcumax than from plain 
curcumin. These studies strongly suggest that curcumin may be consumed as 
turmeric/Biocurcumax in lipophilic vehicles instead of plain curcumin for maximum 
beneficial effects. 
Swarnali Das et al., 2010, designed Eudragit RL 100 nanoparticles by nanoprecipitation 
method for ocular drug delivery. The particles were prepared by solvent displacement or 
nanoprecipitation method. The non-biodegradable positively charged polymer Eudragit RL 
100 was used to prepare the different formulations with varying ratios of drug and polymer. 
The formulations were evaluated in terms of particle size, zeta potential, and differential 
scanning calorimetry measurements. Drug entrapment and release properties were also 
examined. The antimicrobial activity against Fusarium solani was determined. In vivo eye 
irritation study was carried out by a modified Draize test. All the formulations remained 
within a size range of 130 to 300 nm in fresh preparation as well as after 2 months. The zeta 
potential was positive (+22 to +42 mV) for all the formulations and was suitable for 
ophthalmic application. A prolonged drug release was shown by all the formulations. The 
formulation possesses a good antifungal activity against Fusarium solani when tested by disk 
diffusion method, and no eye irritation on in vivo testing was found. 
Rezaei Mokarram et al., 2010, prepared and evaluated indomethacin nanoparticles. Nano-
solid suspension of indomethacin in polyvinyl pyrrolidine (PVP) was prepared by controlled 
precipitation technique, characterized by differential scanning calorimetry (DSC), X-ray 
diffraction (XRD), Fourier Transform Infrared Spectroscopy (FTIR) and evaluated for in 
vitro solubility and dissolution rate. Absence of thermal and diffractional peaks in DSC and 
XRD studies indicated that indomethacin interacts with PVP in solid phase. The solubility of 
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indomethacin in nano-solid suspension compared to crystalline form was increased to about 
four-fold. It was found that particle size distribution depend to the polymer MW and drug: 
polymer ratios. Spectroscopy methods and Transmission Electron Microscopy (TEM) images 
showed that indomethacin dispersed as amorphous nanosized particles in freeze dried 
powder. Enhanced solubility and dissolution rate of indomethacin compared to physical 
mixtures and crystalline form of indomethacin (polymorph I), demonstrated that it interacts 
with PVP via hydrogen bond and probably forming eutectic mixture. 
Yadav et al., 2009, formulated and evaluated carvedilol loaded Eudragit E 100 nanoparticles. 
Nanoparticles of Carvedilol with Eudragit E 100 were prepared by the nanoprecipitation 
method using polymeric stabilizer poloxamer 407. Nanoparticles of Carvedilol were obtained 
with high encapsulation efficiency. The particles were characterized for particle size by 
photon correlation spectroscopy and transmission electron microscopy. The in vitro release 
studies were carried out by USP type II apparatus in SGF without enzyme (pH 1.2).The 
particle size of the prepared nanoparticles ranged from 190 nm – 270 nm. Nanoparticles of 
Carvedilol were obtained with high encapsulation efficiency (85-91%). The drug release from 
the carvedilol nanoparticles showed within 5 minutes. These studies suggest that the 
feasibility of formulating carvedilol – loaded Eudragit E 100 nanoparticles for the treatment 
of hypertension. 
Giuseppe Trapani et al., 2009, developed and characterized new nanoparticle systems based 
on Eudragit RS 100 and cyclodextrins (CDs) for the transmucosal administration of 
glutathione (GSH). For this purpose, nanoparticles (NPs) with the mucoadhesive properties 
of Eudragit RS 100 and the penetration enhancing and peptide protective properties of CDs 
were prepared and evaluated. The quasi-emulsion solvent diffusion technique was used to 
prepare the NPs with natural and chemically modified (HP-b-CD and Me-b-CD) CDs. The 
NPs prepared showed homogeneous size distribution, mean diameters between 99 and         
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156 nm, a positive net charge and spherical morphology. Solid state FT-IR, thermal analysis 
(DSC), and X-ray diffraction studies suggest that the nanoencapsulation process produces a 
marked decrease in crystallinity of GSH. The encapsulation efficiency of the peptide was 
found to be between 14.8% and 24%. The results indicate that mean diameters, surface 
charges and drug-loaded NPs were not markedly affected by the CD, whereas the presence of 
the latter influences drug release and to some extent peptide stability and absorption. Finally, 
it has been shown that CD/Eudragit RS 100 NPs may be used for transmucosal absorption of 
GSH without any cytotoxicity using the epithelial human HaCaT and murine monocytes 
macrophage RAW264.7 cell lines. 
Singh et al., 2009, developed the Poly (d, l-lactide) nanosuspensions of risperidone for 
parenteral delivery: Formulation and In-Vitro Evaluation. Polymeric nanoparticles 
suspensions containing risperidone made of poly (D, Lactide) were designed by 
nanoprecipitation method using polymeric stabilizer (Pluronic® F-68 or Pluronic® F-127). 
The prepared nanosuspensions were characterized for particle size by photon correlation 
spectroscopy and scanning electron microscopy. The free dissolved drug in the 
nanosuspension was determined by bulk equilibrium reverse dialysis bag technique. In vitro 
release studies were carried out using dialysis bag diffusion technique. The particle size of 
the prepared nanoparticles in the nanosuspensions ranged between 78-184 nm. Nanoparticles 
of risperidone in the nanosuspensions were obtained with high encapsulation efficiency (91 - 
94 %). The drug release from the risperidone nanosuspension was sustained in some batches 
for more than 24 h with 75% drug release whereas release from risperidone solution showed 
release within 1.5 h. The release pattern of drug is analyzed and found to follow first order 
equation and Fickian diffusion kinetics. These studies suggest the feasibility of formulating 
risperidone loaded poly(D, L-Lactide) nanoparticles suspension for the treatment of psychotic 
disorders. 
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Jawahar et al., 2009, developed and characterized PLGA-nanoparticles containing 
carvedilol. Prepared nanoparticles were examined for physicochemical characteristics,          
in vitro release kinetics and invivo biodistribution studies. Average size of the nanoparticles 
were in range of 132-234nm. The drug encapsulation efficiency was 77.6% at 33% drug 
loading. In vitro cumulative release from the nanoparticles was 72% at 24hr. In vivo 
biodistribution studies in rats revealed that these particles are distributed in heart, liver and 
kidney at higher concentration may allow their delivery to target sites. 
Manish K Gupta et al., 2009, developed the nanoparticulate drug delivery system of 
cyclosporine .Cyclosporine (CYA) loaded Eudragit RL100 nanoparticles were prepared using 
solvent evaporation technique, with 2% PVA as stabilizer. Four batches of nanoparticles with 
varying drug concentrations (CYN-1, CYN-2, CYN-3 and CYN-4) were prepared. 
Cumulative % drug release of formulations CYN-1, CYN-2, CYN-3 and CYN-4 was 
94.35%, 93.89%, 88.28% and 85.36% respectively. Formulation CYN-2, which proved to be 
the best showed a mean particle size of 236 nm and entrapment efficiency of 58.27%. The in 
vivo result of formulation CYN-2 revealed that the drug loaded nanoparticles showed 
preferential drug targeting to liver followed by spleen, lungs and kidneys. Stability studies 
showed that maximum drug content and closest in vitro release to initial data was found in 
the sample (formulation CYN-2) stored at 4ºC. So, in the present study Cyclosporine loaded 
Eudragit Nanoparticles were prepared and targeted to various organs to a satisfactory level 
and the prepared nanoparticles were stable at 4ºC. 
Adlin et al., 2009, formulated and evaluated the nanoparticles containing Flutamide. 
Nanoparticles of Flutamide were formulated using chitosan polymer by ionic gelation 
technique. Nanoparticles of different core: coat ratio were formulated and analyzed for total 
drug content, loading efficiency, particle size and in vitro drug release studies. From the drug 
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release studies it was observed that nanoparticles prepared with chitosan in the core: coat 
ratio 1:4 gives better sustained release for about 12 hrs as compared to other formulations. 
Le Thi Mai Hoa et al., 2009, formulated the polymeric drug nanoparticles by emulsion 
solvent evaporation method. In this study, prepared polymeric drug nanoparticles consist of 
ketoprofen and Eudragit E 100. The morphological structure was investigated by scanning 
electron microscopy (SEM). The interactions between the drug and polymer were 
investigated by Fourier transform infrared spectroscopy (FTIR). The size distribution was 
measured by means of Dynamic Light Scattering. The nanoparticles have an average size of 
about 150 nm. The incorporation ability of drugs in the polymeric nanoparticles depended on 
the integration between polymer and drug as well as the glass transition temperature of the 
polymer. 
Gershon Golomb et al., 2009, developed the new double emulsion solvent diffusion 
technique for encapsulating hydrophilic molecules in PLGA nanoparticles. The new NP 
preparation technique, double emulsion solvent diffusion (DES-D), resulted in improved 
formulation characteristics including smaller size, lower size distribution, higher 
encapsulation yield, and more biocompatible ingredients in comparison to classical methods. 
The utilization of partially water-miscible organic solvent (ethyl acetate) enabled rapid 
diffusion through the aqueous phase forming smaller NP. In addition, the formulated 
alendronate NP exhibited profound inhibition of raw 264 macrophages, depletion of rabbit's 
circulating monocytes, and inhibition of restenosis in the rat model. It is concluded that the 
new technique is advantageous in terms of smaller size, lower size distribution, higher 
encapsulation yield, and more biocompatible ingredients, with unaltered bioactivity. 
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Sanjay Singh et al., 2009, developed the PLGA nanoparticle formulations of risperidone: 
preparation and neuropharmacological evaluation. PLGA nanoparticles of risperidone were 
designed by nanoprecipitation method using polymeric stabilizer (Poloxamer 407). The 
prepared nanoparticles were characterized for particle size by photon correlation 
spectroscopy and atomic force microscopy. Poloxamer 407–based in situ gel containing 
PLGA nanoparticles of risperidone was prepared by modified cold method to control the 
initial rapid release from the nanoparticles. The in vivo efficacy (antipsychotic effect) of 
prepared formulations (nanoparticles and in situ gel containing nanoparticles) was studied by 
administering them subcutaneously to mice. Extra pyramidal side effects of the formulations 
were also studied. The particle size of the prepared nanoparticles ranged between 85 and 219 
nm. About 89% to 95% drug encapsulation efficiency was achieved when risperidone was 
loaded at 1.7% to 8.3% by weight of the polymer. During in vivo studies prepared risperidone 
formulations showed an antipsychotic effect that was significantly prolonged over that of 
risperidone solution for up to 72 hours with fewer extra pyramidal side effects. The 
prolonged effect of risperidone was obtained from the risperidone formulations administered 
subcutaneously, and this may improve the treatment of psychotic disorders by dose reduction. 
Mohammad Reza Siahi Shadbad et al., 2008, studied the kinetic analysis of drug release 
from nanoparticles. Ten conventional models and three models developed in our laboratory 
were applied to release data of 32 drugs from 106 nanoparticle formulations collected from 
literature. The accuracy of the models was assessed employing mean percent error (E) of 
each data set, overall mean percent error (OE) and number of Es less than 10 percent. Among 
the models the novel reciprocal powered time (RPT), Weibull (W) and log- probability (LP) 
ones produced OE values of 6.47, 6.39 and 6.77, respectively. The OEs of other models were 
higher than 10%. Also the number of errors less than 10% for the models was 84.9, 80.2 and 
78.3 percents of total number of data sets. Considering the accuracy criteria the reciprocal 
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powered time model could be suggested as a general model for analysis of multi mechanistic 
drug release from nanoparticles. Also W and LP models were the closest to the suggested 
model.  
Weigen Lu et al., 2008, reported on preparation and characterization of intravenously 
injectable nimodipine nanosuspension which was prepared by high-pressure homogenization 
(HPH). The effects of the production parameters such as pressure, cycle numbers and 
crushing principles on the mean particle size, 99% diameter and polydispersity of the 
nanosuspension were investigated. Characterization of the product was performed by 
scanning electron microscope (SEM) and differential scanning calorimeter (DSC). The safety 
of the nimodipine nanosuspension was discussed with special attention to contamination by 
microparticles and the increase in saturation solubility Cs. Irritability study in rabbits showed 
that this formulation provided less local irritation and phlebitis risks than the commercial 
ethanol product, which represented a promising new drug formulation for intravenous therapy 
of subarachnoid hemorrhage (SAH)-related vasospasm. 
Christine Vauthier et al., 2007, studied the influence of polymer behaviour in organic 
solution on the production of polylactide nanoparticles by nanoprecipitation. Poly(d,l)-
lactides (PLAs) from a homologous series of different molar masses were nanoprecipitated at 
different initial polymer concentrations from two organic solvents, acetone and 
tetrahydrofuran (THF), into water without surfactant according to a standardized procedure. 
Quasi-elastic light scattering and gel permeation chromatography with universal detection 
were used respectively to size the particles and to determine the molar mass distribution of 
the polymeric chains forming both nanoparticles and bulk aggregates. The intrinsic viscosity 
of the polymers as a function of molar mass and solvent were determined by kinematic 
viscosity measurements in organic solutions. High yields of small nanoparticles were 
obtained with polymers of lower molar mass (22 600 and 32 100 g/mol). For a given polymer 
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concentration in organic solution, the particle diameter was always lower from acetone than 
from THF. For initial molar masses higher than 32 100 g/mol, only dilute organic solutions 
gave significant yields of nanoparticles. Furthermore, polymer mass fractionation occurred 
with increasing initial molar mass and/or concentration: the nanoparticles were formed by 
polymeric chains of molar masses significantly lower than the average initial one. In general, 
nanoparticle production was satisfactory when the initial organic solution of polymer was in 
the dilute rather than the semi-dilute regime. Moreover, acetone, which acted as a theta 
solvent for PLA, always led to smaller particles and better yields than THF. 
Bernadette D’Souza et al., 2007, performed everted gut sac technique an ex vivo screening 
method for new drugs. The ex vivo everted sac technique is useful for screening the 
permeability parameter of drug substances associated with their in vivo absorbability. In this 
method, the intestinal sac is everted to expose the mucosal surface. It is then incubated in 
mucosal fluids and oxygenated to keep the tissue viable. The drug to be tested is then 
introduced into mucosal fluid and absorption mechanism is studied and compared. The 
transport of the drug across the mucosal membrane into the serosal (absorption) as well as the 
movement of drug from the serosal to the mucosal side (secretion) can be studied. Reasons 
for poor oral bioavailability of drugs can be assessed and appropriate modifications made. 
The everted gut sac permeability screening, when coupled with dissolution studies, allows for 
systematic evaluation of the potential absorbability of a drug in its initial stages of 
development. 
Ravi Kumar et al., 2007, developed the estradiol loaded PLGA nanoparticles for oral 
administration: Effect of polymer molecular weight and copolymer composition on release 
behavior in vitro and in vivo. Nanoparticles were prepared by emulsion–diffusion–
evaporation method employing didodecyl dimethyl ammonium bromide (DMAB) as 
stabilizer. The effect of polymer molecular weight and copolymer composition on particle 
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properties and release behavior (in vitro and in vivo) has been reported. Drug release in vitro 
decreased with increase in molecular weight and lactide content of PLGA. Zero order release 
was obtained with low molecular weight (14,500 and 45,000 Da) PLGA, while high 
molecular weight (85,000 and 213,000 Da) and different copolymer compositions followed 
square root of time (Higuchi's pattern) dependent release. The bioavailability of estradiol 
from nanoparticles was assessed in male Sprague Dawley (SD) rats at a dose of 1 mg 
estradiol/rat. The in vivo performance of the nanoparticles was found to be dependent on the 
particle size, polymer molecular weight and copolymer composition. The Cmax of drug in 
the plasma was dependent on the polymer molecular weight and composition while particle 
size was found to influence the duration of release, suggesting smaller is better. The 
histopathological examination revealed absence of any inflammatory response with the 
formulations prepared of low/high molecular weight or high lactide content polymers for the 
studied period. Together, these results indicate that nanoparticulate formulations are ideal 
carriers for oral administration of estradiol having great potential to address the dose related 
issues of estradiol. 
Annick Ludwig et al., 2006, studied on the evaluation of ciprofloxacin-loaded Eudragit® 
RS100 or RL100/PLGA nanoparticles. The particles were prepared by water-in-oil-in-water 
(w/o/w) emulsification and solvent evaporation, followed by high-pressure homogenization. 
Two non-biodegradable positively charged polymers, Eudragit® RS100 and RL100, and the 
biodegradable polymer poly (lactic-co-glycolic acid) or PLGA were used alone or in 
combination, with varying ratios. The formulations were evaluated in terms of particle size 
and zeta potential. Differential scanning calorimetry measurements were carried out on the 
nanoparticles and on the pure polymers Eudragit® and PLGA. Drug loading and release 
properties of the nanoparticles were examined. The antimicrobial activity against 
Pseudomonas aeruginosa and Staphylococcus aureus was determined. During solvent 
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evaporation, the size and zeta potential of the nanoparticles did not change significantly. The 
mean diameter was dependent on the presence of Eudragit® and on the viscosity of the 
organic phase. The zeta potential of all Eudragit® containing nanoparticles was positive in 
ultrapure water (around +21/+25 mV). No burst effect but a prolonged drug release was 
observed from all formulations. The particles activity against P. aeruginosa and S. aureus was 
comparable with an equally concentrated ciprofloxacin solution. 
Ronald J. Neufeld et al., 2006, studied the nanoencapsulation methods for preparation of 
drug-loaded polymeric nanoparticles. Polymeric nanoparticles have been extensively studied 
as particulate carriers in the pharmaceutical and medical fields, because they show promise as 
drug delivery systems as a result of their controlled- and sustained-release properties, sub 
cellular size, and biocompatibility with tissue and cells. Several methods to prepare 
nanoparticles have been developed during the last two decades, classified according to 
whether the particle formation involves a polymerization reaction or arises from a 
macromolecule or preformed polymer. In this review the most important preparation methods 
are described, especially those that make use of natural polymers. Advantages and 
disadvantages will be presented so as to facilitate selection of an appropriate 
nanoencapsulation method according to a particular application. 
Ugo Bilati et al., 2005, investigated on formulation and process modifications to improve the 
versatility of the nanoprecipitation technique, particularly with respect to the encapsulation of 
hydrophilic drugs (e.g. proteins). More specifically, the principal objective was to explore the 
influence of such modifications on nanoparticle size. Selected parameters of the 
nanoprecipitation method, such as the solvent and the non-solvent nature, the solvent/non-
solvent volume ratio and the polymer concentration, were varied so as to obtain polymeric 
nano-carriers. The feasibility of such a modified method was assessed and resulting unloaded 
nanoparticles were characterized with respect to their size and shape. It was shown that the 
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mean particle size was closely dependent on the type of non-solvent selected. When alcohols 
were used, the final mean size increased in the sequence: methanol < ethanol < propanol. 
Surfactants added to the dispersing medium were usually unnecessary for final suspension 
stabilization. Changing the solvent/non-solvent volume ratio was also not a determinant 
factor for nanoparticle formation and their final characteristics, provided that the final 
mixture itself did not become a solvent for the polymer. A too high polymer concentration in 
the solvent, however, prevented nanoparticle formation. Both poly (lactic acid) (PLA) and 
poly (DL lactic-co-glycolic acid) (PLGA) could be used by accurately choosing the polymer 
solvent and in this respect, some non-toxic solvents with different dielectric constants were 
selected. The nanoparticles obtained ranged from about 85–560 nm in size. The nanoparticle 
recovery step however needs further improvements, since bridges between particles which 
cause flocculation could be observed. Finally, the presented results demonstrate that the 
nanoprecipitation technique is more versatile and flexible than previously thought and that a 
wide range of parameters can be modified. 
Ubrich et al., 2005, evaluated the cyclosporin-loaded Eudragit RS or RL nanoparticles in 
rabbits orally. The hydrophobic cyclic undecapeptide cyclosporin A (CyA) used in the 
prevention of graft rejection and in the treatment of autoimmune diseases was encapsulated 
by nanoprecipitation within non-biodegradable polymeric nanoparticles. The effect of 
polymers (Eudragit® RS or RL) and additives within the alcoholic phase (fatty acid esters 
and polyoxyethylated castor oil) on the size, zeta potential and the encapsulation efficiency of 
the nanoparticles was investigated. The mean diameter of the various CyA nanoparticles 
ranged from 170 to 310 nm. The size as well as the zeta potential increased by adding fatty 
acid ester and polyoxy ethylated castor oil within the organic phase. No significant 
differences in surface potential were observed for all formulations tested. Probably due to the 
very low water solubility of the drug, high encapsulation efficiencies were observed in a 
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range from 70 to 85%. The oral absorption of CyA from these polymeric nanoparticles was 
studied in rabbits and compared to that of Neoral® capsule. Based on comparison of the area 
under the blood concentration–time curve values, the relative bioavailability of CyA from 
each nanoparticulate formulation ranged from 20 to 35%. 
Harivardhan Reddy et al., 2005, developed the etoposide-loaded nanoparticles made from 
glyceride lipids: characterization, in vitro drug release, and stability evaluation. The 
nanoparticles were prepared by melt emulsification and homogenization followed by spray 
drying of nano dispersion. Spray drying created powder nanoparticles with excellent 
redispersibility and a minimal increase in particle size (20-40 nm). Experimental variables, 
such as homogenization pressure, number of homogenization cycles, and surfactant 
concentration, showed a profound influence on the particle size and distribution. Spray drying 
of Poloxamer 407-stabilized nanodispersions lead to the formation of matrix-like structures 
surrounding the nanoparticles, resulting in particle growth. The in vitro steric stability test 
revealed that the lipid nanoparticles stabilized by sodium tauro glycocholate exhibit excellent 
steric stability compared with Poloxamer 407. All 3 glyceride nanoparticle formulations 
exhibited sustained release characteristics, and the release pattern followed the Higuchi 
equation. The spray-dried lipid nanoparticles stored in black polypropylene containers 
exhibited excellent long-term stability at 25ºC and room light conditions. Such stable lipid 
nanoparticles with in vitro steric stability can be a beneficial delivery system for intravenous 
administration as long circulating carriers for controlled and targeted drug delivery. 
Qiang Zhang et al., 2004, developed the pH-sensitive nanoparticles for improving the oral 
bioavailability of cyclosporine A. The CyA-pH sensitive nanoparticles were prepared by 
using poly (methacrylic acid and methacrylate) copolymer. The characterization and the 
dispersion state of CyA at the surface or inside the polymeric matrices of the nanoparticles 
were investigated. The in vitro release studies were conducted by ultracentrifuge method. The 
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bioavailability of CyA from nanoparticles and neural micro emulsion was assessed in 
Sprague–Dawley (SD) rats at a dose of 15 mg/kg. The particle size of the nanoparticles was 
within the range from 37.4 ± 5.6 to 106.7 ± 14.8 nm. The drug entrapment efficiency was 
very high (from 90.9 to 99.9%) and in all cases the drug was amorphous or molecularly 
dispersed within the nanoparticles polymeric matrices. In vitro release experiments revealed 
that the nanoparticles exhibited perfect pH-dependant release profiles. The relative 
bioavailability of CyA was markedly increased by 32.5% for CyA-S100 nanoparticles          
(P < 0.05), and by 15.2% and 13.6% for CyA-L100-55 and CyA-L100 nanoparticles 
respectively, while it was decreased by 5.2% from CyA-E100 nanoparticles when compared 
with the neoral microemulsion. With these results, the potential of pH-sensitive nanoparticles 
for the oral delivery of CyA was confirmed. 
Karen I. Winey et al., 2004, developed an emulsion-solvent evaporation method for 
producing haloperidol loaded PLGA nanoparticles with up to 2 % (wt/wt. of polymer) drug 
content, in-vitro release duration of over 13 days and less than 20% burst release. The free 
haloperidol is removed from the nanoparticle suspension using a novel solid phase extraction 
technique. This leads to a more accurate determination of drug incorporation efficiency than 
the typical washing methods. We have discovered that PLGA end groups have a strong 
influence on haloperidol incorporation efficiency and its release from PLGA nanoparticles. 
The hydroxyl terminated PLGA (uncapped) nanoparticles have a drug incorporation 
efficiency of more than 30% as compared to only 10% with methyl terminated PLGA 
(capped) nanoparticles. The in-vitro release profile of nanoparticles with uncapped PLGA has 
a longer release period and a lower initial burst as compared to capped PLGA. By varying 
other processing and materials parameters, we also controlled the size, haloperidol 
incorporation and haloperidol release of our haloperidol loaded PLGA nanoparticles. 
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Francesco Castelli et al., 2003, developed the eudragit as controlled release system for anti-
inflammatory drugs. Nanosuspensions were prepared by a modification of the quasi-emulsion 
solvent diffusion technique (QESD), a particular approach to the general solvent-change 
method. This kind of system was planned for the ophthalmic release of non-steroidal anti-
inflammatory drugs in ocular diseases associated with inflammatory processes (i.e. post-
cataract surgery or uveitis). The drug release was monitored by differential scanning 
calorimetry (DSC), following the effects exerted by IBU on the thermotropic behaviour of 
DMPC multilamellar vesicles. IBU affects the main transition temperature (Tm) of 
phospholipid vesicles, causing a shift towards lower values, driven by the drug fraction 
entering the lipid bilayer. The obtained values have been used as a calibration curve. DSC 
was performed on suspensions of blank liposomes added to fixed amounts of unloaded and 
IBU-loaded Eudragit RS100® and RL100® nanosuspensions as well as to powdered free 
drug. The Tm shifts caused by the drug released from the polymer system or by the free drug, 
during incubation cycles at 37 ◦C, were compared to the calibration curve in order to obtain 
the fraction of drug released. The results were also compared with in vitro dialysis release 
experiments. The suitability of the two different techniques to follow the drug release as well 
as the differences between the RL and RS polymer systems was compared, confirming the 
efficacy of DSC for studying the release from polymer nanoparticulate systems.  
Amarnath Maitra et al., 2003, studied the Cross-linked polyvinylpyrrolidone nanoparticles: 
a potential carrier for hydrophilic drugs. Injectable hydrogel polymeric nanoparticles of 
polyvinylpyrrolidone cross-linked with N, N- methylene bis-acrylamide and encapsulating 
water-soluble macromolecules such as FITC–dextran (FITC–Dx) have been prepared in the 
aqueous cores of reverse micellar droplets. These particles are 100 nm and below in diameter 
with a narrow size distribution. When dispersed in aqueous buffer these particles appear to be 
transparent and give an optically clear solution. Lyophilized powder of these nanoparticles is 
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redispersable in aqueous buffer without any change in the size and morphology of the 
particles. The efficiency of FITC–Dx entrapment by these nanoparticles is high (> 70%) and 
depends on the amount of cross-linking agent present in the polymeric material. The release 
of the entrapped molecules from these nanoparticles depends on the degree of cross-linking 
of the polymer, particle size, pH of the medium, and extent of loading, as well as 
temperature. 
Ken-ichi nezasa et al., 2002, studied on liver-specific distribution of rosuvastatin in rats: The 
liver is the target organ for the lipid-regulating effect of rosuvastatin; therefore liver-selective 
uptake of this drug is a desirable property. The aim of this study was to investigate, and 
compare with pravastatin and simvastatin, the tissue specific distribution of rosuvastatin. 
Bolus intravenous doses (5 mg/kg) of radiolabeled rosuvastatin, pravastatin, and Simvastatin 
were administered to rats, and initial uptake clearance (CLuptake) in various tissues was 
calculated. Hepatic CLuptake of rosuvastatin (0.885 ml/min/g tissue) was significantly (p < 
0.001) larger than that of pravastatin (0.703 ml/min/g tissue), and rosuvastatin was taken up 
by the hepatic cells more selectively and efficiently than pravastatin. Hepatic CLuptake of 
simvastatin (1.24 ml/min/g tissue) was significantly larger than that of rosuvastatin (p < 0.01) 
and pravastatin (p < 0.001). However, adrenal CLuptake of simvastatin (1.55 ml/min/g tissue) 
was larger than hepatic CLuptake, and Simvastatin was distributed to other tissues more 
easily than rosuvastatin. Microautoradiography of the liver, spleen, and adrenal was 
undertaken 5 min after administration of the study drugs; distribution was quantified by 
counting the number of silver grains. After administration of rosuvastatin and pravastatin, 
silver grains were distributed selectively in the intracellular space of the liver, but more 
rosuvastatin (3.3- 1.0 - 105 particles/mm2) than pravastatin (2.0 - 0.3 - 105 particles/mm2) 
tended to distribute to the liver. Simvastatin was less liver-specific (it also distributed to the 
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spleen and adrenal). The results of this study indicated that rosuvastatin was taken up by 
hepatic cells more selectively and more efficiently than pravastatin and simvastatin. 
Kristl et al., 2002, Investigated the polymeric nanoparticles as carriers of enalaprilat for oral 
administration. Nanoparticle dispersions were prepared by the emulsification–diffusion 
method and characterized according to particle size, zeta potential, entrapment efficiency and 
physical stability. Effective permeabilities through rat jejunum of enalaprilat in solution and 
in enalaprilat-loaded nanoparticles were compared using side-by-side diffusion chambers. 
The solubility of enalaprilat is very low in many acceptable organic solvents, but in benzyl 
alcohol is sufficient to enable the production of nanoparticles by the emulsification–diffusion 
process. The diameters of drug-loaded PMMA and PLGA nanoparticles were 297 and 204 
nm, respectively. The concentration of the stabilizer polyvinyl alcohol (PVA) in dispersion 
had an influence on particle size but not on drug entrapment. The type of polymer had a 
decisive influence on drug content- 7 and 13% for PMMA and PLGA nanoparticles, 
respectively. In vitro release studies show a biphasic release of enalaprilat from nanoparticle 
dispersions—fast in the first step and very slow in the second. The apparent permeability 
coefficient across rat jejunum of enalaprilat entrapped in PLGA nanoparticles is not 
significantly improved compared with enalaprilat in solution. 
Snjezana Stolnik  et al., 1999, formulated the PLGA nanoparticles by nanoprecipitation 
method: Approaches investigated for drug incorporation efficiency enhancement included the 
influence of aqueous phase pH, replacement of procaine hydrochloride with procaine 
dihydrate and the inclusion of excipients: poly (DL-lactide) (PLA) oligomers, poly(methyl 
methacrylate-co-methacrylic acid) (PMMA–MA) or fatty acids into the formulation. The 
nanoparticles produced were submicron size (210 nm) and of low polydispersity. It was 
found that an aqueous phase pH of 9.3, replacement of procaine hydrochloride with procaine 
dihydrate and the incorporation of PMMA–MA, lauric and caprylic acid into the formulation 
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could enhance drug incorporation efficiency without the size, morphology and nanoparticle 
recovery being adversely influenced. For instance changing the aqueous phase pH from 5.8 to 
9.3 increased nanoparticle recovery from 65.1 to 93.4%, drug content from 0.3 to 1.3% w/w 
and drug entrapment from 11.0 to 58.2%. However, the presence of high ratios of lauric acid 
and procaine dihydrate in the formulation adversely affected the morphology and size of the 
nanoparticles. Also, PLA oligomers were not considered a feasible approach since it 
decreased drug entrapment from 11.0 to 8.4% and nanoparticle recovery from 65.1 to 19.6%. 
Drug release from nanoparticles appears to consist of two components with an initial rapid 
release followed by a slower exponential stage. This study has demonstrated that formulation 
variables can be exploited in order to enhance the incorporation of a water soluble drug into 
PLGA nanoparticles by the nanoprecipitation technique. 
Philippe Maincent et al., 1997, reported on preparation and characterization of nanoparticles 
containing an antihypertensive agent.PCL nanoparticles were larger than nanoparticles 
prepared with the other polymers. The zeta potential of the nanoparticles was negative, with 
values of about -25 mV which promoted good stabilization of the particles. The amorphous 
state of PLA and PLAGA non-loaded nanoparticles and the semi-crystalline state of PCL 
were demonstrated with X-ray diffraction and differential scanning calorimetry. For all 
nanoparticles, isradipine was found to be totally amorphous in the polymer which suggested 
that the drug was molecularly dispersed in the matrix. The colloidal suspensions displayed a 
sustained release profile in comparison with the drug release profile of isradipine in a PEG 
solution. Results from this investigation suggest that these nanospheres will be a good 
candidate delivery system for oral administration, to reduce the initial hypotensive peak and 
to prolong the antihypertensive effect of the drug. 
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Quaroni et al., 1996, developed the intestinal cell culture models for drug transport and 
metabolism studies. From a drug discovery perspective, cell culture models can be used to 
expedite identification of compounds with favorable pharmacokinetic properties, and to 
evaluate structure-absorption/metabolism relationships. In this review, we will use the 
intestinal epithelium as an example for discussing issues associated with the development of 
new cell culture models for evaluating drug metabolism. Specifically, we will discuss 
biological properties of the intestinal epithelium and address biological and practical 
consideration in the application of tumor cell lines, short-term primary cultures, and stem-like 
cell cultures. And oncogene immortalized cells as approaches to establishing models for the 
intestinal epithelium. 
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CHAPTER-IV 
SCOPE OF WORK 
 The aim of this study is to formulate and evaluate oral nanoparticulate drug delivery 
of rosuvastatin calcium used in the treatment of hypercholesterolemia. 
 Management of hypercholesterolemia continues to be challenging with the currently 
available drugs due to poor bioavailability by the oral route and due to toxicity which occur at 
higher doses. Since, the preferred route of oral administration is limited to those drug 
molecules due to its poor solubility and/or poor permeability across the gastric mucosa. A 
large majority of the new chemical entities (NCE) and many existing drug molecules are 
poorly soluble and/or poorly permeable, thereby limiting their potential uses and increasing 
the difficulty of formulating bioavailable drug products. These limitations necessitate urgent 
requirement of novel drug delivery which do not suffer from such problems. 
 Rosuvastatin calcium is a potent inhibitor of HMG CoA reductase, which is widely 
used in the treatment of hypercholesterolemia and may decrease the relative risk of heart 
attack and stroke. Currently this drug is administered orally as tablets. Since the drug is 
sparingly soluble and poorly permeable (partition coefficient (octanol/water) – 0.13 at        
pH 7.0) across the gastric mucosa, the drug displays oral bioavailability                           
(absolute bioavailability-20%) problems in conventional dosage forms. Reported side effects 
are myopathy, rhabdomyolysis which occur at higher doses. Thus it could be a promising 
candidate in nanoparticulate drug delivery taking into accounts its poor solubility and poor 
permeability.   
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Nanoparticulate drug delivery systems appear to be promising for improving 
bioavailability of drugs. These nanoparticulate systems are a type of colloidal drug delivery 
systems where the particle size varies from 10nm – 1000 nm in diameter. Nanoparticles have 
important potential application for the administration of therapeutic, diagnostic agents and 
represent very promising drug delivery system of controlled and targeted drug release. 
Though a wide range of polymers are being used for the development of nanoparticles, the 
present study included Eudragit L-100 and Eudragit S-100 as polymers and Pluronic F68 and 
PVA as stabilizers.  
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CHAPTER- V 
PLAN OF WORK 
 
PART –I 
STANDARD CURVES FOR ROSUVASTATIN CALCIUM 
• Preparation of calibration medium. 
• Estimation of absorption maximum (λmax). 
• Preparation of standard curves for rosuvastatin calcium in distilled water, 
hydrochloric acid buffer pH 1.2, phosphate buffer pH 6.8 and phosphate buffer saline 
pH 7.4. 
PART-II 
•  Drug- polymer interaction studies using Fourier Transform- Infra Red spectroscopy 
(FT-IR) and Differential Scanning Caloimetry (DSC). 
PART-III 
• Formulation of rosuvastatin calcium loaded polymeric nanoparticles using different 
polymers (Eudragit L100 and Eudragit S100) at different ratios and different 
stabilizers (Pluronic F68 and PVA) at different concentrations by nanoprecipitation 
method. 
PART-IV 
CHARACTERIZATION OF ROSUVASTATIN CALCIUM LOADED POLYMERIC 
NANOPARTICLES 
• Determination of particle size and polydispersity index using Malvern particle size 
analyzer.  
• Determination of zeta potential. 
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• Determination of drug content. 
• Determination of drug entrapment efficiency by centrifugation method. 
• Invitro release studies of rosuvastatin calcium loaded polymeric nanoparticle 
formulations using dialysis membrane. 
• Kinetics of drug release. 
PART-V 
• Selection of best formulation. 
PART-VI 
EVALUATION OF SELECTED BEST FORMULATION 
• Solubility studies. 
• Ex vivo intestinal permeability studies using Albino rats. 
• Morphological studies of rosuvastatin calcium loaded polymeric nanoparticles by 
using Transmission electron microscopy (TEM). 
• Stability studies. 
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CHAPTER-VI 
MATERIALS AND EQUIPMENTS 
MATERIALS USED 
1. Rosuvastatin calcium              - Gift sample from Safe tab Life Science,  
                                                                     Pondicherry. 
2. Eudragit L100               - Gift sample from Orchid                                
                                                                     Pharmaceuticals, Chennai. 
3. Eudragit S100                                     - Gift sample from Orchid                                                     
                                                              Pharmaceuticals, Chennai. 
4. Pluronic F68                                      - Gift sample from Orchid                                                     
                                                              Pharmaceuticals, Chennai. 
5. PVA                                       - Gift sample from Orchid                                                     
                                                              Pharmaceuticals, Chennai. 
6.   Methanol                                             - Changshu Yangyuah chemicals, 
                                                                              China. 
7.   Acetone                                              -  High purity laboratory chemicals, 
                                                                               Mumbai. 
8. Potassium dihydrogen phosphate - High purity laboratory chemicals,                  
                                                                              Mumbai. 
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9.   Disodium hydrogen phosphate - Nice chemicals Pvt Ltd, 
                                                                              Kerala. 
10.  Sodium chloride   - Central Drug House (P) Ltd, New Delhi.    
       11. Hydrochloric acid   - Universal Scientifics, Madurai. 
 
       12. Sodium hydroxide   - Universal Scientifics, Madurai. 
 
       13. Dialysis membrane 50 – LA 387       -           Himedia Lab, Mumbai.   
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EQUIPMENTS USED 
1. Electronic weighing balance  - A & D Company, Japan. 
2. UV-Visible spectrophotometer - Shimadzu Corporation, Japan. 
3. FT-IR     - Shimadzu, Japan. 
4. Differential Scanning Calorimetry     -            DSC Q 200, Mumbai. 
5. Homogenizer               -           M.S.E Ltd, England. 
6. Refrigerator                                        - Kelvinator, India. 
7. Cooling Centrifuge Apparatus           -  Eppendorf Centrifuge 5417R, Germany. 
8. Transmission electron microscope - Hitachi, Japan. 
9. Particle size analyzer   - Malvern, U.K. 
10. Environmental chamber  - Inlab equipments (Madras) Pvt. Ltd. 
11. Rotary shaker    - Secor, India. 
 
 
 
 
 
 
 
 
 
 
 
  
STRUCTURAL FORMULA
 
SYNONYMS 
• Rosuvastatin calcium  
• ZD-4522  
EMPIRICAL FORMULA 
 
• C22H28FN3O6S 
 
 
CHEMICAL NAME 
 
• (3R,5R,6E)-7-[4-(4-fluo
pyrimidin-5-yl]-3, 5-dih
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CHAPTER-VII 
DRUG PROFILE 
ROSUVASTATIN CALCIUM 
 
 
 
rophenyl)-2-(N-methylmethanesulfonamido)
ydroxyhept-6-enoic acid. 
-6-(propan-2-yl) 
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DESCRIPTION 
• Nature     : White crystalline powder 
• Molecular weight    : 1001.14 
• Solubility     : Sparingly soluble in water 
• partition coefficient (octanol/water)  :  0.13 at pH 7.0  
• pKa      : 14.65 
 
MECHANISM OF ACTION 
 
Rosuvastatin is a competitive inhibitor of HMG-CoA reductase. HMG-CoA reductase 
catalyzes the conversion of HMG-CoA to mevalonate, an early rate-limiting step in 
cholesterol biosynthesis. Rosuvastatin acts primarily in the liver. Decreased hepatic 
cholesterol concentrations stimulate the upregulation of hepatic low density lipoprotein 
(LDL) receptors which increases hepatic uptake of LDL. Rosuvastatin also inhibits hepatic 
synthesis of very low density lipoprotein (VLDL). The overall effect is a decrease in plasma 
LDL and VLDL. In vitro and in vivo animal studies also demonstrate that rosuvastatin exerts 
vasculoprotective effects independent of its lipid-lowering properties. Rosuvastatin exerts an 
anti-inflammatory effect on rat mesenteric microvascular endothelium by attenuating 
leukocyte rolling, adherence and transmigration. The drug also modulates nitric oxide 
synthase (NOS) expression and reduces ischemic-reperfusion injuries in rat hearts. 
Rosuvastatin increases the bioavailability of nitric oxide upregulating NOS and by increasing 
the stability of NOS through post-transcriptional polyadenylation. It is unclear as to how 
rosuvastatin brings about these effects though they may be due to decreased concentrations of 
mevalonic acid. 
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PHARMACOKINETICS 
• Absorption: In clinical pharmacology studies in man, peak plasma concentrations of 
rosuvastatin were reached 3 to 5 hours following oral dosing. Both Cmax and AUC 
increased in approximate proportion to rosuvastatin dose. The absolute bioavailability 
of rosuvastatin is approximately 20%. The AUC of rosuvastatin does not differ 
following evening or morning drug administration. 
• Distribution: Mean volume of distribution at steady-state of rosuvastatin is 
approximately 134 liters. Rosuvastatin is 88% bound to plasma proteins, mostly 
albumin. This binding is reversible and independent of plasma concentrations. 
• Metabolism: Rosuvastatin is not extensively metabolized; approximately 10% of a 
radiolabeled dose is recovered as metabolite. The major metabolite is N-desmethyl 
rosuvastatin, which is formed principally by cytochrome P450 2C9, and in vitro 
studies have demonstrated that N-desmethyl rosuvastatin has approximately one-sixth 
to one-half the HMG-CoA reductase inhibitory activity of the parent compound. 
Overall, greater than 90% of active plasma HMG-CoA reductase inhibitory activity is 
accounted for by the parent compound. 
• Excretion: Following oral administration, rosuvastatin and its metabolites are 
primarily excreted in the feces (90%). The elimination half-life (t1/2) of rosuvastatin 
is approximately 19 hours.  
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INDICATIONS AND USAGE 
 
• Used as an adjunct to dietary therapy to treat primary hypercholesterolemia 
(heterozygous familial and nonfamilial), mixed dyslipidemia and 
hypertriglyceridemia. Also indicated for homozygous familial 
hypercholesterolemia as an adjunct to other lipid-lowering therapies or when other 
such therapies are not available. 
 DOSE 
 
• 5-40 mg orally once daily 
 
• The effects of rosuvastatin on LDL cholesterol are dose-related. At the 10 mg dose, 
the average LDL cholesterol reduction was found to be 46% in one trial. Increasing 
the dose from 10 mg to 40 mg gave a modest additional 9% absolute reduction in 
LDL levels (55% below baseline levels). 
DOSAGE FORMS 
 
Tablet- Oral 10 mg  
Tablet -Oral 20 mg  
Tablet -Oral 40 mg  
Tablet -Oral 5 mg 
ADVERSE EFFECTS  
 
• Rhabdomyolysis with myoglobinuria and acute renal failure and myopathy (including 
myositis). 
• headache  
• myalgia  
• abdominal pain  
• asthenia 
• nausea 
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OVERDOSAGE 
• There is no specific treatment in the event of overdose. In the event of overdose, the 
patient should be treated symptomatically and supportive measures instituted as 
required. Hemodialysis does not significantly enhance clearance of rosuvastatin (Drug 
bank: rosuvastatin calcium). 
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CHAPTER-VIII 
EXCIPIENTS PROFILE 
 
EUDRAGIT L100 (POLYMETHACRYLATE) 
 
Synonyms   :  Acryl-EZE; Acryl-EZE MP; Eastacryl 30D; Eudragit                               
                                                             KollicoatMAE 30 D; Kollicoat MAE 30 DP;  
                                                             Polymeric methacrylates. 
Nonproprietary names : BP:  Methacrylic acid–ethyl acrylate copolymer (1: 1) 
PhEur: Acidum methacrylicum et ethylis acrylas 
polymerisatum    (1: 1)                                                                                
Acidum methacrylicum et ethylis acrylas 
 polymerisatum 
(1: 1) dispersion 30 per centum 
Acidum methacrylicum et methylis methacrylas 
 (1: 1) 
Acidum methacrylicum et methylis methacrylas 
Polymerisatum (1: 2) 
Copolymerum methacrylatis butylati basicum 
Polyacrylatis dispersion 30 per centum 
USPNF:             
Ammonio methacrylate copolymer 
Methacrylic acid copolymer 
d copolymer dispersion 
Chemical name  : Poly (methacrylic acid, methyl methacrylate) 1 : 1 
 Empirical formula  
Structural formula  
    
  
Description   
• Nature  
• Solubility  
• Molecular weight 
 
Functional categories  
    
 
    
 
 
Properties  
Loss on drying  
Methyl methacrylate and          
methacrylic acid                      
Sulfated ash                            
Apparent viscosity             
Stability and storage             
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: (C5 H8 O2 ) n 
 
       R1, R3, R4  = CH3,  R2  = H  
: White free flowing powder 
: Soluble in acetone and alcohol 
:  ≥100 000 
: Film former 
 Tablet binder 
 Tablet diluents 
: ≤ 5.0% 
                                                                        
: ≤ 0.1% 
: ≤ 0.1%                                               
: 50–200 mPa s 
:  Dry powders are stable for at least 3 y
  stored  in a tightly closed container at 
  30ºC. 
 
  
                          
ears if  
less than  
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EUDRAGIT S100 (POLYMETHACRYLATE) 
 
Synonyms   :  Acryl-EZE; Acryl-EZE MP; Eastacryl 30D; Eudragit;                               
KollicoatMAE 30 D; Kollicoat MAE 30 DP;  
polymeric methacrylates. 
Nonproprietary names : BP: Methacrylic acid–ethyl acrylate copolymer (1 : 1) 
PhEur:                                                                                     
Acidum methacrylicum et ethylis acrylas 
polymerisatum 
(1 : 1) 
Acidum methacrylicum et ethylis acrylas 
 polymerisatum 
(1 : 1) dispersio 30 per centum 
Acidum methacrylicum et methylis methacrylas 
Polymerisatum (1 : 1) 
Acidum methacrylicum et methylis methacrylas 
Polymerisatum (1 : 2) 
Copolymerum methacrylatis butylati basicum 
Polyacrylatis dispersion 30 per centum 
USPNF:             
Ammonio methacrylate copolymer 
Methacrylic acid copolymer 
Methacrylic acid copolymer dispersion 
Chemical name  : Poly(methacrylic acid, methyl methacrylate) 1 : 2 
 
 Empirical formula  
 
Structural formula  
    
  
Description   
• Nature  
• Solubility  
• Molecular weight 
 Functional categories  
    
    
Properties  
Loss on drying           : 
Methyl methacrylate and   
methacrylic acid                   : 
Sulfated ash                          : 
Apparent viscosity              : 
Stablility and storage           : 
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: (C5 H8 O2) n 
 
 
      R1, R3, R4  = CH3, R2 = H      
  
: White free flowing powder 
: Soluble in acetone and alcohol 
: ≥100 000 
: Film former 
 Tablet binder 
 Tablet diluents 
 ≤ 5.0% 
 ≤ 0.1% 
 ≤ 0.1%                                               
 50–200 mPa s 
 Dry powders are stable for at least 3 ye
 stored in a tightly closed container at le
  
ars if  
ss than 30ºC. 
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PLURONIC F68 (POLOXAMER) 
Nonproprietary Names   : BP: Poloxamers 
      PhEur: Poloxamera 
      USPNF: Poloxamer 
 Synonyms    : Lutrol 
      Monolan 
      Pluronic 
       Poloxalkol 
      Polyethylene–propylene glycol copolymer 
      Polyoxyethylene–polyoxypropylene    
      Supronic 
       Synperonic 
Chemical Name   : α-Hydro-ω-hydroxypoly(oxyethylene)-  
      poly(oxypropylene) poly(oxyethylene)- 
       block copolymer. 
 
Empirical formula   : HO (C2H4O)a (C3H6O)b (C2H4O)a H 
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Structural Formula      
 
Description      
 Poloxamers generally occur as white, waxy, free-flowing prilled granules, or as cast 
solids. They are practically odorless and tasteless.  
Functional Category 
• Dispersing agent 
• Emulsifying agent 
• Co emulsifying agent 
• Solubilizing agent 
• Tablet lubricant 
• Wetting agent 
 
Properties 
 Density   :  1.06 g/cm3 at 25°C 
 Flash point   :  260°C 
 Flowability   :  Free flowing. 
 HLB value   :  29 
 Melting point   : 52–57°C 
 Solubility      : Freely soluble in water and ethanol.  
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8.4 POLYVINYL ALCOHOL 
Nonproprietary Names   : PhEur: Poly(vinylis acetas) 
      USP: Polyvinyl alcohol 
 Synonyms    : Airvol 
      Alcotex 
      Elvanol 
      Gelvatol 
      Gohsenol  
      Lemol 
      Mowiol 
      Polyvinol 
      PVA  
      Vinyl alcohol polymer   
  
Chemical Name   : Ethenol 
 
Empirical formula   : (C2H4O) n 
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Structural Formula      
 
Description      
 Polyvinyl alcohol occurs as an odorless, white to cream-colored granular powder. 
 
Functional Category 
• Coating agent 
•  Lubricant 
•  Stabilizing agent 
•  Viscosity-increasing agent 
 
Properties 
 Melting point  : 228°C for fully hydrolyzed grades; 180–190°C for  
     partially hydrolyzed grades. 
 Solubility  :  soluble in water; slightly soluble in ethanol   
     (95%); Insoluble in organic solvents  
 Specific gravity : 1.19–1.31 for solid at 25°C 
 Specific heat  :  1.67 J/g (0.4 cal/g) (Raymond C. Rowe., 2006) 
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CHAPTER-IX 
EXPERIMENTAL PROTOCOL 
9.1 STANDARD CURVES FOR ROSUVASTATIN CALCIUM 
Preparation of calibration medium      
Hydrochloric Acid Buffer pH 1.2 
 50ml of 0.2 M potassium chloride solution is placed in a 200ml volumetric flask.85ml of 
0.2M hydrochloric acid is added and makeup to the volume with distilled water. 
• 0.2M potassium chloride 
14.911 g of potassium chloride is dissolved in distilled water and the volume is makeup to 
1000ml. 
• 0.2M Hydrochloric acid 
7.292 g of hydrochloric acid is diluted to 1000ml with distilled water. 
Phosphate Buffer pH 6.8 
 50ml of 0.2M potassium dihydrogen phosphate is placed in a 200ml volumetric flask. 22.4ml    
of 0.2M sodium hydroxide is added and makeup to the volume with distilled water. 
• 0.2 M potassium dihydrogen phosphate 
27.218 g of potassium dihydrogen phosphate is dissolved and diluted to 1000ml with water. 
• 0.2 M sodium hydroxide 
8 g of sodium hydroxide is dissolved and makeup to 1000ml with water. 
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 Phosphate Buffer Saline (PBS) pH 7.4  
2.38 g of disodium hydrogen phosphate, 0.19 g of potassium dihydrogen phosphate and 8.0 g 
of sodium chloride are dissolved in sufficient quantity of distilled water and made up to    
1000 ml (IP 1996). 
9.1.1 Estimation of absorption maximum (λmax) 
• Stock solution: 
Rosuvastatin calcium (100mg) is accurately weighed and dissolved in 100ml methanol to 
form a stock solution (1000µg/ml). 
• Working standard solution:  
The stock solution is further diluted suitably with pH 6.8 phosphate buffer to get a working 
standard solution of concentration 100µg/ml.  
This working standard solution is suitably diluted to get a concentration of 10µg/ml and the 
resultant solution is scanned in the range of 200-400 nm in UV Spectrophotometer to get 
absorption maximum(Alka Gupta et al., 2009). 
9.1.2 Preparation of standard curves 
 From the working standard solution, 2ml, 4ml, 6ml, 8ml, 10ml, 12ml, 14ml, 16ml, 18ml and 
20ml are taken separately and diluted to 100ml with the same pH 6.8 phosphate buffer, so 
that the final concentrations of 2-20 µg/ml solutions are obtained. The above solutions are 
analyzed by Ultraviolet (UV) spectrophotometer at λmax. 
 
Calibration curve is plotted by taking the concentration in X-axis and respective absorbance 
in Y-axis. 
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Calibration curves are also prepared similarly in hydrochloric acid buffer pH 1.2, PBS pH 
7.4, and Distilled water. 
9.2 DRUG-POLYMER INTERACTION STUDIES 
Preformulation testing is the first step in rational development of dosage forms of a drug 
substance. It gives the information needed to define the nature of the drug substance and 
provide a framework for the drug combination with pharmaceutical excipients in the dosage 
forms. Hence, preformulation studies are performed for the obtained sample of drug for 
compatibility studies (Wadke PA et al., 1980). 
• Compatibility studies 
FT-IR Spectroscopy and DSC studies are carried out to check the compatibility between drug 
and polymer. 
9.2.1 Fourier Transform- Infra Red spectroscopy (FT-IR) 
FT-IR spectroscopy is carried out to find out the compatibility between the drug 
(Rosuvastatin calcium) and the polymers (EL 100, ES 100). 10mg of the sample and 400mg 
of kBr are taken in a mortar and triturated (Bivash Mandal et al., 2010). A small amount of 
the triturated sample is taken into a pellet maker and it is compressed at 10 kg/cm2 using a 
hydraulic press. The pellet is kept onto the sample holder and scanned from 4000 cm-1 to 400 
cm-1 in FT-IR spectrophotometer, Shimadzu, Japan. Samples are prepared for drug, polymers 
and physical mixture of drug and polymers. The spectra obtained are compared and 
interpreted for the shifting of functional peaks and disappearance or appearance of new 
functional peaks (Poovi G et al., 2011).      
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9.2.2 Differential Scanning Calorimetry (DSC)  
DSC is a useful tool to monitor the effect of additives on the thermal behavior of material 
(Sivabalan M et al., 2011). Accurately weighed samples, equivalent to 5mg of drug 
(Rosuvastatin Calcium) are placed into the sealed standard aluminum pans with lids. 
Subsequently, the polymers (EL 100, ES 100) and physical mixtures of drug and polymers 
are ascertained using the differential scanning calorimetry thermogram analysis, DSC Q200, 
Shimadzu, Japan. The heating rate is 20°C/min and the heat flow is recorded from 20°C to 
180°C. The aluminum oxide and indium powders are employed as reference and standard, 
respectively. DSC analysis of pure rosuvastatin calcium, Eudragit L 100 and Eudragit S100 is 
performed to identify the drug melting point peak and polymer glass transition temperature 
(TG) respectively. As a control the physical mixtures of rosuvastatin calcium- Eudragit L100, 
Eudragit S 100 are analyzed to observe the changes of the melting endotherm of rosuvastatin 
calcium (Khosro Adibkia et al., 2011).   
9.3 FORMULATION OF ROSUVASTATIN CALCIUM LOADED 
POLYMERIC NANOPARTICLES 
Nanoparticles containing rosuvastatin calcium are prepared by Nanoprecipitation according 
to the method developed by Fessi et al., 1992; Ugo Bilati et al., 2005. 
Briefly, a 20mg of rosuvastatin calcium and 200mg of Eudragit L100/ Eudragit S 100 are 
dissolved in 20 mL of acetone (Swarnali Das et al., 2010). This organic phase is quickly 
injected into the aqueous phase containing 40 mL of an either 1% or 2% w/v of          
Pluronic F68/PVA solution with moderate magnetic stirring at room temperature               
(Manish K Gupta et al., 2009; Kurt E. Geckeler et al., 2011).  
The organic phase to aqueous phase ratio is 1:2 (Christine Vauthier et al., 2007). 
Nanoparticles are spontaneously formed and turned the solution slightly turbid. Then, acetone 
is removed by continuous stirring for 3-4 hrs.  
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Drug free nanoparticles are prepared by the same procedure omitting the drug                       
(Snjezana Stolnik et al., 1999). 
The process variables involved in NPs preparation is presented in Table XVI –XIX. 
In this study, the effects of various process parameters on nanoparticles mean diameter and 
drug entrapment efficiencies are assessed, including different drug-to-polymer ratios 
(1:10,1:20,1:30,1:40,1:50) , Pluronic F68 concentration(1%,2%) in the aqueous phase, PVA 
concentration (1%,2%) in the aqueous phase (Xiangrong Song et al., 2008). 
9.4 CHARACTERIZATION OF ROSUVASTATIN CALCIUM LOADED     
POLYMERIC NANOPARTICLES 
All the formulations are evaluated for its particle size, polydispersity index, zeta potential, 
drug content, entrapment efficiency, in vitro drug release studies, and kinetics of drug release. 
9.4.1 Particle size and poly dispersity index 
Particle size and size distribution are the most important characteristics to be evaluated for 
nanoparticles systems (Mohanraj VJ et al., 2006). The particle size distribution is reported as 
Poly Dispersity Index (PDI). 
The particle size and Polydispersity index (PDI) of rosuvastatin calcium loaded polymeric 
nanosuspension are measured using a Zeta sizer nano ZS (Malvern Instruments Ltd., 
Malvern, UK) (Angela Lopedota et al., 2009).The samples are placed in the analyzer 
chamber and the readings are carried out at a 90° angle with respect to the incident beam. 
Disposable cuvettes of 0.75ml capacity are used for all measurements                           
(Bivash Mandal et al., 2010). 
9.4.2 Zeta potential 
The zeta potential of nanoparticles is commonly used to characterize the surface charge 
property of nanoparticles (Mohanraj VJ et al., 2006). The zeta potential of rosuvastatin 
calcium loaded polymeric nanosuspension are measured using a Zeta sizer Nano ZS  
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(Malvern Instruments Ltd., Malvern, UK) at 25 ± 0.5°C (Dhananjay S. Singare et al., 2010 ; 
Xiangrong  Song et al., 2008).  A potential of ±150 mV is set in the instrument. Disposable 
cuvettes of 0.75ml capacity are used for all measurements (Bivash Mandal et al., 2010). 
9.4.3 Drug content 
The total drug content in nanosuspension is quantified by Spectrophotometric analysis 
(Angela Lopedota et al., 2009; Sanjay Singh et al., 2009). 
1 mg equivalent of rosuvastatin calcium polymeric nanosuspension is dissolved  in 1 ml of 
acetone and the volume is made up to 100 ml to make 10 µg / ml concentration and the 
absorbance is measured at 241 nm (λmax) using UV spectrophotometer.  
The calculation is performed as follows: 
     Vol. Total 
Total drug content =       x Drug amount in aliquot 
    Vol. Aliquot 
9.4.4 Entrapment efficiency 
The amount of rosuvastatin calcium embedded in the NPs is calculated from the difference 
between the total amount incorporated in the NP formation medium and the amount of           
non-embedded rosuvastatin calcium remaining in the aqueous suspending medium           
(Angela Lopedota et al., 2009). The latter amount is determined by the separation of 
rosuvastatin calcium loaded NPs from the aqueous medium by centrifugation using 
refrigerated centrifuge (Eppendorf, 5417R, Germany) at 14,000 rpm for 2 hrs at 4°C. After 
centrifugation, the supernatant solution is made up to desired volume with buffer and the 
amount of free drug is determined by measuring the absorbance of samples at 241 nm using 
UV spectrophotometer. 
The % entrapment efficiency is calculated by following formula: 
             (Total drug – Drug in supernatant liquid)  
       % drug entrapment =                        × 100. 
                                                               Total drug 
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9.4.5 In vitro release studies 
Dialysis bag diffusion technique is used to study in vitro release of drug from the prepared 
nanosuspension (Mishra B et al., 2010). 
 Dialysis membrane having pore size 2.4 nm, molecular weight cut off 14,000 is used. The 
nanosuspension equivalent to 1 mg of rosuvastatin calcium (2 ml) is placed in the dialysis 
bag, hermetically sealed and immersed into a 250ml beaker containing 100ml of the release 
media maintained at 37±0.5° C. 
Aliquots of samples (5 ml) are withdrawn at pre determined intervals and immediately 
restored with the same volume of fresh media maintained at the same temperature            
(Mishra B et al., 2010).  
The study is carried out by buffer change method using acidic buffer (pH 1.2) for the first 2 
hrs and phosphate buffer (pH 6.8) for the rest of the study period, i.e. 10 hrs                       
(Mishra B et al., 2010; Martine Leroueil-Le Verger et al., 1998; Angela Lopedota et al., 
2009). 
The amount of rosuvastatin calcium dissolved is determined with UV spectrophotometer at 
241nm. All the experiments were repeated three times and the average values were taken. 
9.4.6 Kinetics of drug release 
  
In order to analyze the drug release mechanism, in vitro release data are fitted into a 
• Zero-order 
• First order 
• Higuchi 
• Hixon-Crowell cube root law 
• Korsmeyer-peppas model. 
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• The zero order rate Eq. (1) describes the systems where the drug release rate is 
Independent of its concentration. 
     C = k0t                                                     (1) 
Where C is the concentration of the drug at time (t) and k0 is the zero-order release rate                           
constant. 
• The first order Equation Eq. (2) describes the release from a system where the release rate 
is concentration dependent. 
 log C = log C0 - kt / 2.303                                            (2)   
Where C is the concentration of the drug at time (t), C0 is the initial concentration of the drug 
and k is the first-order release rate constant. 
• Higuchi described the release of drugs from porous, insoluble matrix as a square root of 
time dependent process based on Fickian diffusion as shown in Eq .(3). 
 Q = kt1/2                                                     (3) 
Where Q is the amount of drug released in time t. 
• The Hixson-Crowell cube root law Eq. (4) describes the release from systems where there 
is a change in surface area and diameter of particles. 
W0
1/3 – Wt
1/3 = κt                                                                           (4) 
Where W0 is the initial amount of drug in the pharmaceutical dosage form, Wt   is the 
remaining amount of drug in the   pharmaceutical dosage form at time t, and κ is the constant 
incorporating the surface-volume relationship (Suvakanta Dash et al., 2010; Mohammad 
Barzegar-Jalali et al., 2008). 
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9.5 SELECTION OF BEST FORMULATION 
The best formulation is selected depending on the results obtained from particle size, 
entrapment efficiency, in vitro drug release studies, and kinetics of drug release. 
9.6 EVALUATION OF SELECTED BEST FORMULATION 
9.6.1 Solubility studies 
The solubility of the best formulation is compared with the solubility of the pure drug 
solution. For this purpose, saturation solubility measurement is carried out. Accurately 
weighed amount of pure drug and rosuvastatin calcium loaded polymeric nanoparticles are 
introduced into separate 25 ml stoppered conical flask containing 10 ml of distilled water. 
The sealed flask is agitated on a rotary shaker for 24 hr. An aliquot is filtered and the filtrate 
is suitably diluted and analyzed on a UV spectrophotometer (Arunkumar N et al., 2009; 
Rezaei Mokkarram et al., 2010; Akbari B.V et al., 2011; Yasushi Shono et al., 2010).   
9.6.2 Ex vivo intestinal permeability studies 
Ex vivo intestinal permeability studies are useful for screening the permeability of drug 
substances associated with their in vivo absorbability. The in vitro rat intestinal model is 
useful for screening passive drug absorption in humans than the drug absorbed by carrier-
mediated mechanism (Lennernas et al., 1997).  
The ex vivo intestinal permeability studies was approved by the institutional ethical 
committee (Ref. No: 14024/ E1/ 4/ 2011) using 9 albino male rat. Male Albino rats weighing 
150-200 g are used for the study. After overnight fasting, rats are anesthetized by some ether 
sprinkled to a piece of cotton wool in a glass container equipped with a lid (Hussain 
Kooshapur et al., 1999). After making a midline incision in the abdomen, the intestinal 
segments are isolated as follows: duodenum segment of 8 cm is isolated starting from the 
pylorus; jejunum segment of 10-15 cm is isolated 25 cm from the pylorus; an ileum segment 
of 10-15 cm is isolated 20 cm upward from caecum (Mallikarjun Chitneni et al., 2011).  
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The isolated segments are washed with pH 7.4 phosphate buffer saline (USP 30) to remove 
any mucous and lumen contents. These segments are tied at one end with suture thread and 
the selected formulations of rosuvastatin calcium Nanosuspension (equivalent to 1mg of 
drug) and pure drug solution (drug in PBS pH7.4 equivalent to 1 mg) are injected separately 
into the different parts of intestine using a syringe and the other end of intestine are tied with 
the help of suture thread. Then the tied segments are placed separately in a beaker containing 
100ml of PBS (pH7.4) continuously bubbled with 95% O2  and 5 % CO 2  with constant 
stirring at 37ºC.  
The studies are completed in triplicates and aliquots of samples (5ml) are withdrawn at 
15,30,60,90 and 120 min. The samples are measured using a UV-Visible spectrophotometer 
at a wave length of 241 nm. The cumulative amount of drug permeated is plotted against time 
to calculate apparent permeability coefficient (Papp) (Shishu et al., 2010; Arpan Chudasama et 
al., 2011; Ibrahim A. Alsarra et al., 2005). 
The apparent permeability coefficient (Papp) (cm/s) is calculated as follows: 
Papp =


	
 
where dQ/dt is the rate of drug appearance in the receptor (µg/s), A is the surface area of the 
intestinal sac (cm2 ) and C is the initial concentration of the drug in the sac (µg/ml) (Qiu S X           
et al., 2006; Albert H. L. Chow et al., 2005; Abdullah M. Al-Mohizea et al., 2010). 
Statistical analysis 
Statistical analysis for the determination of differences in permeability profiles of 
rosuvastatin calcium loaded polymeric nanosuspensions and rosuvastatin calcium pure drug 
solution was assessed by the use of Student’s t-test (Graph pad Instat Version 3.0 software). 
Statistical probability (p) values less than 0.05 were considered significantly different           
(Arpan Chudasama et al., 2011). 
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9.6.3 Transmission electron microscopy (TEM) 
The morphology of the prepared nanosuspension formulations is determined by TEM: 
(Hitachi, Japan). Before analysis, the samples were diluted 1:5 and stained with 2% (w/v) 
phosphotungstic acid for 30 s and placed on copper grids with films for observation 
(Xiangrong Song et al., 2008). 
9.6.4 Stability Studies 
Stability is defined as the ability of particular drug or dosage form in a specific container to 
remain with its physical, chemical and therapeutic specifications. Stability tests are the series 
of tests designed to obtain information on the stability of the pharmaceutical product in order 
to define its shelf life and utilization period under specified packaging and storage conditions. 
The purpose of stability testing is to provide information on how the quality of a drug product 
varies with time under the influence of variety of environmental factors such as temperature, 
humidity and light, and to establish a shelf life for the drug product at recommended storage 
conditions. 
Stability testing of pharmaceutical product is done for the following purposes: 
• To ensure the efficacy, safety and quality of active drug substance and dosage forms. 
• To establish shelf life or expiration period. 
Procedure: 
The selected best formulation is tested for stability studies. Stability studies are done 
according to ICH and WHO guidelines. The formulation is divided into 2 sample sets and 
stored at: 
  4 ± 1oC 
  25± 2oC and 60 ± 5% RH. 
The entrapment efficiency of the best formulation is determined for a period of 3 months.  
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CHAPTER-X 
RESULTS AND DISCUSSION 
10.1 STANDARD CURVES FOR ROSUVASTATIN CALCIUM  
10.1.1 Estimation of absorption maximum (λmax) 
The λ max of rosuvastatin calcium was estimated by scanning the 10µg/ml concentration of 
the drug solution in UV region (200-400 nm). It showed the λ max of 241nm (Vishal V. 
Rajkondwar et al., 2009) which were shown in the Figure 17.  
10.1.2 Preparation of standard curves 
The standard curves of rosuvastatin calcium prepared using distilled water, hydrochloric acid 
buffer pH 1.2; phosphate buffer pH 6.8 and phosphate buffer saline pH 7.4 were shown in 
Figure 18- 21 and Table X-XIII. The linear correlation coefficient was obtained for 
calibration of rosuvastatin calcium in each medium. Rosuvastatin calcium obeys the Beer’s 
law within the concentration range of 2 to 20µg/ml (Alka Gupta et al., 2009). 
10.2 DRUG-POLYMER INTERACTION STUDIES  
• Compatibility studies 
10.2.1 Fourier Transform- Infra Red spectroscopy (FT-IR)  
FT- IR spectroscopy was carried out separately to check the compatibility between drug 
(rosuvastatin calcium) and the polymers (Eudragit L 100, Eudragit S 100) used for the 
preparation of nanoparticles.   
 
115 
 
The FT- IR was performed for pure drug, polymers and physical mixture of drug and 
polymers. The spectra studied at 4000cm-1 to 400 cm-1 were shown in Figure 22 a,b,c,d,e and               
Table XIV. It was found from the spectra that there was no major shifting as well as any loss 
of functional peaks in the spectra of drug, polymers and physical mixture of drug and 
polymers. The results indicate that the selected polymers (Eudragit L 100, Eudragit S 100) 
were found to be compatible with the chosen drug rosuvastatin calcium. 
10.2.2 Differential Scanning Calorimetry (DSC) 
DSC is a useful tool to monitor the effect of additives on the thermal behavior of 
materials.DSC thermograms of pure drug (rosuvastatin calcium), polymers (Eudragit L100 
and Eudragit S100) and the physical mixtures of drug and polymers were shown in the            
Figure 23 a,b,c,d,e and Table XV.  Pure rosuvastatin calcium showed a sharp endothermic 
peak at 88.12°C, Eudragit L 100 showed a melting endothermic peak at 83.02°C, Eudragit S 
100 at 91.50°C. The physical mixture of drug (rosuvastatin calcium) and polymer (Eudragit 
L100) exhibited an endothermic peak at 85.36°C and the physical mixture of drug 
(rosuvastatin calcium) and polymer (Eudragit S 100) exhibited an endothermic peak at 
88.93°C. Thus, an endothermic peak corresponding to the melting point of pure drug (88°C) 
was prominent in all the drug polymer mixtures, which suggested clearly that there was no 
interaction between the drug and the polymers and thus the drug found to be existed in its 
unchanged form. 
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10.3 FORMULATION OF ROSUVASTATIN CALCIUM LOADED 
POLYMERIC NANOPARTICLES 
Eudragit L 100 and Eudragit S 100 nanosuspensions were successfully prepared by the 
Nanoprecipitation technique (Fessi et al., 1992). The method was simple, reproducible, fast, 
economic and one of the easiest procedure for the preparation of nanospheres (Ugo Bilati et 
al., 2004). The nanoparticle formation was instantaneous and entire procedure was carried out 
in only one step. Briefly it required two solvents that were miscible. Ideally, both the 
polymers and the drug must dissolve in the first one (the organic solvent- acetone), but not in 
the second system (the non-solvent-water). Indeed, as soon as the polymer containing solvent 
had diffused into the dispersing medium, the polymers precipitates, involving immediate drug 
entrapment.   
Thus,  nanoparticles were spontaneously formed when the organic phase (acetone) 
containing Eudragit L100 (EL 100) and Eudragit S100 (ES 100) with or without Rosuvastatin 
calcium was added dropwise into stirred aqueous surfactant solution (1%w/v, 2%w/v 
Pluronic F68/PVA) resulting in a colloidal suspension. 
Instantaneous formation of a colloidal suspension occurred as a result of the polymer 
deposition on the interface between the organic phase and water, when partially water 
miscible organic solvent (acetone) diffused out quickly into the aqueous phase from each 
transient particle intermediate. According to the “Marangoni effect” the transient particle 
intermediate causes a size reduction to the nano range (Quintanar – Guerrero et al., 1998). 
Various formulations of Rosuvastatin calcium (F1-F40) were prepared using different 
polymers (EL 100/ES 100) at different ratios (1:10,1:20,1:30,1:40,1:50) and different 
stabilizers (Pluronic F68/PVA) at different concentrations (1%,2%). 
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The polymer ratios and stabilizer concentrations were selected arbitrarily as shown in          
Table XVI-XIX with a view to study the effect on physicochemical and release of the 
polymeric nanoparticles.  
10.4  CHARACTERIZATION OF ROSUVASTATIN CALCIUM LOADED 
POLYMERIC NANOPARTICLES 
10.4.1 Particle size and polydispersity index 
Particle size plays a critical role in influencing the physico chemical and biological 
characteristics of the nanoparticles. Nanoparticles were charactized by mean particle diameter 
and their distribution. The average diameters, polydispersity index of rosuvastatin calcium 
loaded nanoparticles were listed in Table XX a,b,c,d,e,f,g,h and Figure 24; smaller particles 
less than 400nm were most preferred in pharmaceutical process development. 
In the present study the particle size of nanoparticles ranged between  125.9 nm - 191.9 nm 
with respect to nanoparticles prepared with EL100 containing Pluronic F68 (1%) as stabilizer 
(F1-F5), 110.5 nm-182.8 nm with respect to nanoparticles prepared with EL100 containing 
Pluronic F68 (2%) as stabilizer (F6-F10), 135.9 nm-209.3 nm with respect to nanoparticles 
prepared with EL 100 containing PVA (1%) as stabilizer (F11-F15), 127.0 nm-190.1 nm with 
respect to nanoparticles prepared with EL100 containing PVA (2%) as stabilizer (F16-F20), 
139.2 nm-229.3 nm with respect to nanoparticles prepared with ES100 containing Pluronic 
F68 (1%) as stabilizer (F21-F25), 131.0 nm-210.1 nm with respect to nanoparticles prepared 
with ES100 containing Pluronic F68 (2%) as stabilizer (F26-F30), 149 nm-231.0 nm with 
respect to nanoparticles prepared with ES100 containing PVA (1%) as stabilizer (F31-F35),                  
137.0 nm-229.5 nm with respect to nanoparticles prepared with ES100 containing PVA (2%) 
as stabilizer   (F36-F40). 
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EFFECT OF PREPARATION VARIABLES ON PARTICLE SIZE: 
1. Effect of drug –polymer ratio: 
The influence of different drug- polymer ratios of Rosuvastatin calcium loaded EL100 and 
ES100 nanoparticles on the particle size was investigated. The results were presented in 
Table XX a,b,c,d,e,f,g,h and Figure 24. 
Formulations F1-F5 prepared using different ratios of polymer (EL 100) (1:10, 1:20, 1:30, 
1:40 and 1:50) containing Pluronic F68 (1%) as stabilizer showed the particle size of         
125.9 nm, 142.2 nm, 166.2 nm, 178.5 nm and 191.9 nm respectively. 
Formulations F6-F10 prepared using different ratios of polymer (EL 100) (1:10, 1:20, 1:30, 
1:40 and 1:50) containing Pluronic F68 (2%) as stabilizer showed the particle size of         
110.5 nm, 133.9 nm, 152.2 nm, 168.3 nm and 182.8 nm respectively. 
Formulations F11-F15 prepared using different ratios of polymer (EL 100) (1:10, 1:20, 1:30, 
1:40 and 1:50) containing PVA (1%) as stabilizer showed the particle size of 135.9 nm,  
151.0 nm, 174.1 nm, 187.0 nm and 209.3 nm respectively. 
Formulations F16-F20 prepared using different ratios of polymer (EL 100) (1:10, 1:20, 1:30, 
1:40 and 1:50) containing PVA (2%) as stabilizer showed the particle size of 127.0 nm,  
145.0 nm, 168.0 nm, 174.0 nm and 190.1 nm respectively. 
Formulations F21-F25 prepared using different ratios of polymer (ES 100) (1:10, 1:20, 1:30, 
1:40 and 1:50) containing Pluronic F68 (1%) as stabilizer showed the particle size of           
139.2 nm, 157.1 nm, 174.1 nm, 192.0 nm and 229.3 nm respectively. 
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Formulations F26-F30 prepared using different ratios of polymer (ES 100) (1:10, 1:20, 1:30, 
1:40 and 1:50) containing Pluronic F68 (2%) as stabilizer showed the particle size of       
131.0 nm, 145.0 nm, 164.0 nm, 179.0 nm and 210.1 nm respectively. 
Formulations F31-F35 prepared using different ratios of polymer (ES 100) (1:10, 1:20, 1:30, 
1:40 and 1:50) containing PVA (1%) as stabilizer showed the particle size of 149.0 nm,   
161.0 nm, 178.0 nm, 199.0 nm and 231.0 nm respectively. 
Formulations F36-F40 prepared using different ratios of polymer (ES 100) (1:10, 1:20, 1:30, 
1:40 and 1:50) containing PVA (2%) as stabilizer showed the particle size of 137.0 nm,    
159.0 nm, 165.0 nm, 192.1 nm and 229.5 nm respectively. 
It could be seen that the particle size was affected by increasing the polymer concentration. 
The particle size of rosuvastatin calcium loaded polymeric nanoparticles showed a positive 
relationship with polymer (EL100/ ES100) concentration. 
This is because, increasing EL100 and ES100 concentration led to increase in the viscosity of 
the organic phase. A more viscous organic phase provides a higher mass transfer resistance, 
the diffusion of polymer – solvent phase into the external aqueous phase is reduced and larger 
nanoparticles are formed (Xiangrong Song et al., 2008, Annick Ludwig et al., 2006).             
A decrease in viscosity of the organic phase increase the distribution effect of the polymer – 
solvent phase into the external phase leading to formation of smaller nanoparticles             
(Hatem Fessi et al., 2005). 
2. Effect of stabilizers: 
The effect of stabilizers (Pluronic F68 and PVA) on the particle size of rosuvastatin             
calcium loaded EL 100 and ES 100 nanoparticles were investigated. The results were shown 
in Table XX a,b,c,d,e,f,g,h and Figure 24. Rosuvastatin calcium loaded polymeric 
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nanoparticles prepared with Pluronic F68 were smaller than those prepared with PVA. This 
result is in accord with the earlier studies of Gershon Golomb et al., 2009.   
3. Effect of Pluronic F68 concentration in the aqueous phase: 
The influence of Pluronic F68 concentration (1%, 2%) in the aqueous phase of rosuvastatin 
calcium loaded EL 100/ES 100 nanoparticles on the particle size was investigated. The 
results were shown in Table XX a,b,c,d,e,f,g,h and Figure 24. 
It could be seen that the particle size of rosuvastatin calcium loaded polymeric nanoparticles 
showed a negative relationship with Pluronic F68 concentration. 
The mean diameter of polymeric nanoparticles decreased with the increase of Pluronic F68 
concentration. At high concentration, more Pluronic F68 could be oriented at organic 
solvent/water interface to reduce efficiently the interfacial tension, which resulted in 
significant increase in the net shear stress at a constant energy density during emulsification 
and promoted the formation of smaller emulsion droplets (Xiangrong Song et al., 2008).  
4. Effect of PVA concentration in the aqueous phase : 
Table XX a,b,c,d,e,f,g,h and Figure 24 showed that the mean diameter decreased with 
increasing concentration of PVA. This is because, at high concentration, more PVA could be 
oriented at organic solvent/water interface to reduce efficiently the interfacial tension, which 
resulted in significant increase in the net shear stress at a constant energy density during 
emulsification and promoted the formation of smaller emulsion droplets                  
(Xiangrong Song al., 2008).  
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Polydispersity index (PDI):  
PDI is another factor that represents the dispersion homogenicity, the range for the PDI is 
from 0 to 1. Values close to 0 indicate the homogeneous dispersion, and those greater than 
0.5 indicate high homogenicity. The PDI for all the formulations as shown in                          
Table XX a,b,c,d,e,f,g,h and Figure 24 is smaller than 0.5, which indicates a relative 
homogenous dispersion (Mohammed Reza Avadi et al., 2010). 
10.4.2 Zeta potential 
The rosuvastatin calcium loaded polymeric nanoparticles were characterized to evaluate the 
effect of different polymers and stabilizers at different concentrations on surface charge of 
nanoparticles. The results were presented in Table XXI a,b. 
Zeta potential of formulations F1-F20 prepared with EL 100 showed negative zeta potential 
(-25mV to -29mV). 
Zeta potential of formulations F21-F40 prepared with ES 100 showed negative zeta potential 
(-26mV to -30mV). 
All the formulations showed negative surface charge possibly due to the presence of terminal 
carboxylic acid groups in the polymers (EL 100 and ES 100) (Mora CE-Huertas et al.,2010).  
Commonly, zeta potential is an index of the stability of the nanoparticles. Muller considered 
that a zeta potential of about -25mV allows an ideal stabilization of nanoparticles because the 
repulsive forces prevent aggregation upon ageing (Martine Leroueil-Le Verger.M                    
et al., 1998). 
However, zeta potential values between -25mV and -30mV allow predicting good colloidal 
stability due to high energy barrier between particles (Mora CE-Huertas et al., 2010). 
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10.4.3 Drug content 
Table XXII a,b showed the percentage drug content of all formulations F1-F40. The drug 
content was found to be in the range of 90.75% to 96.86 %, indicating uniform distribution of 
drug. 
10.4.4 Entrapment efficiency 
The entrapment efficiencies of rosuvastatin calcium loaded nanosuspension were listed in the 
Table XXIII a,b,c,d,e,f,g,h and Figure 25 a,b,c,d.The entrapment efficiencies ranged between 
42.1% - 78.59% with respect to nanoparticles prepared with EL 100 containing Pluronic F68 
(1%) as stabilizer (F1-F5),38.35% - 74.25% with respect to nanoparticles prepared with EL 
100 containing Pluronic F68 (2%) as stabilizer (F6-F10), 47.5% - 75.25% with respect to 
nanoparticles prepared with EL 100 containing PVA (1%) as stabilizer (F11-F15), 36.06% - 
70.35% with respect to nanoparticles prepared with EL 100 containing PVA (2%) as 
stabilizer (F16-F20), 33% - 70.5% with respect to nanoparticles prepared with ES 100 
containing PluronicF68 (1%) as stabilizer (F21-F25),28% - 62% with respect to nanoparticles 
prepared with ES 100 containing Pluronic F68 (2%) as stabilizer (F26-F30), 29.5% - 60.4% 
with respect to nanoparticles prepared with ES 100 containing PVA (1%) as stabilizer ( F31-
F35), 28% - 55.5% with respect to nanoparticles prepared with ES 100 containing PVA (2%) 
as stabilizer ( F36-F40). 
The fabrication parameters such as different drug-polymer ratios and different stabilizers at 
different concentrations were used to achieve the highest entrapment of rosuvastatin calcium. 
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EFFECT OF PREPARATION VARIABLES ON ENTRAPMENT EFFICIENCY: 
1. Effect of drug-polymer ratio 
The effect of different drug- polymer ratios of rosuvastatin calcium loaded EL100/ ES100 
nanoparticles on the entrapment was investigated. The results were shown in                           
Table XXIII a,b,c,d,e,f,g,h and Figure 25 a,b,c,d. 
Formulations F1-F5 prepared using different ratios of polymer (EL 100) (1:10, 1:20, 1:30, 
1:40 and 1:50) containing Pluronic F68 (1%) as stabilizer showed the entrapment efficiency 
of 42.1%, 54.42%, 69.95%, 75.81% and 78.59% respectively. 
Formulations F6-F10 prepared using different ratios of polymer (EL 100) (1:10, 1:20, 1:30, 
1:40 and 1:50) containing Pluronic F68 (2%) as stabilizer showed the entrapment efficiency 
of 38.35%, 50.84%, 63.97%, 69.25 and 74.25% respectively. 
Formulations F11-F15 prepared using different ratios of polymer (EL 100) (1:10, 1:20, 1:30, 
1:40 and 1:50) containing PVA (1%) as stabilizer showed the entrapment efficiency of 
47.5%, 55.5%, 65.09%, 71.45% and 75.25% respectively. 
Formulations F16-F20 prepared using different ratios of polymer (EL 100) (1:10, 1:20, 1:30, 
1:40 and 1:50) containing PVA (2%) as stabilizer showed the entrapment efficiency of 
36.06%, 47.65%, 54.9%, 66.6% and70.35% respectively. 
Formulations F21-F25 prepared using different ratios of polymer (ES 100) (1:10, 1:20, 1:30, 
1:40 and 1:50) containing Pluronic F68 (1%) as stabilizer showed the entrapment efficiency 
of 33.0%, 42.0%, 52.6%, 60.2% and 70.5% respectively. 
Formulations F26-F30 prepared using different ratios of polymer (ES 100) (1:10, 1:20, 1:30, 
1:40 and 1:50) containing Pluronic F68 (2%) as stabilizer showed the entrapment efficiency 
of 28.0%, 39.8%, 49.0%, 54.35% and 62.0% respectively. 
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Formulations F31-F35 prepared using different ratios of polymer (ES 100) (1:10, 1:20, 1:30, 
1:40 and 1:50) containing PVA (1%) as stabilizer showed the entrapment efficiency of 
29.5%, 34.6%,47.0%,54.9% and 60.4% respectively. 
Formulations F36-F40 prepared using different ratios of polymer (ES 100) (1:10, 1:20, 1:30, 
1:40 and 1:50) containing PVA (2%) as stabilizer showed the entrapment efficiency of 
28.0%, 32.0%, 41.7%,47.0% and 55.5% respectively. 
It could be seen that the entrapment was affected by increasing the polymer concentration.   
The entrapment efficiency of Rosuvastatin calcium loaded polymeric nanoparticles showed a 
positive relationship with polymer (EL100/ES100) concentration.  
This is because, increase in polymer concentration in organic phase increases drug 
entrapment due to increase in organic phase viscosity, which increases the diffusional 
resistance to drug molecules from organic phase to aqueous phase, thereby entrapping more 
drug in the polymeric nanoparticles(Swarnali Das et al., 2010 ; Xiangrong Songet al., 2008). 
2. Effect of stabilizers: 
The effect of stabilizers (Pluronic F68 and PVA) on the entrapment efficiency of rosuvastatin 
calcium loaded EL 100 and ES 100 nanoparticles were investigated. The results were shown 
in Table XXIII a,b,c,d,e,f,g,h and Figure 25 a,b,c,d. 
Rosuvastatin calcium loaded polymeric nanoparticles prepared with Pluronic F68 showed 
better entrapment than those prepared with PVA. This result was in accord with the earlier 
studies of Gershon Golomb et al., 2009.   
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3. Effect of Pluronic F68 concentration in the aqueous phase: 
The influence of Pluronic F68 concentration (1%, 2%) in the aqueous phase on the 
entrapment efficiency of rosuvastatin calcium polymeric nanoparticles was investigated. The 
results were shown in Table XXIII a,b,c,d,e,f,g,h and Figure 25 a,b,c,d. 
It could be seen that the entrapment efficiencies of rosuvastatin calcium loaded polymeric 
nanoparticles showed a negative relationship with Pluronic F68 concentration. 
The entrapment efficiencies of polymeric nanoparticles decreased with the increase of 
Pluronic F68 concentration. This was probably caused by the decrease in particle size.     
Moreover , with the increase of  Pluronic F68 concentration ,more molecules of drug may 
partition out rapidly in to the aqueous phase during emulsification procedure and less drug 
molecules remained in emulsion droplets to interact with polymers(EL 100/ES100), hence 
decreasing the entrapment efficiencies (Xiangrong Song al., 2008).  
4. Effect of PVA concentration in the aqueous phase : 
Table XXIII a,b,c,d,e,f,g,h and Figure 25 a,b,c,d showed that the entrapment efficiencies 
decreased with increasing concentration of PVA. This was probably caused by the decrease 
in particle size. Moreover, with the increase of  PVA concentration ,more molecules of drug 
may partition out rapidly in to the aqueous phase during emulsification procedure and less 
drug molecules remained in emulsion droplets to interact with polymers(EL 100/ES100), 
hence decreasing the entrapment efficiencies (Xiangrong Song al., 2008).  
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10.4.5 In vitro release studies 
The suitability of EL 100/ES 100 nanoparticles for the release of rosuvastatin calcium was 
studied in vitro at pH 1.2 and 6.8 to mimic the in vivo condition eg: gastric pH and intestinal 
pH, since the aim of this study was to administer the nanoparticles by the oral route. 
Rosuvastatin calcium loaded polymeric nanoparticles containing two different polymers (EL 
100 and ES 100) displayed a similar biphasic drug release pattern with a burst release within 
2 hours followed by sustained release. The values are shown in Table XXIV a,b,c,d,e,f,g,h 
and Figure 26a,b,c,d,e,f,g and h.  
Formulations F1-F5 prepared using different ratios of polymer (EL 100) (1:10,1:20,1:30,1:40 
and 1:50) containing Pluronic F68 (1%) as stabilizer showed a burst release of 33.3%, 37.7%, 
26.2%, 23.1% and 20.7% at 2 hours followed by sustained release of 81.0%, 75.2%, 70.6%, 
65.6% and 60.5% at 12 hours.  
Formulations F6-F10 prepared using different ratios of polymer (EL 100) 
(1:10,1:20,1:30,1:40 and 1:50) containing Pluronic F68 (2%) as stabilizer showed a burst 
release of 38.9%, 33.1%, 32.4%, 31.3% and 28.5% at 2 hours followed by sustained release 
of 88.1%, 78.2%, 76.4%, 70.9% and 65.9% at 12 hours.  
Formulations F11-F15 prepared using different ratios of polymer (EL 100) 
(1:10,1:20,1:30,1:40 and 1:50) containing PVA (1%) as stabilizer showed a burst release of 
40.0%, 36.4%, 32.8%, 30.0% and 26.0% at 2 hours followed by sustained release of 86.1%, 
81.1%, 75.8%, 69.1% and 65.6% at 12 hours.  
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Formulations F16-F20 prepared using different ratios of polymer (EL 100) 
(1:10,1:20,1:30,1:40 and 1:50) containing PVA (2%) as stabilizer showed a burst release of 
41.3%, 39.4%, 36.0%, 33.0% and 31.7% at 2 hours followed by sustained release of 92.5%, 
85.8%, 79.0%, 72.6% and 68.2% at 12 hours.  
Formulations F21-F25 prepared using different ratios of polymer (ES 100) 
(1:10,1:20,1:30,1:40 and 1:50) containing Pluronic F68 (1%) as stabilizer showed a burst 
release of 38.6%, 34.2%, 31.6%, 29.4% and 27.1% at 2 hours followed by sustained release 
of 88.5%, 78.4%, 72.6%, 67.6% and 62.9%at 12 hours.  
Formulations F26-F30 prepared using different ratios of polymer (ES 100) 
(1:10,1:20,1:30,1:40 and 1:50) containing Pluronic F68 (2%) as stabilizer showed a burst 
release of 40.1%, 35.8%, 33.2%, 30.6% and 29.3% at 2 hours followed by sustained release 
of 91.2%, 82.2%, 77.3%, 71.0% and 67.2% at 12 hours.  
Formulations F31-F35 prepared using different ratios of polymer (ES 100) 
(1:10,1:20,1:30,1:40 and 1:50) containing PVA (1%) as stabilizer showed a burst release of 
40.0%, 35.9%, 33.3%, 31.7% and 28.6% at 2 hours followed by sustained release of 91.2%, 
81.8%, 76.9%, 71.8% and 66.2% at 12 hours.  
Formulations F35-F40 prepared using different ratios of polymer (ES 100) 
(1:10,1:20,1:30,1:40 and 1:50) containing PVA (2%) as stabilizer showed a burst release of 
41.3%, 39.0%, 35.1%, 32.5%  and 30.4% at 2 hours followed by sustained release of 93.7%, 
87.9%, 80.1%, 74.7% and 70.2% at 12 hours.     
The reason for burst release is possibly due to the unentrapped drug adsorbed on the surface 
of nanoparticles (Swarnali Das et al., 2010). Burst phase was, however, followed by 
hydration and swelling of the nano-matrix which eventually led to a controlled release 
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profile. Hydration brings about an increment in the diffusional path length of molecules and 
consequently the rate of their diffusion becomes lower (Wong CF et al., 1999). Therefore, 
gaining of controlled release profile and its maintenance could be assumed to be dependent 
upon the relative hydration rate of the polymer and integrity of hydrated matrix (Mishra B et 
al., 2010). 
Therefore, superiority of one formulation over the other could be established on the basis of 
avoidance of burst release, achievement of a controlled release profile and its maintenance in 
a time dependent manner. 
Influence of particle size and entrapment efficiency on rosuvastatin calcium release was 
studied. 
1. Influence of particle size on in vitro release studies 
Among all formulations, F6 (EL 100 1:10, Pluronic F68 2%) showing lower particle size 
(110.5 nm) provided a higher burst effect when compared to formulation F35 (ES 100 1:50, 
Pluronic 1%) showing larger particle size (231nm). 
Formulation provided burst effect in the order of  
F6 (burst release-38.9% at 2 hours) > F35 (burst release-28.6% at 2 hours) 
This is because decrease in the mean particle size in nanoparticles leads to an increase in the 
release rate which could be explained on the basis of surface area relationship                   
(Lemos-Senna E et al.,1998, Hans and Lowman et al., 2002).   
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2. Influence of entrapment efficiency on in vitro release studies 
Among all formulations, F5 (EL 100 1:50, Pluronic F68 1%) showing higher entrapment 
(78.59%) provided a better controlled release when compared to formulation F26 (ES 100 
1:10, Pluronic 2%) showing lower entrapment (28.0%). 
Formulation provided better controlled release in the order of  
F5 (release-60.5% at 12 hours) > F26 (release-91.2% at 12 hours) 
This is because, increase in entrapment efficiency leads to a better controlled release which 
could be explained on the basis of free drug concentration on the surface of nanoparticles 
(Wong CF et al., 1999). 
10.4.6 Kinetics of drug release 
The results obtained from the in vitro release studies were attempted to fit into various 
mathematical models as follows: 
a) Cumulative percentage drug release Vs time (zero order rate kinetics) 
b) Log cumulative percentage drug remaining Vs time (first order rate kinetics) 
c) Cumulative percentage drug release Vs square root of time (Higuchi classical 
diffusion model) 
d) Cube root of percentage drug remaining Vs time (Hixon Crowell erosion equation). 
e) Log cumulative percentage drug release Vs log time (Korsmeyer Peppas exponential 
equation) 
Plots of zero order, first order, Higuchi matrix, Korsmeyer - Peppas and Hixon - Crowell 
were depicted in Figure 27-31. The regression coefficient (r2) and n values were tabulated in 
Table XXV a,b,c,d,e,f,g and h. 
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Among the models tested, the drug release profile of all formulations F1-F40 were best fitted 
with first order with r2 values ranging from 0.943-0.994 and Higuchi model with r2 values 
ranging from 0.966-0.999. 
Thus Higuchi model describes drug release was purely diffusion controlled. 
Fickian and non Fickian anomalous behaviors have been used for determining the mechanism 
of drug release of polymeric nanoparticles. Korsmeyer Peppas model was used, which plots 
the log cumulative percentage of drug release up to 60% Vs log time and the release exponent 
n which indicated the release mechanism was determined. 
Different values of n for cylindrical, spherical and slab of geometrices are available in the 
literature. For spheres, values of 0.5, 0.5 < n < 1.0, 1.0 and higher than 1.0 are related to 
Fickian diffusion, anomalous, case II transport and super case II transport 
respectively(Korsmeyer et al., 1983; Paulo Costa et al., 2001). 
According to the data presented in the tables, the values of exponent n were within 0.5 which 
indicated that the drug release mechanism followed pure Fickian diffusion. This report was in 
accord with the earlier studies of Annick Ludwig et al., 2006.    
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10.5 SELECTION OF BEST FORMULATION 
From the above results of characterization, F5 and F25 were selected as the best formulation 
showing, 
 
 F5: 
Particle size     :   191.9nm 
Entrapment efficiency  :   78.59%  
In vitro drug release            :   60.5% in 12 hours.  
Release kinetics               : Closest linearity to first order kinetics                           
           (R2 - 0.994) and Higuchi model (R2- 0.999). 
 
 
 
        
 F25: 
Particle size     :   229.3nm 
Entrapment efficiency  :   70.5%  
In vitro drug release            :   62.9% in 12 hours.  
Release kinetics               : Closest linearity to first order kinetics                           
          (R2 - 0.992) and Higuchi model (R2- 0.997). 
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10.6 EVALUATION OF SELECTED BEST FORMULATION 
10.6.1 Solubility studies 
The solubility of pure drug solution was about 357.60µg/ml and the rosuvastatin calcium 
loaded polymeric nanoparticles had the solubility of about 743.94µg/ml (F5) and                    
624.60 µg/ml (F25). The results were shown in Figure 32 and Table XXVI. 
It has been reported that a progressive reduction in particle size increases the solubility. 
According to Thomson – Freundlich equation, solubility of low soluble drug is increased by 
decrease in particle size. So, reduction of particle size of poorly soluble drug rosuvastatin 
calcium had an influent effect on drug solubility (Rezaei Mokkarram et al., 2010).  
In conclusion solubility of rosuvastatin calcium polymeric nanoparticles compared to pure 
drug form was increased to about two-fold. 
10.6.2 Ex vivo intestinal permeability studies 
The results were shown in Table XXVII a,b,c,d,e and Figure 33 a,b,c,d.  
In the duodenum region, the cumulative amount of drug permeated for pure drug solution 
was about 0.32 mg and the nanoparticle formulations had the permeability of about 1.00 mg 
(F5) and 0.91 mg (F25) at the end of 2 hrs. 
Similarly in the jejunum region also, the cumulative amount of drug permeated for pure drug 
solution was 0.35 mg and for the nanoparticle formulations had the permeability of 1.00 mg           
( F5) and 0.89 ( F25) at the end of 2 hrs. 
The same type of results was also obtained from the ileum region of rat intestine. The pure 
drug solution had the cumulative amount of drug permeability of 0.327 mg and the 
formulations had the permeability of 0.99 mg (F5) and 0.87 mg (F25) at the end of 2 hrs. 
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The intestinal permeability was found to be increase in the order of 
F5 (EL 100 1:50, Pluronic F 68 1%) > F25 (ES 100 1:50, Pluronic F 68 1%) > Pure drug 
solution. 
From the results, it was observed that all the nanoparticle formulations showed better 
permeability than the pure drug solution.  
Effect of particle size on intestinal permeation                                                                 
Polymeric nanoparticles showed particle size dependent permeation through intestinal 
segments. Maximum permeation was observed for F5 (191.9nm size). Increase in particle 
size of polymeric nanoparticles F25 (229.3nm size) revealed decrease in permeation through 
intestinal segments (Kimiko Makino et al., 2008).  
The Anova analysis of apparent permeability (Papp) values in the duodenum region indicated 
that the best formulations F5 and F25 exhibited significant increase in rosuvastatin calcium 
permeability compared to pure drug (p<0.001), similarly in  the jejunum and ileum region 
also, the apparent permeability values showed significant increase when compared to pure 
drug (p<0.001).  Hence, from these results it was inferred that the, nanoparticle formulations 
showed significant improvement in the rosuvastatin calcium permeability compared to pure 
drug.    
10.6.3 Transmission electron microscopy (TEM) 
TEM was used to investigate the morphology of nanoparticles. The TEM micrograph of the 
best formulation F5 is presented in Figure 34. 
TEM shows nanoparticles with mean diameter of 101 nm, spherical shape and smooth 
surface. The size of the formulation F5 (Rosuvastatin calcium: EL 100 (1:50) containing 
Pluronic F68 (1%) as stabilizer) determined by Photon correlation spectroscopy (PCS) was 
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not consistent with that determined by TEM, which was probably caused by the different 
mechanisms of the two methods. PCS and TEM were based on scattering (Hydrodynamic 
radius) and diffraction technique in particle size measurement, respectively. 
The diameters detected by PCS were ‘hydrated diameters’, which are usually larger than their 
genuine diameters. In the case of TEM sample preparation, the formulation F5 were stained 
with 2% w/v phosphotungstic acid and all the free water and even some   hydrated water 
were stained. This implied that the size of formulation F5 derived from TEM might be 
considerably smaller than their real diameters (Xiangrong Song et al., 2008). 
10.6.4 Stability studies 
The formulation F5 (EL 100 1:50, Pluronic F 68 1%) and F25 (ES 100 1:50, Pluronic  F 68 
1%) divided into two sample sets and stored at refrigeration temperature (4 ± 2°C ) and 
25ºC± 60% RH  at the accelerated stability chamber were examined for entrapment efficiency 
for a period of 3 months.  
The physical appearance of the F5 and F25 nanosuspensions did not change when samples 
were stored at 4°C for 3 months. A loose, thin layer of sediment were observed when the F5 
and F25 nanosuspensions were stored in accelerated stability chamber at 25ºC± 60% RH. 
However, the sediment disappeared with slight hand shaking.  
The entrapment efficiencies of formulation F5 and F25 stored at 4ºC and 25ºC± 60% RH 
were shown in Table XXVIII a,b. These findings thus indicate that the nanoparticles were 
stable over storage at 4ºC and 25ºC± 60% RH for the period of 3 months. 
Based on the observations, it was concluded that the developed rosuvastatin calcium 
polymeric nanoparticles are physically and chemically stable and retain their pharmaceutical 
properties at various temperature and humidity conditions over a period of 3 months. This 
result was in accord with the earlier studies of Bivash Mandal et al., 2010.   
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Table X Calibration of Rosuvastatin Calcium in Distilled Water 
 
 
S. NO 
 
 
 
CONCENTRATION(µg/ml) 
 
 
ABSORBANCE ± SD
* 
 
1 
 
2 
 
0.071 ± 0.005 
 
2 
 
4 
 
0.142 ± 0.007 
 
3 
 
6 
 
0.213 ± 0.003 
 
4 
 
8 
 
0.284 ± 0.006 
 
5 
 
10 
 
0.355 ± 0.008 
 
6 
 
12 
 
0.426 ± 0.003 
 
7 
 
14 
 
0.497 ± 0.002 
 
8 
 
16 
 
0.568 ± 0.006 
 
9 
 
18 
 
0.639 ± 0.004 
 
10 
 
20 
 
0.709 ± 0.007 
      γ = 0.9999992 
  
n=3
* 
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Table XI   Calibration of Rosuvastatin Calcium in pH 1.2 
 
 
S. NO 
 
 
 
CONCENTRATION(µg/ml) 
 
 
ABSORBANCE ± SD
* 
 
1 
 
2 
 
0.079 ± 0.003 
 
2 
 
4 
 
0.137 ± 0.006 
 
3 
 
6 
 
0.206 ± 0.004 
 
4 
 
8 
 
0.279 ± 0.004 
 
5 
 
10 
 
0.353 ± 0.004 
 
6 
 
12 
 
0.425 ± 0.004 
 
7 
 
14 
 
0.488 ± 0.001 
 
8 
 
16 
 
0.563 ± 0.001 
 
9 
 
18 
 
0.634 ± 0.002 
 
10 
 
20 
 
0.717 ± 0.006 
       γ = 0.999650 
  
n=3
*
 
 
 
 
 
 
 
 
137 
 
Table XII Calibration of Rosuvastatin Calcium in pH 6.8 
 
 
S. NO 
 
 
 
CONCENTRATION(µg/ml) 
 
 
ABSORBANCE ± SD
* 
 
1 
 
2 
 
0.073 ± 0.003 
 
2 
 
4 
 
0.136 ± 0.002 
 
3 
 
6 
 
0.216 ± 0.001 
 
4 
 
8 
 
0.288 ± 0.001 
 
5 
 
10 
 
0.360 ± 0.005 
 
6 
 
12 
 
0.424 ± 0.003 
 
7 
 
14 
 
0.496 ± 0.007 
 
8 
 
16 
 
0.568 ± 0.001 
 
9 
 
18 
 
0.638 ± 0.005 
 
10 
 
20 
 
0.716 ± 0.006 
       γ = 0.999858 
  
n=3
* 
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Table XIII Calibration of Rosuvastatin Calcium in PBS of pH 7.4 
 
S. NO 
 
CONCENTRATION(µg/ml) 
 
ABSORBANCE ± SD
* 
 
1 
 
2 
 
0.073 ± 0.0008 
 
2 
 
4 
 
0.143 ± 0.0009 
 
3 
 
6 
 
0.227 ± 0.0009 
 
4 
 
8 
 
0.297 ± 0.001 
 
5 
 
10 
 
0.370 ± 0.0004 
 
6 
 
12 
 
0.445 ± 0.0009 
 
7 
 
14 
 
0.520 ± 0.0004 
 
8 
 
16 
 
0.593 ± 0.0009 
 
9 
 
18 
 
0.669 ± 0.0004 
 
10 
 
20 
 
0.744 ± 0.001 
                                         γ = 0.999946 
   
n=3
* 
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Table XIV FT-IR Peaks of Drug, Polymers and Physical Mixture of Drug and Polymers 
 
S.NO 
 
 
DESCRIPTION 
 
CHARACTERISTIC PEAKS (cm
-1
) OBTAINED 
 
 
 
1 
 
 
 
Rosuvastatin 
calcium 
 
358.77, 516.94, 570.95, 636.53, 717.54, 775.41, 812.06, 844.85, 
900.79, 964.44, 1070.53, 1153.47, 1195.91, 1228.7, 1334.78, 
1381.08, 1437.02, 1510.31, 1545.03, 1600.97, 2933.83, 2968.55, 
3375.54 
 
 
 
2 
 
 
 
Eudragit L100 
 
360.7, 520.8, 759.98, 788.91, 850.64, 935.51, 1020.38, 1166.97, 
1178.55, 1265.35, 1386.86, 1452.45, 1475.59, 1707.06,1735.99, 
2615.56, 2937.68, 2985.91, 3545.28 
 
 
 
3 
 
 
 
Eudragit S100 
 
484.15, 520.8, 754.19, 842.92, 968.3, 1066.67, 1157.33, 
1193.98,1269.2, 1390.72, 1448.59, 1483.31, 1645.33, 1726.35, 
2953.12, 2997.48, 3525.99 
 
 
 
 
4 
 
 
Physical 
mixture of 
Rosuvastatin 
calcium and 
Eudragit L100 
  
 
 
516.94, 570.95, 632.67, 775.41, 812.06, 844.85, 900.79, 964.44, 
1153.47, 1228.7, 1332.86, 1383.01,1438.94, 1510.31, 1546.96, 
1600.97,1697.41, 1741.78, 2931.9, 2968.55, 3394.83 
 
 
 
5 
 
 
Physical 
mixture of 
Rosuvastatin 
calcium and 
Eudragit S100 
 
 
 
516.94, 570.95, 632.67, 775.41, 844.85, 900.79, 964.44, 
1068.60,1153.47, 1193.98, 1234.48,  1440.87, 1508.38, 1546.96, 
1602.9, 1730.21, 2956.97, 3427.62  
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Table XV Endothermic Peak of Drug, Polymers and Physical Mixture of Drug and 
Polymers 
 
S.NO 
 
 
DESCRIPTION 
 
ENDOTHERMIC 
PEAKS OBTAINED 
 
 
1 
 
 
 
Rosuvastatin calcium 
 
 
 
 
88.12
°
C 
 
 
2 
 
 
 
Eudragit L100 
 
 
 
 
83.02
°
C 
 
 
3 
 
 
 
Eudragit S100 
 
 
 
 
91.50
°
C 
 
 
4 
 
 
 
Physical mixture of Rosuvastatin 
calcium and Eudragit L100 
 
 
  
 
 
 
85.36
°
C 
 
 
 
5 
 
 
 
Physical mixture of Rosuvastatin 
calcium and Eudragit S100 
 
 
 
 
 
88.93
°
C 
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Table XVI Composition of Rosuvastatin Calcium Loaded Eudragit L 100 Nanoparticles Containing Pluronic F68 as Stabilizer 
 
FORMULATION 
CODE 
 
AMOUNT OF 
DRUG ( mg) 
 
 
AMOUNT OF POLYMER 
 
 
DRUG:POLYMER 
 
 
STABILIZER 
CONCENTRATION 
 
EUDRAGIT L 100(mg) 
 
PLURONIC F68 (%) 
F1 20  200 1:10 1 
F2 20 400 1:20 1 
F3 20 600 1:30 1 
F4 20 800 1:40 1 
F5 20 1000 1:50 1 
F6 20 200 1:10 2 
F7 20 400 1:20 2 
F8 20 600 1:30 2 
F9 20 800 1:40 2 
F10 20 1000 1:50 2 
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Table XVII Composition of Rosuvastatin Calcium Loaded Eudragit L 100 Nanoparticles Containing PVA as Stabilizer 
 
FORMULATION 
CODE 
 
AMOUNT OF 
DRUG ( mg) 
 
AMOUNT OF POLYMER 
 
 
DRUG:POLYMER 
 
 
STABILIZER 
CONCENTRATION 
 
EUDRAGIT L 100(mg) 
 
PVA (%) 
F11 20  200 1:10 1 
F12 20 400 1:20 1 
F13 20 600 1:30 1 
F14 20 800 1:40 1 
F15 20 1000 1:50 1 
F16 20 200 1:10 2 
F17 20 400 1:20 2 
F18 20 600 1:30 2 
F19 20 800 1:40 2 
F20 20 1000 1:50 2 
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Table XVIII Composition of Rosuvastatin Calcium Loaded Eudragit S 100 Nanoparticles Containing Pluronic F68 as 
Stabilizer 
 
FORMULATION 
CODE 
 
AMOUNT OF 
DRUG ( mg) 
 
AMOUNT OF POLYMER 
 
 
DRUG:POLYMER 
 
 
STABILIZER 
CONCENTRATION 
 
EUDRAGIT S 100(mg) 
 
PLURONIC F68 (%) 
F21 20  200 1:10 1 
F22 20 400 1:20 1 
F23 20 600 1:30 1 
F24 20 800 1:40 1 
F25 20 1000 1:50 1 
F26 20 200 1:10 2 
F27 20 400 1:20 2 
F28 20 600 1:30 2 
F29 20 800 1:40 2 
F30 20 1000 1:50 2 
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Table XIX Composition of Rosuvastatin Calcium Loaded Eudragit S 100 Nanoparticles Containing PVA as Stabilizer 
 
FORMULATION 
CODE 
 
AMOUNT OF 
DRUG ( mg) 
 
AMOUNT OF POLYMER 
 
 
DRUG:POLYMER 
 
 
STABILIZER 
CONCENTRATION 
 
EUDRAGIT S 100(mg) 
 
PVA (%) 
F31 20  200 1:10 1 
F32 20 400 1:20 1 
F33 20 600 1:30 1 
F34 20 800 1:40 1 
F35 20 1000 1:50 1 
F36 20 200 1:10 2 
F37 20 400 1:20 2 
F38 20 600 1:30 2 
F39 20 800 1:40 2 
F40 20 1000 1:50 2 
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Table XX a Particle Size of Rosuvastatin Calcium Loaded EL 100 (Different Ratios) Nanoparticles 
Containing   Pluronic F68 (1%) as Stabilizer 
 
FORMULATION 
CODE 
 
 
DRUG: POLYMER 
 
 
MEAN 
DIAMETER(nm) 
 
PDI 
 
F1 
 
 
1:10 
 
125.9 
 
0.095 
 
F2 
 
 
1:20 
 
142.2 
 
0.092 
 
F3 
 
 
1:30 
 
166.2 
 
0.162 
 
F4 
 
 
1:40 
 
178.5 
 
0.185 
 
F5 
 
 
1:50 
 
191.9 
 
0.109 
 
Table XX b Particle Size of Rosuvastatin Calcium Loaded EL 100 (Different Ratios) Nanoparticles 
Containing Pluronic F68 (2 %) as Stabilizer 
 
FORMULATION 
CODE 
 
 
DRUG: POLYMER 
 
 
MEAN 
DIAMETER(nm)  
 
PDI 
 
F6 
 
 
1:10 
 
110.5 
 
0.095 
 
F7 
 
 
1:20 
 
133.9 
 
0.159 
 
F8 
 
 
1:30 
 
152.2 
 
0.132 
 
F9 
 
 
1:40 
 
168.3 
 
0.123 
 
F10 
 
 
1:50 
 
182.8 
 
0.192 
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Table XX c Particle Size of Rosuvastatin Calcium Loaded EL 100 (Different Ratios) Nanoparticles 
Containing PVA (1%) as Stabilizer 
 
FORMULATION 
CODE 
 
 
DRUG: POLYMER 
 
 
MEAN 
DIAMETER(nm)  
 
PDI 
 
F11 
 
 
1:10 
 
135.9 
 
0.159 
 
F12 
 
 
1:20 
 
151.0 
 
0.161 
 
F13 
 
 
1:30 
 
174.1 
 
0.173 
 
F14 
 
 
1:40 
 
187.0 
 
0.175 
 
F15 
 
 
1:50 
 
209.3 
 
0.192 
 
Table XX d   Particle Size of Rosuvastatin Calcium Loaded EL 100 (Different Ratios) Nanoparticles 
Containing PVA (2%) as Stabilizer 
 
FORMULATION 
CODE 
 
 
DRUG: POLYMER 
 
 
MEAN 
DIAMETER(nm)  
 
PDI 
 
F16 
 
 
1:10 
 
127.0 
 
0.167 
 
F17 
 
 
1:20 
 
145.0 
 
0.159 
 
F18 
 
 
1:30 
 
168.0 
 
0.123 
 
F19 
 
 
1:40 
 
174.0 
 
0.173 
 
F20 
 
 
1:50 
 
190.1 
 
0.175 
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Table XX e Particle Size of Rosuvastatin Calcium Loaded ES 100 (Different Ratios) Nanoparticles 
Containing Pluronic F68 (1%) as Stabilizer 
 
FORMULATION 
CODE 
 
 
DRUG: POLYMER 
 
 
MEAN 
DIAMETER(nm)  
 
PDI 
 
F21 
 
 
1:10 
 
139.2 
 
0.092 
 
F22 
 
 
1:20 
 
157.1 
 
0.174 
 
F23 
 
 
1:30 
 
174.1 
 
0.164 
 
F24 
 
 
1:40 
 
192.0 
 
0.175 
 
F25 
 
 
1:50 
 
229.3 
 
0.175 
 
Table XX f Particle Size of Rosuvastatin Calcium Loaded ES 100 (Different Ratios) Nanoparticles 
Containing Pluronic F68 (2%) as Stabilizer 
 
FORMULATION 
CODE 
 
 
DRUG: POLYMER 
 
 
MEAN 
DIAMETER(nm)  
 
PDI 
 
F26 
 
 
1:10 
 
131.0 
 
0.159 
 
F27 
 
 
1:20 
 
145.0 
 
0.176 
 
F28 
 
 
1:30 
 
164.0 
 
0.182 
 
F29 
 
 
1:40 
 
179.0 
 
0.169 
 
F30 
 
 
1:50 
 
210.1 
 
0.109 
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Table XX g Particle Size of Rosuvastatin Calcium Loaded ES 100 (Different Ratios) Nanoparticles 
Containing PVA (1%) as Stabilizer 
 
FORMULATION 
CODE 
 
 
DRUG: POLYMER 
 
 
MEAN 
DIAMETER(nm)  
 
PDI 
 
F31 
 
 
1:10 
 
149.0 
 
0.161 
 
F32 
 
 
1:20 
 
161.0 
 
0.141 
 
 
F33 
 
 
1:30 
 
178.0 
 
0.094 
 
F34 
 
 
1:40 
 
199.0 
 
0.109 
 
F35 
 
 
1:50 
 
231.0 
 
0.175 
 
 
Table XX h Particle Size of Rosuvastatin Calcium Loaded ES 100 (Different Ratios) Nanoparticles 
Containing PVA (2%) as Stabilizer 
 
FORMULATION 
CODE 
 
 
DRUG: POLYMER 
 
 
MEAN 
DIAMETER(nm)  
 
PDI 
 
F36 
 
 
1:10 
 
137.0 
 
0.163 
 
F37 
 
 
1:20 
 
159.0 
 
0.093 
 
F38 
 
 
1:30 
 
165.0 
 
0.135 
 
F39 
 
 
1:40 
 
192.1 
 
0.175 
 
F40 
 
 
1:50 
 
229.5 
 
0.175 
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Table XXI a Zeta Potential Values of Rosuvastatin Calcium Loaded EL 100 Nanoparticles 
 
 
S.NO 
 
 
FORMULATION CODE 
 
 
ZETA POTENTIAL 
(mV) 
 
1 F 1 
 
-25.3 
 
2 F 2 -26.4 
3 F 3 -27.6 
4 F 4 -25.9 
5 F 5 -28.4 
6 F 6 -26.5 
7 F 7 -28.5 
8 F 8 -25.8 
9 F 9 -25.4 
10 F 10 -26.9 
11 F 11 -28.6 
12 F 12 -28.1 
13 F 13 -25.2 
14 F 14 -26.7 
15 F 15 -27.5 
16 F 16 -28.3 
17 F 17 -26.8 
18 F 18 -27.3 
19 F 19 -28.7 
20 F 20 -25.8 
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Table XXI b Zeta Potential Values of Rosuvastatin Calcium Loaded ES 100 Nanoparticles 
 
 
S.NO 
 
 
FORMULATION CODE 
 
 
ZETA POTENTIAL 
(mV) 
 
1 F 21 
 
-26.2 
2 F 22 -26.1 
3 F 23 -29.4 
4 F 24 -28.9 
5 F 25 -27.5 
6 F 26 -26.4 
7 F 27 -29.8 
8 F 28 -26.1 
9 F 29 -29.9 
10 F 30 -27.4 
11 F 31 -26.7 
12 F 32 -26.1 
13 F 33 -27.8 
14 F 34 -28.9 
15 F 35 -29.4 
16 F 36 -29.5 
17 F 37 -27.2 
18 F 38 -28.5 
19 F 39 -27.2 
20 F 40 -26.2 
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Table XXII a Drug Content of Rosuvastatin Calcium Loaded 
EL100 Nanoparticles 
 
 
S.NO 
 
 
FORMULATION CODE 
 
 
DRUG CONTENT (%) 
±SD* 
 
1 F 1 
 
91.45 % ±0.98 
2 F 2 96.78 % ±0.66 
3 F 3 92.48 % ±0.56 
4 F 4 95.56 % ±0.45 
5 F 5 92.34 % ±0.33 
6 F 6 93.78 % ±0.24 
7 F 7 91.58 % ±0.37 
8 F 8 96.86 % ±0.67 
9 F 9 95.87 % ±0.34 
10 F 10 94.10 % ±0.42 
11 F 11 95.50 % ±0.56 
12 F 12 91.80 % ±0.56 
13 F 13 93.90 % ±0.87 
14 F 14 90.75 % ±0.45 
15 F 15 95.90 % ±0.88 
16 F 16 91.50 % ±0.72 
17 F 17 93.70 % ±0.31 
18 F 18 94.90 % ±0.56 
19 F 19 92.79 % ±0.67 
20 F 20 91.92 % ±0.34 
 
  n=3* 
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Table XXII b Drug Content of Rosuvastatin Calcium Loaded 
ES 100 Nanoparticles 
 
 
S.NO 
 
 
FORMULATION CODE 
 
 
DRUG CONTENT (%) 
±SD* 
 
1 F 21 
 
94.55 % ±0.67 
2 F 22 93.08 % ±0.34 
3 F 23 95.48 % ±0.78 
4 F 24 92.66 % ±0.98 
5 F 25 96.34 % ±0.56 
6 F 26 92.18 % ±0.45 
7 F 27 91.46 % ±0.67 
8 F 28 94.21 % ±0.56 
9 F 29 93.37 % ±0.23 
10 F 30 94.60 % ±0.33 
11 F 31 94.70 % ±0.43 
12 F 32 92.45 % ±0.45 
13 F 33 92.56 % ±1.09 
14 F 34 94.25 % ±0.34 
15 F 35 93.40 % ±0.23 
16 F 36 95.56 % ±0.94 
17 F 37 95.76 % ±0.98 
18 F 38 95.07 % ±0.66 
19 F 39 95.71 % ±0.45 
20 F 40 94.23 % ±0.78 
 
  n=3* 
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Table XXIII a Entrapment Efficiencies of Rosuvastatin Calcium Loaded EL 100 (Different    
Ratios) Nanoparticles Containing Pluronic F68 (1%) as Stabilizer 
 
FORMULATION 
CODE 
 
 
DRUG: POLYMER 
 
 
ENTRAPMENT 
EFFICIENCY (%) 
± S.D* 
 
F1 
 
 
1:10 
 
42.1 ±0.78 
 
F2 
 
 
1:20 
 
54.4 ±0.45 
 
F3 
 
 
1:30 
 
69.9 ±0.67 
 
F4 
 
 
1:40 
 
75.8 ±0.98 
 
F5 
 
 
1:50 
 
78.5 ±0.12 
 
Table XXIII b Entrapment Efficiencies of Rosuvastatin Calcium Loaded EL 100 (Different Ratios) 
Nanoparticles Containing Pluronic F68 (2 %) as Stabilizer 
 
FORMULATION 
CODE 
 
 
DRUG: POLYMER 
 
 
ENTRAPMENT 
EFFICIENCY (%) 
± S.D* 
 
F6 
 
 
1:10 
 
38.3 ±0.45 
 
F7 
 
 
1:20 
 
50.8 ±0.78 
 
F8 
 
 
1:30 
 
63.9 ±0.98 
 
F9 
 
 
1:40 
 
69.2 ±0.23 
 
F10 
 
 
1:50 
 
74.2 ±0.56 
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Table XXIII c Entrapment Efficiencies of Rosuvastatin Calcium Loaded EL 100 (Different Ratios) 
Nanoparticles Containing PVA (1%) as Stabilizer 
 
FORMULATION 
CODE 
 
 
DRUG: POLYMER 
 
 
ENTRAPMENT 
EFFICIENCY (%) 
± S.D*  
 
F11 
 
 
1:10 
 
47.5 ±0.66 
 
F12 
 
 
1:20 
 
55.5 ±0.44 
 
F13 
 
 
1:30 
 
65.0 ±0.34 
 
F14 
 
 
1:40 
 
71.4 ±0.76 
 
F15 
 
 
1:50 
 
75.2 ±0.45 
 
Table XXIII d Entrapment Efficiencies of Rosuvastatin Calcium Loaded EL 100 (Different Ratios) 
Nanoparticles Containing PVA (2%) as Stabilizer 
 
FORMULATION 
CODE 
 
 
DRUG: POLYMER 
 
 
ENTRAPMENT 
EFFICIENCY (%) 
± S.D* 
 
F16 
 
 
1:10 
 
36.0 ±0.45 
 
F17 
 
 
1:20 
 
47.6 ±0.32 
 
F18 
 
 
1:30 
 
54.9 ±0.65 
 
F19 
 
 
1:40 
 
66.6 ±0.13 
 
F20 
 
 
1:50 
 
70.3 ±0.98 
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Table XXIII e Entrapment Efficiencies of Rosuvastatin Calcium Loaded ES 100 (Different Ratios) 
Nanoparticles Containing Pluronic F68 (1%) as Stabilizer 
 
FORMULATION 
CODE 
 
 
DRUG: POLYMER 
 
 
ENTRAPMENT 
EFFICIENCY (%) 
± S.D* 
 
F21 
 
 
1:10 
 
33.0 ±0.45 
 
F22 
 
 
1:20 
 
42.0 ±0.43 
 
F23 
 
 
1:30 
 
52.6 ±0.66 
 
F24 
 
 
1:40 
 
60.2 ±0.32 
 
F25 
 
 
1:50 
 
70.5 ±0.18 
 
Table XXIII f Entrapment Efficiencies of Rosuvastatin Calcium Loaded ES 100 (Different Ratios) 
Nanoparticles Containing Pluronic F68 (2%) as Stabilizer 
 
FORMULATION 
CODE 
 
 
DRUG: POLYMER 
 
 
ENTRAPMENT 
EFFICIENCY (%) 
± S.D* 
 
F26 
 
 
1:10 
 
28.0 ±0.99 
 
F27 
 
 
1:20 
 
39.8 ±0.45 
 
F28 
 
 
1:30 
 
49.0 ±0.23 
 
F29 
 
 
1:40 
 
54.3 ±0.43 
 
F30 
 
 
1:50 
 
62.0 ±0.15 
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Table XXIII g Entrapment Efficiencies of Rosuvastatin Calcium Loaded ES 100 (Different 
Ratios) Nanoparticles Containing PVA (1%) as Stabilizer 
 
FORMULATION 
CODE 
 
 
DRUG: POLYMER 
 
 
ENTRAPMENT 
EFFICIENCY (%) 
± S.D* 
 
F31 
 
 
1:10 
 
29.5 ±0.45 
 
F32 
 
 
1:20 
 
34.6 ±0.66 
 
F33 
 
 
1:30 
 
47.0 ±0.12 
 
F34 
 
 
1:40 
 
54.9 ±0.45 
 
F35 
 
 
1:50 
 
60.4 ±0.76 
 
Table XXIII h Entrapment Efficiencies Of Rosuvastatin Calcium Loaded ES 100 (Different Ratios) 
Nanoparticles Containing PVA (2%) as Stabilizer 
 
FORMULATION 
CODE 
 
 
DRUG: POLYMER 
 
 
ENTRAPMENT 
EFFICIENCY (%) 
± S.D* 
 
F36 
 
 
1:10 
 
28.0 ±0.22 
 
F37 
 
 
1:20 
 
32.0 ±1.02 
 
F38 
 
 
1:30 
 
41.7 ±0.98 
 
F39 
 
 
1:40 
 
47.0 ±0.45 
 
F40 
 
 
1:50 
 
55.5 ±0.12 
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Table XXIV a Comparison of Invitro Release of Rosuvastatin Calcium Loaded EL 100 
(Different Ratios) Nanoparticles Containing Pluronic F68 (1%) as Stabilizer 
pH TIME(HRS) 
 
CUMULATIVE %  DRUG RELEASE ± S.D* 
 
 
F1 
EL 100(1:10) 
 
F2 
EL 100(1:20) 
 
F3 
EL 100(1:30) 
 
F4 
EL 100(1:40) 
 
F5 
EL 100(1:50) 
 
 
 
1.2 
0.25 9.2 ± 0.72 7.1 ± 0.80 6.2 ± 0.70 5.1 ± 0.41 3.7 ± 0.41 
0.50 11.5 ± 0.23 10.3 ± 0.31 8.0 ± 0.70 7.3 ± 0.76 6.2 ± 0.43 
0.75 15.5 ± 0.90 13.0 ± 0.50 10.7 ± 0.75 9.6 ± 0.91 10.1 ± 0.70 
1.00 20.7 ± 0.34 20.0 ± 0.72 15.3 ± 0.34 13.8 ± 0.49 13.3 ±0.28 
1.50 27.5 ± 0.87 24.7 ± 0.38 21.5 ± 0.70 18.5 ± 0.47 16.9 ± 0.60 
2.00 33.3 ± 0.20 29.5 ± 0.89 26.2 ± 0.15 23.1 ± 0.29 20.7 ± 0.35 
 
 
 
 
 
 
 
 
 
 
 
6.8 
2.50 41.9 ± 0.36 36.6 ± 0.96 32.8 ± 0.88 28.7 ± 0.80 25.7 ± 0.25 
3.00 43.7 ± 0.90 37.7 ± 0.68 33.8 ± 0.27 29.7 ± 0.52 26.5 ± 0.60 
3.50 45.0 ± 0.86 39.2 ± 0.15 35.7 ± 0.95 31.5 ± 0.87 27.5 ± 0.89 
4.00 47.6 ± 0.23 41.2 ± 0.15 36.9 ± 0.91 33.1 ± 0.83 29.2 ± 0.51  
4.50 48.7 ± 0.89 42.4 ± 0.40 38.4 ± 0.83 34.2 ± 0.83 30.1 ± 0.52 
5.00 50.4 ± 0.45 44.6 ± 0.57 39.8 ± 0.83 35.3 ± 0.69 31.1 ± 0.49 
5.50 52.1 ± 0.54 46.2 ± 0.31 41.8 ± 0.22 37.1 ± 0.58 32.1 ± 0.51 
6.00 54.1 ± 0.33 48.1 ± 0.41 44.5 ± 0.53 39.8 ± 0.72 33.9 ± 0.28 
6.50 55.7 ± 0.67 49.9 ± 0.53 47.0 ± 0.59 41.6 ± 0.70 35.5 ± 0.47 
7.00 57.6 ± 0.45 51.9 ± 0.34 49.4 ± 0.90 44.0 ± 0.40 37.4 ± 0.37 
7.50 60.1 ± 0.87 54.1 ± 0.95 51.4 ± 0.82 46.6 ± 0.13 39.1 ± 0.75 
8.00 61.7 ± 0.39 56.0 ± 0.63 53.5 ± 0.85 48.6 ± 0.26 41.8 ± 0.24  
8.50 64.2 ± 0.56 58.8 ± 0.95 55.8 ± 0.76 51.0 ± 0.53 44.0 ± 0.81 
9.00 66.9 ± 0.67 60.9 ± 0.55 57.6 ± 0.82 53.0 ± 0.53 47.5 ± 0.36  
9.50 68.9 ± 0.93 62.9 ± 0.42 59.5 ± 0.73 55.1 ± 0.32 49.8 ± 0.92 
10.00 71.0 ± 0.78 65.4 ± 0.33 61.6 ± 0.56 57.4 ± 0.20 51.7 ± 0.81 
10.50 73.0 ± 0.45 67.7 ± 0.10 63.7 ± 0.82 59.3 ± 0.30 54.0 ± 0.91 
11.00 75.5 ± 0.63 70.0 ± 0.43 66.1 ± 0.67 61.4 ±0.57 55.9 ± 0.70 
11.50 77.8 ± 0.39 72.6 ± 0.65 68.2 ± 0.87 63.1 ± 0.59 57.9 ± 0.75  
12.00 81.0 ± 0.45 75.2 ± 0.72 70.6 ± 0.79 65.6 ± 0.51 60.5 ± 0.60 
 
n=3
* 
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Table XXIV b Comparison of Invitro Release of Rosuvastatin Calcium Loaded EL 100 
(Different Ratios) Nanoparticles Containing Pluronic F68 (2%) as Stabilizer 
pH TIME(HRS) 
 
CUMULATIVE %  DRUG RELEASE ± S.D* 
 
 
F6 
EL 100(1:10) 
 
F7 
EL 100(1:20) 
 
F8 
EL 100(1:30) 
 
F9 
EL 100(1:40) 
 
F10 
EL 100(1:50) 
 
 
 
1.2 
0.25 9.1 ± 0.70 7.5 ± 0.50 7.1 ± 0.10 6.7 ±  0.41 5.3 ± 0.28 
0.50 16.3 ± 0.60 13.2 ± 0.47 12.7 ± 0.83 12.7 ± 0.52 9.7 ± 0.31  
0.75 19.7 ± 0.56 16.0 ± 0.49 15.8 ± 0.75 15.5 ± 0.60 14.1 ± 0.43 
1.00 24.9 ± 0.25 21.9 ± 0.75 88.0 ± 0.15 20.8 ± 0.37 17.5 ± 0.42  
1.50 32.7 ± 0.61 28.5 ± 0.80 28.2 ± 0.83 27.6 ± 0.20 24.3 ± 0.13 
2.00 38.9 ± 0.86 33.1 ± 0.85 32.4 ± 0.96 31.3 ± 0.32 28.5 ± 0.41 
 
 
 
 
 
 
 
 
 
 
 
6.8 
2.50 48.9 ± 0.56 41.5 ± 0.26 40.5 ± 0.15 38.8 ± 0.28 35.6 ± 0.40 
3.00 49.9 ± 0.60 42.5 ± 0.17 41.3 ± 0.27 39.6 ± 0.26 36.2 ± 0.40 
3.50 50.9 ± 0.90 43.5 ± 0.55 42.2 ± 0.22 40.8 ± 0.05 37.1 ± 0.45  
4.00 52.3 ± 0.80 44.4 ± 0.73 43.6 ± 0.84 41.7 ± 0.15 37.7 ± 0.40 
4.50 54.2 ± 0.70 45.8 ± 0.64 44.7 ± 0.18 42.8 ± 0.17 38.9 ± 0.56  
5.00 55.9 ± 0.74 47.1 ± 0.90 46.0 ± 0.20 44.4 ± 0.15 40.4 ± 0.41 
5.50 57.7 ± 0.87 49.3 ± 0.70 47.6 ± 0.73 46.1 ± 0.11 41.6 ± 0.41  
6.00 60.2 ± 0.17 51.0 ± 0.62 49.1 ± 0.76 47.5 ± 0.20 42.8 ± 0.41 
6.50 62.5 ± 0.25 52.8 ± 0.90 50.9 ± 0.22 49.1 ± 0.25 44.3 ± 0.41 
7.00 64.5 ± 0.32 55.0 ± 0.29 52.9 ± 0.57 50.7 ± 0.20 46.1 ± 0.49 
7.50 66.4 ± 0.95 57.1 ± 0.42 54.6 ± 0.66 52.5 ± 0.55 48.1 ± 0.42 
8.00 68.4 ± 0.24 59.1 ± 0.28 57.1 ± 0.32 53.9 ± 0.40 49.7 ± 0.51  
8.50 71.2 ± 0.44 61.2 ± 0.26 59.4 ± 0.26 56.1 ± 0.52 51.2 ± 0.52 
9.00 73.0 ± 0.27 63.6 ± 0.61 62.2 ± 0.44 58.0 ± 0.63 53.3 ± 0.53 
9.50 75.5 ± 0.80 65.7 ± 0.28 64.0 ± 0.28 59.8 ± 0.45 54.9 ± 0.38 
10.00 77.4 ± 0.15 67.5 ± 0.31 66.1 ± 0.33 62.1 ± 0.40 56.6 ± 0.77 
10.50 80.1 ± 0.52 69.9 ± 0.16 68.2 ± 0.75 64.3 ± 0.35 58.7 ± 0.47 
11.00 82.4 ± 0.95 72.5 ± 0.98 70.7 ± 0.57 66.2 ± 0.25 60.7 ± 0.47 
11.50 85.4 ± 0.44 75.2 ± 0.15 73.5 ± 0.86 68.4 ± 0.61 63.2 ± 0.64 
12.00 88.1 ± 0.12 78.2 ± 0.12 76.4 ± 0.72 70.9 ± 0.61 65.9 ± 0.70 
 
n=3
* 
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Table XXIV c Comparison of Invitro Release of Rosuvastatin Calcium Loaded EL 100 
(Different Ratios) Nanoparticles Containing PVA (1%) as Stabilizer 
pH TIME(HRS) 
 
CUMULATIVE %  DRUG RELEASE ± S.D* 
 
 
F11 
EL 100(1:10) 
 
F12 
EL 100(1:20) 
 
F13 
EL 100(1:30) 
 
F14 
EL 100(1:40) 
 
F15 
EL 100(1:50) 
 
 
 
1.2 
0.25 10.8 ± 0.58 8.9 ± 0.42 7.6 ± 0.28 6.7 ± 0.28 5.9 ± 0.28 
0.50 17.5 ± 0.61 15.8 ± 0.41 14.0 ± 0.43 12.5 ± 0.41  12.3 ± 0.43   
0.75 23.9 ± 0.76 22.9 ± 0.30 18.7 ± 0.56 17.1 ± 0.42 15.8 ± 0.30   
1.00 30.2 ± 0.24 26.4 ± 0.32 24.1 ± 0.27 20.8 ± 0.28 18.6 ± 0.44 
1.50 33.3 ± 0.67 30.6 ±0.69 29.4 ± 0.46 25.2 ± 0.29 21.8 ± 0.45 
2.00 40.0 ± 0.48 36.4 ± 0.73 32.8 ± 0.47 30.0 ± 0.24 26.0 ± 0.37 
 
 
 
 
 
 
 
 
 
 
 
6.8 
 
2.50 51.8 ± 0.14 46.2 ± 0.21 41.3 ± 0.52 37.9 ± 0.13 33.2 ± 0.13 
3.00 53.4 ± 0.12 47.3 ± 0.09 42.5 ± 0.82 38.6 ± 0.06 34.4 ± 0.12 
3.50 54.6 ± 0.10 48.6 ± 0.98 43.7 ± 0.96 39.8 ± 0.08 35.3 ± 0.14 
4.00 55.6 ± 0.25 49.7 ± 0.72 45.0 ± 0.98 40.9 ± 0.35 36.4 ± 0.15 
4.50 57.4 ± 0.23 50.9 ± 0.54 46.3 ± 0.87 41.9 ± 0.44 37.8 ± 0.17 
5.00 58.6 ±0.22 52.5 ± 0.39 47.4 ± 0.89 43.0 ± 0.30 39.3 ± 0.12 
5.50 60.1 ± 0.88 53.8 ± 0.37 48.9 ± 0.75 44.2 ± 0.31 40.6 ± 0.13 
6.00 61.3 ± 0.12 55.1 ± 0.79 51.1 ± 0.76 45.3 ± 0.16 42.0 ± 0.22 
6.50 62.8 ± 0.16 57.0 ± 0.52 53.0 ± 0.77 47.0 ± 0.23 43.5 ± 0.11 
7.00 64.5 ± 0.15 58.6 ± 0.83 54.6 ± 0.77 48.6 ± 0.34 45.0 ±0.62  
7.50 66.7 ± 0.68 60.5 ± 0.68 56.5 ± 0.92 50.2 ± 0.16 46.8 ± 0.32 
8.00 68.5 ± 0.12 62.0 ± 0.76 58.5 ± 1.07 51.9 ± 0.17 48.6 ± 0.17 
8.50 70.3 ± 0.95 63.5 ± 0.84 60.4 ± 1.09 53.7 ± 0.32 50.4 ± 0.18 
9.00 71.9 ± 0.76 65.0 ± 0.94 62.4 ± 0.84 55.5 ± 0.41 52.5 ± 0.34 
9.50 73.7 ± 0.89 67.1 ± 0.34 64.4 ± 0.85 57.4 ± 0.43 54.2 ± 0.36 
10.00 75.3 ± 0.44 69.8 ± 0.14 66.4 ± 0.75 59.3 ± 0.44 56.4 ± 0.37 
10.50 77.6 ± 0.40 72.6 ± 0.47 69.0 ± 0.66 61.4 ± 0.53 58.6 ± 0.22  
11.00 80.2 ± 0.43 75.4 ± 0.25 71.4 ± 0.86 63.5 ± 0.55 60.9 ± 0.46 
11.50 83.1 ± 0.60 78.1 ± 0.36 73.4 ± 0.60 66.3 ± 0.76 63.1 ± 0.49 
12.00 86.1 ± 0.60 81.1 ± 0.31 75.8 ± 0.68 69.1 ± 0.51 65.6 ± 0.49 
 
n=3
* 
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Table XXIV d Comparison of Invitro Release of Rosuvastatin Calcium Loaded EL 100 
(Different Ratios) Nanoparticles Containing PVA (2%) as Stabilizer. 
pH TIME(HRS) 
 
CUMULATIVE %  DRUG RELEASE ± S.D* 
 
 
F16 
EL 100(1:10) 
 
F17 
EL 100(1:20) 
 
F18 
EL 100(1:30) 
 
F19 
EL 100(1:40) 
 
F20 
EL 100(1:50) 
 
 
 
1.2 
0.25 10.9 ± 0.28 9.6 ± 0.16 8.5 ± 0.16 7.3 ± 0.28 6.5 ± 0.16 
0.50 17.7 ± 0.29 16.8 ± 0.28 14.7 ± 0.27 12.8 ± 0.44 11.8 ± 0.28 
0.75 24.6 ± 0.69 23.4 ± 0.14 21.3 ± 0.42 20.0 ± 0.44 18.5 ± 0.44 
1.00 29.9 ± 0.45 29.7 ± 0.41 27.0 ± 0.43 25.2 ± 0.29 24.2 ± 0.32 
1.50 33.4 ± 0.61 33.0 ± 0.28 31.1 ± 0.18 28.9 ± 0.31 27.95 ± 0.33 
2.00 41.3 ± 0.47 39.4 ± 0.44 36.0 ± 0.46 33.0 ± 0.24 31.7 ± 0.35 
 
 
 
 
 
 
 
 
 
 
 
6.8 
2.50 52.7 ± 0.48 49.9 ± 0.45 45.9 ±0.48 42.0 ± 0.16 40.2 ± 0.58 
3.00 54.1 ± 0.43 50.9 ± 0.59 46.7 ± 0.63 43.0 ± 0.17 41.2 ± 0.58 
3.50 55.5 ± 0.53 51.8 ± 0.61 47.6 ± 0.63 44.0 ± 0.49 42.0 ± 0.59 
4.00 56.8 ± 0.38 53.1 ± 0.68 48.7 ± 0.68 44.9 ± 0.36 43.1 ± 0.60 
4.50 58.7 ± 0.43 54.4 ± 0.63 50.0 ± 0.65 46.2 ± 0.22 44.0 ± 0.65 
5.00 60.0 ± 0.43 56.4 ± 0.64 51.4 ± 0.65 47.4 ± 0.23 45.1 ± 0.66 
5.50 61.9 ± 0.55 57.7 ± 0.77 52.8 ± 0.81 48.6 ± 0.24 46.3 ± 0.67 
6.00 63.4 ± 0.37 59.3 ± 0.78 54.0 ± 0.83 49.9 ± 0.25 47.5 ± 0.68 
6.50 65.9 ± 0.44 61.1 ± 0.67 55.9 ± 0.84 51.2 ± 0.26 48.8 ± 0.69 
7.00 68.3 ± 0.44 63.0 ± 0.57 57.3 ± 0.85 52.8 ± 0.27 50.3 ± 0.65 
7.50 69.8 ± 0.44 64.7 ± 0.73 58.9 ± 0.72 54.2 ± 0.29 52.0 ± 0.71 
8.00 71.9 ± 0.58 66.6 ± 0.50 60.7 ± 0.72 55.7 ± 0.22 53.4 ± 0.72 
8.50 73.9 ± 0.77 68.9 ± 0.67 62.3 ± 0.88 57.5 ± 0.42 55.2 ± 0.73 
9.00 76.4 ± 0.61 71.3 ± 0.52 64.8 ± 0.89 59.5 ± 0.19 56.7 ± 0.81 
9.50 79.0 ± 0.78 73.4 ± 0.59 66.8 ± 0.61 61.7 ± 0.64 58.3 ± 0.82 
10.00 81.5 ± 0.64 75.8 ± 0.59 68.8 ± 0.61 63.7 ± 0.45 60.0 ± 0.69 
10.50 84.5 ± 0.74 78.1 ± 0.69 71.1 ± 0.49 65.5 ± 0.12 61.7 ± 0.72 
11.00 86.9 ± 0.53 80.5 ± 0.54 73.6 ± 0.51 67.7 ± 0.28 63.8 ± 0.72 
11.50 89.5 ± 0.31 82.8 ± 0.55 76.3 ± 0.59 70.3 ± 0.42 65.9 ± 0.71 
12.00 92.5 ± 0.84 85.8 ± 0.60 79.0 ± 0.66 72.6 ± 0.22 68.2 ± 0.86 
 
n=3
* 
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Table XXIV e Comparison of Invitro Release of Rosuvastatin Calcium Loaded ES 100 
(Different Ratios) Nanoparticles Containing Pluronic F68 (1%) as Stabilizer. 
pH TIME(HRS) 
 
CUMULATIVE %  DRUG RELEASE ± S.D* 
 
 
F21 
ES 100(1:10) 
 
F22 
ES 100(1:20) 
 
F23 
ES 100(1:30) 
 
F24 
ES 100(1:40) 
 
F25 
ES 100(1:50) 
 
 
 
1.2 
0.25 9.8 ± 0.28 9.3 ± 0.28 7.9 ± 0.28 7.0 ± 0.28 5.9 ± 0.28 
0.50 17.0 ± 0.15 14.9 ± 0.32 13.1 ± 0.16 12.5 ± 0.16 10.7 ± 0.29 
0.75 21.2 ± 0.27 18.4 ± 0.32 16.9 ± 0.17 15.9 ± 0.14 14.9 ± 0.18 
1.00 26.2 ± 0.28 24.1 ± 0.17 22.3 ± 0.30 21.6 ± 0.27 18.7 ± 0.19 
1.50 32.0 ± 0.16 28.9 ± 0.30 27.3 ± 0.31 26.0 ± 0.28 24.2 ± 0.19 
2.00 38.6 ± 0.30 34.2 ± 0.29 31.6 ± 0.33 29.4 ± 0.30 27.1 ± 0.31 
 
 
 
 
 
 
 
 
 
 
 
6.8 
2.50 48.8 ± 0.38 43.2 ± 0.48 40.1 ± 0.54 37.5 ± 0.48 34.7 ± 0.51 
3.00 50.1 ± 0.40 44.4 ± 0.47 41.1 ± 0.55 38.3 ± 0.37 35.7 ± 0.52 
3.50 51.3 ± 0.34 46.0 ± 0.65 42.6 ± 0.55 39.7 ± 0.54 36.9 ± 0.65 
4.00 53.0 ± 0.55 47.3 ± 0.57 43.5 ± 0.56 40.9 ± 0.50 38.0 ± 0.66 
4.50 54.7 ± 0.24 48.6 ± 0.74 44.4 ± 0.57 42.1 ± 0.50 39.0 ± 0.71 
5.00 56.5 ± 0.24 49.8 ± 0.53 45.3 ± 0.63 43.0 ± 0.50 39.8 ± 0.58 
5.50 58.3 ± 0.18 51.1 ± 0.54 46.4 ± 0.58 44.1 ± 0.66 40.7 ± 0.59 
6.00 60.0 ± 0.17 52.4 ± 0.55 47.9 ± 0.59 45.6 ± 0.57 41.5 ± 0.45 
6.50 62.2 ± 0.24 53.8 ± 0.56 49.3 ± 0.73 47.0 ± 0.67 42.7 ± 0.50 
7.00 64.3 ± 0.24 55.4 ± 0.68 50.9 ± 0.61 48.5 ± 0.60 44.0 ±0.47 
7.50 66.2 ± 0.15 56.8 ± 0.55 52.2 ± 0.62 49.8 ± 0.56 45.0 ± 0.48 
8.00 68.2 ± 0.15 58.5 ± 0.56 53.8 ± 0.76 51.0 ± 0.62 46.4 ± 0.48 
8.50 70.7 ± 0.25 60.6 ± 0.56 55.5 ± 0.77 52.7 ± 0.62 47.7 ± 0.51 
9.00 72.7 ± 0.29 62.7 ± 0.33 57.9 ± 0.78 54.5 ± 0.58 49.2 ± 0.52 
9.50 75.2 ± 0.13 65.0 ±0.56 59.8 ± 0.80 56.0 ± 0.44 51.1 ± 0.38 
10.00 77.9 ± 0.44 67.3 ± 0.57 62.6 ± 0.69 57.9 ± 0.44 53.5 ± 0.38 
10.50 80.0 ± 0.14 69.8 ± 0.45 65.0 ± 0.68 60.1 ± 0.57 55.3 ± 0.52 
11.00 83.2 ± 0.13 72.3 ± 0.45 67.6 ± 0.71 62.1 ± 0.30 57.5 ± 0.53 
11.50 85.6 ± 0.13 75.2 ± 0.36 69.9 ± 0.87 64.6 ± 0.35 60.2 ± 0.39 
12.00 88.5 ± 0.29 78.4 ± 0.29 72.6 ± 0.74 67.6 ± 0.60 62.9 ± 0.39 
 
n=3
* 
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Table XXIV f Comparison of Invitro Release of Rosuvastatin Calcium Loaded ES 100 
(Different Ratios) Nanoparticles Containing Pluronic F68 (2%) as Stabilizer 
pH TIME(HRS) 
 
CUMULATIVE %  DRUG RELEASE ± S.D* 
 
 
F26 
ES 100(1:10) 
 
F27 
ES 100(1:20) 
 
F28 
ES 100(1:30) 
 
F29 
ES 100(1:40) 
 
F30 
ES 100(1:50) 
 
 
 
1.2 
0.25 10.9 ± 0.28 9.9 ± 0.16 9.1 ± 0.16 8.0 ± 0.16 6.9 ± 0.16 
0.50 17.7 ± 0.29 16.9 ± 0.17 14.3 ± 0.15 13.1 ± 0.15 11.3 ± 0.28  
0.75 23.6 ± 0.25 21.7 ± 0.17 18.8 ± 0.28 17.8 ± 0.16 16.4 ± 0.15 
1.00 29.0 ± 0.31 27.0 ± 0.30 23.7 ± 0.29 22.5 ± 0.15 21.4 ± 0.16 
1.50 34.8 ± 0.17 31.3 ± 0.13 28.2 ± 0.19 27.2 ± 0.16 25.8 ± 0.17 
2.00 40.1 ± 0.14 35.8 ± 0.13 33.2 ± 0.18 30.6 ± 0.15 29.3 ± 0.15 
 
 
 
 
 
 
 
 
 
 
 
6.8 
2.50 49.7 ± 0.78 45.5 ± 0.64 42.1 ± 0.38 39.1 ± 0.27 37.3 ± 0.30 
3.00 52.2 ± 0.40 46.8 ± 0.05 43.4 ± 0.19 40.2 ± 0.15 38.1 ± 0.33 
3.50 53.5 ± 0.28 48.2 ± 0.11 44.6 ± 0.08 41.5 ± 0.15 39.1 ± 0.33 
4.00 54.9 ± 0.29 49.7 ± 0.18 46.0 ± 0.14 42.8 ± 0.26 40.8 ± 0.13 
4.50 56.8 ± 0.21 51.4 ± 0.21 47.9 ± 0.30 43.9 ± 0.02 41.8 ± 0.30 
5.00 58.7 ± 0.21 52.8 ± 0.08 49.4 ± 0.10 44.9 ± 0.18 42.7 ± 0.31 
5.50 60.6 ± 0.30 54.1 ± 0.09 50.6 ± 0.15 45.9 ± 0.19 43.6 ± 0.31 
6.00 62.2 ± 0.26 55.7 ± 0.10 52.3 ± 0.12 47.0 ± 0.25 44.6 ± 0.32 
6.50 64.6 ± 0.23 57.0 ± 0.24 53.6 ± 0.15 48.5 ± 0.28 45.6 ± 0.35 
7.00 66.6 ± 0.40 58.4 ± 0.26 55.0 ± 0.15 50.1 ± 0.18 46.8 ± 0.33 
7.50 68.7 ± 0.11 59.9 ± 0.27 56.5 ± 0.15 51.4 ± 0.27 48.0 ± 0.36 
8.00 70.7 ± 0.44 61.9 ± 0.18 58.5 ± 0.89 52.6 ± 0.35 49.5 ± 0.35 
8.50 72.9 ± 0.33 64.2 ± 0.14 60.1 ± 0.27 54.2 ± 0.29 51.1 ± 0.41 
9.00 75.4 ± 0.46 66.2 ± 0.13 62.1 ± 0.16 56.0 ± 0.29 52.6 ± 0.42 
9.50 78.0 ± 0.35 68.2 ± 0.14 64.2 ± 0.21 57.8 ± 0.30 54.5 ± 0.38 
10.00 80.6 ± 0.36 70.2 ± 0.15 66.4 ± 0.16 59.8 ± 0.31 57.0 ± 0.28 
10.50 83.0 ± 0.45 73.0 ± 0.17 68.7 ± 0.14 61.8 ± 0.31 59.0 ± 0.27 
11.00 85.7 ± 0.31 75.4 ± 0.33 71.3 ± 0.24 64.5 ± 0.32 61.6 ± 0.13 
11.50 88.3 ± 0.32 78.4 ± 0.24 74.1 ± 0.04 67.7 ± 0.46 64.3 ± 0.37 
12.00 91.2 ± 0.32 82.2 ± 0.26 77.3 ± 0.23 71.0 ± 0.47 67.2 ± 0.28 
 
n=3
* 
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Table XXIV g Comparison of Invitro Release of Rosuvastatin Calcium Loaded ES 100 
(Different Ratios) Nanoparticles Containing PVA (1%) as Stabilizer 
pH TIME(HRS) 
 
CUMULATIVE %  DRUG RELEASE ± S.D* 
 
 
F31 
ES 100(1:10) 
 
F32 
ES 100(1:20) 
 
F33 
ES 100(1:30) 
 
F34 
ES 100(1:40) 
 
F35 
ES 100(1:50) 
 
 
 
1.2 
0.25 11.0 ± 0.16 10.7 ± 0.28 9.7 ± 0.16 8.5 ± 0.16 7.4 ± 0.16 
0.50 17.9 ± 0.16 16.1 ± 0.16 14.8 ± 0.28 13.8 ± 0.15 11.5 ± 0.15 
0.75 22.5 ± 0.27 19.8 ± 0.29 19.5 ± 0.73 17.5 ± 0.16 15.2 ± 0.28 
1.00 26.9 ± 0.27 24.5 ± 0.18 23.5 ± 0.26 22.4 ± 0.28 19.0 ± 0.29 
1.50 33.5 ± 0.27 31.0 ± 0.19 29.0 ± 0.30 26.7 ± 0.16 24.8 ± 0.18 
2.00 40.0 ± 0.27 35.9 ± 0.30 33.3 ± 0.13 31.7 ± 0.26 28.6 ± 0.30 
 
 
 
 
 
 
 
 
 
 
 
6.8 
2.50 50.5 ± 0.31 45.1 ± 0.19 42.2 ± 0.28 40.4 ± 0.40 36.5 ± 0.24 
3.00 52.0 ± 0.33 46.4 ± 0.40 43.2 ± 0.29 41.2 ± 0.13 37.7 ± 0.23 
3.50 54.1 ± 0.99 48.0 ± 0.19 44.6 ± 0.06 42.9 ± 0.53 39.2 ± 0.07 
4.00 55.0 ± 0.19 49.4 ± 0.18 45.9 ± 0.07 43.8 ± 0.42 40.3 ± 0.16 
4.50 57.0 ± 0.27 50.4 ± 0.23 47.1 ± 0.28 45.0 ± 0.42 41.1 ± 0.16 
5.00 59.1 ± 0.19 52.1 ± 0.16 48.0 ± 0.29 46.1 ± 0.47 42.0 ± 0.15 
5.50 60.5 ± 0.26 53.4 ± 0.31 49.2 ± 0.30 47.2 ± 0.64 42.9 ± 0.15 
6.00 62.1 ± 0.39 54.7 ± 0.16 50.5 ± 0.21 48.4 ± 0.44 43.9 ± 0.14 
6.50 64.4 ± 0.40 56.1 ± 0.31 52.1 ± 0.22 49.8 ± 0.45 45.0 ± 0.23 
7.00 66.6 ± 0.28 57.9 ± 0.47 53.6 ± 0.30 51.4 ± 0.46 46.2 ± 0.13 
7.50 68.4 ± 0.40 59.4 ± 0.26 55.0 ± 0.31 52.9 ± 0.52 47.5 ± 0.13 
8.00 70.6 ± 0.23 61.1 ± 0.26 56.8 ± 0.32 54.0 ± 0.54 48.6 ± 0.12 
8.50 73.3 ± 0.40 63.5 ± 0.27 58.4 ± 0.24 55.8 ± 0.61 50.2 ± 0.14 
9.00 75.3 ± 0.40 65.9 ± 0.32 60.9 ± 0.33 57.5 ± 0.50 51.4 ± 0.14 
9.50 78.1 ± 0.13 67.7 ± 0.79 62.8 ± 0.27 59.4 ± 0.51 53.8 ± 0.10 
10.00 80.4 ± 0.28 69.8 ± 0.35 65.7 ± 0.33 61.3 ± 0.52 56.1 ± 0.13 
10.50 82.9 ± 0.03 72.2 ± 0.28 68.3 ± 0.34 63.2 ± 0.51 58.0 ± 0.13 
11.00 85.7 ± 0.27 74.9 ± 0.28 70.9 ± 0.33 65.7 ± 0.55 60.4 ± 0.08 
11.50 88.2 ± 0.28 78.4 ± 0.20 73.6 ± 0.36 68.4 ± 0.52 62.9 ± 0.12 
12.00 91.2 ± 0.28 81.8 ± 0.27 76.9 ± 0.06 71.8 ± 0.53 66.2 ± 0.12 
 
n=3
* 
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Table XXIV h Comparison of Invitro Release of Rosuvastatin Calcium Loaded ES 100 
(Different Ratios) Nanoparticles Containing PVA (2%) as Stabilizer 
pH TIME(HRS) 
 
CUMULATIVE %  DRUG RELEASE ± S.D* 
 
 
F36 
ES 100(1:10) 
 
F37 
ES 100(1:20) 
 
F38 
ES 100(1:30) 
 
F39 
ES 100(1:40) 
 
F40 
ES 100(1:50) 
 
 
 
1.2 
0.25 11.7 ± 0.16 10.6 ± 0.16 9.5 ± 0.28 9.2 ± 0.16 8.0 ± 0.16 
0.50 18.6 ± 0.16 17.3 ± 0.16 15.9 ± 0.28 14.5 ± 0.28 13.9 ± 0.27 
0.75 24.6 ± 0.15 22.5 ± 0.14 21.2 ± 0.30 19.7 ± 0.28 17.7 ± 0.16 
1.00 30.0 ± 0.15 28.0 ± 0.27 25.8 ± 0.31 24.1 ± 0.14 22.8 ± 0.17 
1.50 36.6 ± 0.28 33.4 ± 0.17 30.6 ± 0.11 28.3 ± 0.18 26.7 ± 0.14 
2.00 41.3 ± 0.26 39.0 ± 0.17 35.1 ± 0.25 32.5 ± 0.30 30.4 ± 0.15 
 
 
 
 
 
 
 
 
 
 
 
6.8 
2.50 52.8 ± 0.41 49.6 ± 0.36 44.6 ± 0.25 41.7 ± 0.40 39.0 ± 0.30 
3.00 54.5 ± 0.41 50.8 ± 0.32 46.0 ± 0.37 42.7 ± 0.49 39.7 ± 0.31 
3.50 55.6 ± 0.15 52.1 ± 0.05 47.0 ± 0.26 43.9 ± 0.57 41.1 ± 0.15 
4.00 57.1 ± 0.15 53.5 ± 0.05 48.5 ± 0.11 45.6 ± 0.38 42.7 ± 0.16 
4.50 58.9 ± 0.31 55.2 ± 0.34 49.8 ± 0.15 46.5 ± 0.38 43.8 ± 0.15 
5.00 60.9 ± 0.15 57.0 ± 0.47 51.3 ± 0.15 47.5 ± 0.46 45.0 ± 0.14 
5.50 62.7 ± 0.47 58.3 ± 0.39 53.2 ± 0.15 48.6 ± 0.55 46.0 ± 0.30 
6.00 64.0 ± 0.42 59.7 ± 0.36 54.6 ± 0.08 49.7 ± 0.51 47.5 ± 0.32 
6.50 66.5 ± 0.49 62.0 ± 0.50 56.2 ± 0.26 51.4 ± 0.65 48.6 ± 0.33 
7.00 68.3 ± 0.51 63.3 ± 0.36 57.6 ± 0.37 53.0 ± 0.67 49.7 ± 0.34 
7.50 70.3 ± 0.45 65.6 ± 0.37 59.1 ± 0.37 54.5 ± 0.68 50.8 ± 0.36 
8.00 72.7 ± 0.53 68.1 ± 0.38 60.9 ± 0.25 55.6 ± 0.70 52.1 ± 0.21 
8.50 74.9 ± 0.46 70.0 ± 0.39 62.5 ± 0.38 57.3 ± 0.58 53.5 ± 0.22 
9.00 77.5 ± 0.47 72.0 ± 0.40 63.9 ± 0.37 59.2 ± 0.58 55.1 ± 0.38 
9.50 80.0 ±0.48 74.0 ± 0.45 66.1 ± 0.38 61.1 ± 0.64 57.1 ± 0.24 
10.00 82.5 ± 0.49 77.0 ± 0.47 68.2 ± 0.52 63.0 ± 0.60 59.7 ± 0.11 
10.50 84.8 ± 0.50 79.5 ± 0.48 71.2 ± 0.41 65.6 ± 0.74 61.8 ± 0.24 
11.00 87.5 ± 0.50 81.9 ± 0.33 73.9 ± 0.42 68.0 ± 0.75 64.3 ± 0.12 
11.50 90.0 ± 0.51 84.6 ± 0.17 76.6 ± 0.41 71.4 ± 0.51 67.2 ± 0.12 
12.00 93.7 ± 0.68 87.9 ± 0.55 80.1 ± 0.46 74.7 ± 0.35 70.2 ± 0.19 
 
n=3
* 
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Table XXV a Release Kinetics of Rosuvastatin Calcium Loaded  
EL 100 Nanoparticles (Different Ratios) Containing Pluronic F68 (1%) as Stabilizer 
 
 
 
 
 
Formulation 
code 
 
 
 
 
Zero order 
 
 
 
First order 
 
 
Higuchi 
model 
 
 
 
Korsmeyer 
peppas 
 
 
Hixon-
Crowell 
 
R 
2 
 
 
K0 
(h
-1
) 
 
R 
2
 
 
K1 
(h
-1
) 
 
R 
2
 
 
KH 
(h
-1/2
) 
 
R 
2
 
 
n 
 
R 
2
 
 
KHC 
(h
-1/3
) 
 
F1 
 
 
0.936 
 
5.439 
 
0.975 
 
-0.049 
 
0.986 
 
22.98 
 
0.976 
 
0.485 
 
0.974 
 
-0.135 
 
F2 
 
 
0.953 
 
5.064 
 
0.978 
 
-0.042 
 
0.988 
 
21.58 
 
0.985 
 
0.495 
 
0.979 
 
-0.120 
 
F3 
 
 
0.961 
 
4.988 
 
0.986 
 
-0.038 
 
0.991 
 
21.20 
 
0.984 
 
0.478 
 
0.985 
 
-0.112 
 
F4 
 
 
0.972 
 
4.708 
 
0.987 
 
-0.034 
 
0.989 
 
19.88 
 
0.985 
 
0.497 
 
0.987 
 
-0.102 
 
F5 
 
 
0.972 
 
4.248 
 
0.994 
 
-0.028 
 
0.999 
 
17.80 
 
0.978 
 
0.498 
 
0.978 
 
-0.088 
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Table XXV b Release Kinetics of Rosuvastatin Calcium Loaded  
EL 100 Nanoparticles (Different Ratios) Containing Pluronic F68 (2%) as Stabilizer 
 
 
 
 
 
Formulation 
code 
 
 
 
 
Zero order 
 
 
 
First order 
 
 
Higuchi 
model 
 
 
 
Korsmeyer 
peppas 
 
 
Hixon-Crowell 
 
R 
2 
 
 
K0 
(h
-1
) 
 
R 
2
 
 
K1 
(h
-1
) 
 
R 
2
 
 
KH 
(h
-1/2
) 
 
R 
2
 
 
n 
 
R 
2
 
 
KHC 
(h
-1/3
) 
 
F6 
 
 
0.926 
 
5.632 
 
0.963 
 
-0.061 
 
0.982 
 
24.28 
 
0.973 
 
0.446 
 
0.971 
 
 
-0.158 
 
F7 
 
 
0.936 
 
5.023 
 
0.970 
 
-0.044 
 
0.981 
 
21.53 
 
0.974 
 
0.453 
 
0.969 
 
-0.123 
 
F8 
 
 
0.935 
 
4.891 
 
0.967 
 
-0.042 
 
0.979 
 
20.94 
 
0.970 
 
0.451 
 
0.967 
 
-0.118 
 
F9 
 
 
0.925 
 
4.495 
 
0.969 
 
-0.036 
 
0.979 
 
19.34 
 
0.973 
 
0.431 
 
0.962 
 
-0.104 
 
F10 
 
 
0.923 
 
4.207 
 
0.964 
 
-0.031 
 
0.976 
 
18.10 
 
0.964 
 
0.451 
 
0.955 
 
-0.092 
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Table XXV c Release Kinetics of Rosuvastatin Calcium Loaded  
EL 100 Nanoparticles (Different Ratios) Containing PVA (1%) as Stabilizer 
 
 
 
 
 
Formulation 
code 
 
 
 
 
Zero order 
 
 
 
First order 
 
 
Higuchi 
model 
 
 
 
Korsmeyer 
peppas 
 
 
Hixon-Crowell 
 
R 
2 
 
 
K0 
(h
-1
) 
 
R 
2
 
 
K1 
(h
-1
) 
 
R 
2
 
 
KH 
(h
-1/2
) 
 
R 
2
 
 
n 
 
R 
2
 
 
KHC 
(h
-1/3
) 
 
F11 
 
 
0.891 
 
5.124 
 
0.958 
 
-0.054 
 
0.967 
 
22.33 
 
0.963 
 
0.384 
 
0.953 
 
-0.142 
 
F12 
 
 
0.912 
 
4.866 
 
0.956 
 
-0.046 
 
0.972 
 
21.02 
 
0.967 
 
0.404 
 
0.955 
 
-0.125 
 
F13 
 
 
0.931 
 
4.772 
 
0.973 
 
-0.041 
 
0.982 
 
20.51 
 
0.979 
 
0.423 
 
0.968 
 
-0.116 
 
F14 
 
 
0.924 
 
4.267 
 
0.963 
 
-0.033 
 
0.976 
 
18.35 
 
0.969 
 
0.428 
 
0.957 
 
-0.096 
 
F15 
 
 
0.950 
 
4.207 
 
0.975 
 
-0.031 
 
0.984 
 
17.92 
 
0.978 
 
0.471 
 
0.972 
 
 
-0.092 
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Table XXV d Release Kinetics of Rosuvastatin Calcium Loaded  
EL 100 Nanoparticles (Different Ratios) Containing PVA (2%) as Stabilizer 
 
 
 
 
 
Formulation 
code 
 
 
 
 
Zero order 
 
 
 
First order 
 
 
Higuchi 
model 
 
 
 
Korsmeyer 
peppas 
 
 
Hixon-
Crowell 
 
R 
2 
 
 
K0 
(h
-1
) 
 
R 
2
 
 
K1 
(h
-1
) 
 
R 
2
 
 
KH 
(h
-1/2
) 
 
R 
2
 
 
n 
 
R 
2
 
 
KHC 
(h
-1/3
) 
 
F16 
 
 
0.919 
 
5.790 
 
0.943 
 
-0.073 
 
0.979 
 
25.01 
 
0.970 
 
0.426 
 
0.966 
 
-0.177 
 
F17 
 
 
0.912 
 
5.218 
 
0.962 
 
-0.055 
 
0.974 
 
22.57 
 
0.971 
 
0.396 
 
0.962 
 
-0.143 
 
F18 
 
 
0.907 
 
4.764 
 
0.960 
 
-0.043 
 
0.970 
 
20.62 
 
0.968 
 
0.391 
 
0.954 
 
-0.120 
 
F19 
 
 
0.904 
 
4.393 
 
0.959 
 
-0.036 
 
0.969 
 
19.03 
 
0.970 
 
0.387 
 
0.948 
 
-0.104 
 
F20 
 
 
0.895 
 
4.132 
 
0.955 
 
-0.032 
 
0.966 
 
17.97 
 
0.972 
 
0.379 
 
0.941 
 
-0.094 
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Table XXV e Release Kinetics of Rosuvastatin Calcium Loaded 
ES 100 Nanoparticles (Different Ratios) Containing Pluronic F68 (1%) as Stabilizer 
 
 
 
 
 
Formulation 
code 
 
 
 
 
Zero order 
 
 
 
First order 
 
 
Higuchi 
model 
 
 
 
Korsmeyer 
peppas 
 
 
Hixon-Crowell 
 
R 
2 
 
 
K0 
(h
-1
) 
 
R 
2
 
 
K1 
(h
-1
) 
 
R 
2
 
 
KH 
(h
-1/2
) 
 
R 
2
 
 
n 
 
R 
2
 
 
KHC 
(h
-1/3
) 
 
F21 
 
 
0.929 
 
5.590 
 
0.958 
 
-0.062 
 
0.982 
 
24.06 
 
0.975 
 
0.441 
 
0.970 
 
-0.158 
 
F22 
 
 
0.921 
 
4.782 
 
0.959 
 
-0.042 
 
0.975 
 
20.59 
 
0.968 
 
0.420 
 
0.957 
 
-0.118 
 
F23 
 
 
0.920 
 
4.456 
 
0.957 
 
-0.036 
 
0.971 
 
19.16 
 
0.964 
 
0.417 
 
0.953 
 
-0.104 
 
F24 
 
 
0.915 
 
4.119 
 
0.960 
 
-0.031 
 
0.974 
 
17.79 
 
0.973 
 
0.408 
 
0.951 
 
-0.092 
 
F25 
 
 
0.908 
 
3.814 
 
0.992 
 
-0.027 
 
0.997 
 
16.47 
 
0.961 
 
0.414 
 
0.939 
 
-0.082 
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Table XXV f   Release Kinetics of Rosuvastatin Calcium Loaded  
ES 100 Nanoparticles (Different Ratios) Containing Pluronic F68 (2%) as Stabilizer 
 
 
 
 
 
Formulation 
code 
 
 
 
 
Zero order 
 
 
 
First order 
 
 
Higuchi model 
 
 
 
Korsmeyer 
peppas 
 
 
Hixon-
Crowell 
 
R 
2 
 
 
K0 
(h
-1
) 
 
R 
2
 
 
K1 
(h
-1
) 
 
R 
2
 
 
KH 
(h
-1/2
) 
 
R 
2
 
 
n 
 
R 
2
 
 
KHC 
(h
-1/3
) 
 
F26 
 
 
0.930 
 
5.685 
 
0.950 
 
-0.068 
 
0.984 
 
24.46 
 
0.981 
 
0.423 
 
0.970 
 
-0.169 
 
F27 
 
 
0.922 
 
4.910 
 
0.958 
 
-0.047 
 
0.977 
 
21.15 
 
 
0.973 
 
0.405 
 
0.960 
 
-0.127 
 
F28 
 
 
0.925 
 
4.752 
 
0.965 
 
-0.041 
 
0.979 
 
20.46 
 
0.974 
 
0.427 
 
0.962 
 
-0.116 
 
F29 
 
 
0.915 
 
4.228 
 
0.954 
 
-0.033 
 
0.971 
 
18.23 
 
0.967 
 
0.405 
 
0.948 
 
-0.097 
 
F30 
 
 
0.908 
 
4.032 
 
0.948 
 
-0.030 
 
0.966 
 
17.40 
 
0.963 
 
0.402 
 
0.941 
 
-0.090 
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Table XXV g Release Kinetics of Rosuvastatin Calcium Loaded  
ES 100 Nanoparticles (Different Ratios) Containing PVA (1%) as Stabilizer 
 
 
 
 
 
Formulation 
code 
 
 
 
 
Zero order 
 
 
 
First order 
 
 
Higuchi 
model 
 
 
 
Korsmeyer 
peppas 
 
 
Hixon-
Crowell 
 
R 
2 
 
 
K0 
(h
-1
) 
 
R 
2
 
 
K1 
(h
-1
) 
 
R 
2
 
 
KH 
(h
-1/2
) 
 
R 
2
 
 
n 
 
R 
2
 
 
KHC 
(h
-1/3
) 
 
F31 
 
 
0.927 
 
5.725 
 
0.950 
 
-0.068 
 
0.982 
 
24.66 
 
 
0.974 
 
0.438 
 
0.969 
 
-0.169 
 
F32 
 
 
0.919 
 
4.904 
 
0.951 
 
-0.046 
 
0.974 
 
21.12 
 
0.965 
 
0.417 
 
0.954 
 
-0.126 
 
F33 
 
 
0.926 
 
4.624 
 
0.955 
 
-0.040 
 
0.973 
 
19.84 
 
0.965 
 
0.416 
 
0.956 
 
-0.113 
 
F34 
 
 
0.912 
 
4.314 
 
0.957 
 
-0.035 
 
0.973 
 
18.64 
 
0.966 
 
0.411 
 
0.949 
 
-0.100 
 
F35 
 
 
0.907 
 
3.988 
 
0.948 
 
-0.029 
 
0.967 
 
17.23 
 
0.956 
 
0.420 
 
0.940 
 
-0.088 
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Table XXV h Release Kinetics of Rosuvastatin Calcium Loaded  
ES 100 Nanoparticles (Different Ratios) Containing PVA (1%) as Stabilizer 
 
 
 
 
 
Formulation 
code 
 
 
 
 
Zero order 
 
 
 
First order 
 
 
Higuchi 
model 
 
 
 
Korsmeyer 
peppas 
 
 
Hixon-
Crowell 
 
R 
2 
 
 
K0 
(h
-1
) 
 
R 
2
 
 
K1 
(h
-1
) 
 
R 
2
 
 
KH 
(h
-1/2
) 
 
R 
2
 
 
n 
 
R 
2
 
 
KHC 
(h
-1/3
) 
 
F36 
 
 
0.923 
 
5.739 
 
0.933 
 
-0.074 
 
0.980 
 
24.75 
 
0.976 
 
0.413 
 
0.964 
 
-0.178 
 
F37 
 
 
0.921 
 
5.387 
 
0.955 
 
-0.059 
 
0.978 
 
23.23 
 
0.973 
 
0.415 
 
0.965 
 
-0.151 
 
F38 
 
 
0.919 
 
4.800 
 
0.959 
 
-0.044 
 
0.976 
 
20.70 
 
0.973 
 
0.407 
 
0.958 
 
-0.121 
 
F39 
 
 
0.916 
 
4.420 
 
0.954 
 
-0.037 
 
0.972 
 
19.05 
 
0.966 
 
0.403 
 
0.950 
 
-0.105 
 
F40 
 
 
0.915 
 
4.175 
 
0.954 
 
-0.033 
 
0.971 
 
18.00 
 
0.968 
 
0.402 
 
0.948 
 
-0.095 
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Table XXVI   Comparison of Solubility of Best Formulations (F5, F25) with Pure Drug 
 
 
 
 
 
TIME(HRS) 
 
SOLUBILITY (µg/ml) ± SD
* 
 
 
 
PURE DRUG  
 
F 5 
EL 100 (1:50), 
Pluronic F 68 1% 
 
F25 
ES 100 (1:50),  
Pluronic F 68 1% 
 
 
 
 
24hrs 
 
 
 
 
 
 
357.73 ± 0.86 
 
 
 
743.94 ± 0.71 
 
 
 
 
 
624.60 ± 0.63 
 
 n=3* 
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Table XXVII a Comparison of Cumulative Amount of Drug Permeated across Duodenum 
Segment 
 
 
 
 
TIME(HRS) 
 
CUMULATIVE AMOUNT OF DRUG PERMEATED(mg)± SD
* 
 
 
PURE DRUG 
SOLUTION 
 
F 5 
EL 100 (1:50), 
Pluronic F 68 1% 
 
F25 
ES 100 (1:50),  
Pluronic F 68 1% 
 
 
 
0.25 0.1038± 0.50 0.2416±  0.10 0.1841±  0.63 
 
 
0.50 0.1465± 0.67 0.2854 ± 0.19 0.2678 ± 0.70 
 
 
1.00 0.1822± 0.89 0.5109 ± 0.18 0.4633 ± 0.83 
 
 
1.50 0.2811± 0.73 0.7588 ± 0.12 0.6464 ± 0.62 
 
 
2.00 0.3246± 0.52 1.0021 ± 0.36 0.9137 ± 0.76 
 
 
n=3
* 
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Table XXVII b   Comparison of Cumulative Amount of Drug Permeated across Jejunum 
Segment 
 
 
 
 
TIME(HRS) 
 
CUMULATIVE AMOUNT OF DRUG PERMEATED(mg)± SD
* 
 
 
PURE DRUG 
SOLUTION 
 
F 5 
EL 100 (1:50), 
Pluronic F 68 1% 
 
F25 
ES 100 (1:50),  
Pluronic F 68 1% 
 
 
 
0.25 0.1136± 0.51 0.2523 ± 0.15 0.1977 ± 0.91 
 
 
0.50 0.1676± 0.82 0.2962 ± 0.83 0.2658 ± 0.24 
 
 
1.00 0.1981± 0.11 0.5190 ± 0.16 0.4533 ± 0.98 
 
 
1.50 0.2887± 0.33 0.7848 ± 0.14 0.6526 ± 0.65 
 
 
2.00 0.3503± 0.81 1.0029 ± 0.44 0.8978 ± 0.53 
 
 
n=3
* 
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Table XXVII c Comparison of Cumulative Amount of Drug Permeated across ileum 
Segment 
 
 
 
 
TIME(HRS) 
 
CUMULATIVE AMOUNT OF DRUG PERMEATED(mg)± SD
* 
 
 
PURE DRUG 
SOLUTION 
 
F 5 
EL 100 (1:50), 
Pluronic F 68 1% 
 
F25 
ES 100 (1:50),  
Pluronic F 68 1% 
 
 
 
0.25 0.1011± 0.11 0.2129 ± 0.12 0.1745 ± 0.11 
 
 
0.50 0.1401± 0.82 0.2874 ± 0.12 0.2485 ± 0.34 
 
 
1.00 0.1791± 0.63 0.5007 ± 0.16 0.4359 ± 0.43 
 
 
1.50 0.2770 ± 0.69 0.7818 ± 0.18 0.6347 ± 0.82 
 
 
2.00 0.3274± 0.93 0.9977 ± 0.71 0.8765 ± 0.76 
 
 
n=3
* 
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Table XXVII d Comparison of Cumulative Amount of Drug Permeated through small 
Intestinal Segments (At 2 Hour) 
 
 
 
SMALL 
INTESTINAL 
SEGMENTS 
 
CUMULATIVE AMOUNT OF DRUG PERMEATED(mg) ± SD
* 
 
 
PURE DRUG 
SOLUTION 
 
F 5 
EL 100 (1:50), 
Pluronic F 68 1% 
 
F25 
ES 100 (1:50),  
Pluronic F 68 1% 
 
 
 
DUODENUM 
 
0.3246± 0.52 
 
1.0021 ± 0.36 
 
0.9137 ± 0.76 
 
 
 
JEJUNUM 
 
0.3503± 0.81 
 
1.0029 ± 0.44 
 
0.8978 ± 0.53 
 
 
 
ILEUM 
 
0.3274± 0.93 
 
0.9977 ± 0.71 
 
0.8765 ± 0.76 
 
 
 n=3* 
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Table XXVII e Comparison of ex vivo Apparent Permeability Coefficient (Papp) of 
Formulations F5, F25 with Pure Drug Solution 
 
 
SMALL 
INTESTINAL 
SEGMENTS 
OF RAT 
 
APPARENT PERMEABILITY (Papp) x 10
-6
 cm/s ± SD
* 
 
 
PURE DRUG 
SOLUTION 
 
 
F 5 
EL 100 (1:50), 
Pluronic F 68 1% 
 
F25 
ES 100 (1:50), 
 Pluronic F 68 1% 
 
 
 
DUODENUM 
 
 
 
 
3.300 ± 0.10 
 
 
11.647 ± 0.22 
 
 
10.680 ± 0.04 
 
 
JEJUNUM 
 
 
 
 
3.400 ± 0.17 
 
 
11.617 ± 0.20 
 
 
10.407 ± 0.18 
 
 
ILEUM 
 
 
 
 
3.367 ± 0.152 
 
 
11.683 ± 0.40 
 
 
10.410 ± 0.08 
 
  n=3* 
 DUODENUM  JEJUNUM    ILEUM  
  Pure drug Vs F5 p>0.001      Pure drug Vs F5 p>0.001    Pure drug Vs F5 p>0.001 
Pure drug Vs F25 p>0.001    Pure drug Vs F25 p>0.001  Pure drug Vs F25 p>0.001 
           F5 Vs F25 p>0.001               F5 Vs F25 p>0.001          F5 Vs F25 p>0.01 
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Table XXVIII a Stability study of best formulation (F5) stored at 4°C and 25°C ± 60%RH 
 
Evaluation 
parameter 
Storing 
Temperature 
0 month 1 month 2 month 3 month 
 
% 
Entrapment 
Efficiency  
 
4°C 
 
79.0±0.87% 
 
79.0±0.56% 
 
78.6±0.57% 
 
78.3±0.44% 
 
25°C ± 60% RH 
 
79.0±0.87% 
 
78.5±0.77% 
 
78.2±0.88% 
 
77.9±0.89% 
 
Table XXVIII b Stability study of best formulation (F25) stored at 4°C and  
       25°C ± 60%RH 
 
Evaluation 
parameter 
Storing 
Temperature 
0 month 1 month 2 month 3 month 
 
% 
Entrapment 
Efficiency  
 
4°C 
 
72.0±0.88% 
 
71.5±0.59% 
 
71.3±0.66% 
 
71.3±0.97% 
 
25°C ± 60% RH 
 
72.0±0.88% 
 
71.2±0.73% 
 
71.0±0.82% 
 
70.8±0.19% 
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Figure 17 Determination of Absorption Maximum (λmax) of Rosuvastatin Calcium in pH 6.8. 
181 
 
0 5 10 15 20 25
0.0
0.2
0.4
0.6
0.8
CONCENTRATION (µg/ml)
A
B
S
O
R
B
A
N
C
E
 
Figure 18 Calibration Curve of Rosuvastatin Calcium in Distilled Water 
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Figure 19 Calibration Curve of Rosuvastatin Calcium in pH 1.2             
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Figure 20 Calibration Curve of Rosuvastatin Calcium in pH 6.8  
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Figure 21 Calibration Curve of Rosuvastatin Calcium in PBS of pH 7.4             
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Figure 22 a FT-IR Spectra of Rosuvastatin Calcium 
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Figure 22 b FT-IR Spectra of Eudragit L 100 
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Figure 22 c FT-IR Spectra of Eudragit S 100 
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Figure 22d FT-IR Spectra of Physical Mixture of Rosuvastatin Calcium and Eudragit L100 
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Figure 22 e FT-IR Spectra of Physical Mixture of Rosuvastatin Calcium and Eudragit S100 
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Figure 23 a DSC Thermogram of Rosuvastatin Calcium 
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Figure 23 b DSC Thermogram of Eudragit L 100 
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Figure 23 c DSC Thermogram of Eudragit S 100 
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Figure 23 d DSC Thermogram of Physical Mixture of Rosuvastatin Calcium and Eudragit L100 
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Figure 23 e DSC Thermogram of Physical Mixture of Rosuvastatin Calcium and Eudragit S100 
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 F1 (EL 100 1:10, PLURONIC F68 1%) 
 
 F2 (EL 100 1:20, PLURONIC F68 1%) 
Figure 24 a Particle size distribution curve of formulations F1 and F2
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(EL 100 1:30, PLURONIC F68 1%) 
 
 F4 (EL 100 1:40, PLURONIC F68 1%) 
Figure 24 b Particle size distribution curve of formulations F3 and F4
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 F5 (EL 100 1:50, PLURONIC F68 1%) 
  F6 (EL 100 1:10, PLURONIC F68 2%) 
Figure 24 c Particle size distribution curve of formulations F5 and F6 
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 F7 (EL 100 1:20, PLURONIC F68 2%) 
 
 F8 (EL 100 1:30, PLURONIC F68 2%) 
Figure 24 d Particle size distribution curve of formulations F7 and F8 
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F9 (EL 100 1:40, PLURONIC F68 2%) 
 
 F10 (EL 100 1:50, PLURONIC F68 2%) 
Figure 24 e Particle size distribution curve of formulations F9 and F10 
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 F11 (EL 100 1:10, PVA 1%) 
 
 F12 (EL 100 1:20, PVA 1%) 
Figure 24 f Particle size distribution curve of formulations F11 and F12 
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 F13 (EL 100 1:30, PLURONIC F68 1%) 
 
F14 (EL 100 1:40, PVA 1%) 
Figure 24 g Particle size distribution curve of formulations F13 and F14 
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 F15 (EL 100 1:50, PVA 1%) 
 
 F16 (EL 100 1:10, PVA 2%) 
Figure 24 h Particle size distribution curve of formulations F15and F16 
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 F17 (EL 100 1:20, PVA 2%) 
 
 F18 (EL 100 1:30, PVA 2%) 
Figure 24 i Particle size distribution curve of formulations F17 and F18 
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 F19 (EL 100 1:40, PVA 2%) 
 
 F20 (EL 100 1:50, PVA 2%) 
Figure 24 j Particle size distribution curve of formulations F19 and F20 
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 F21 (ES 100 1:10, PLURONIC F68 1%) 
 
 F22 (ES 100 1:20, PLURONIC F68 1%) 
Figure 24 k Particle size distribution curve of formulations F21 and F22 
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 F23 (ES 100 1:30, PLURONIC F68 1%) 
 
 F24 (ES 100 1:140, PLURONIC F68 1%) 
Figure 24 l Particle size distribution curve of formulations F23 and F24 
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 F25 (ES 100 1:50, PLURONIC F68 1%) 
 
 F26 (ES 100 1:10, PLURONIC F68 2%) 
Figure 24 m Particle size distribution curve of formulations F25 and F26 
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 F27 (ES 100 1:20, PLURONIC F68 2%) 
 
 F28 (ES 100 1:30, PLURONIC F68 2%) 
Figure 24 n Particle size distribution curve of formulations F27 and F28 
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 F29 (ES 100 1:40, PLURONIC F68 2%) 
 
 F30 (ES 100 1:50, PLURONIC F68 2%) 
Figure 24 o Particle size distribution curve of formulations F29 and F30 
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 F31 (ES 100 1:10, PVA 1%) 
 
 F32 (ES 100 1:20, PVA 1%) 
Figure 24 p Particle size distribution curve of formulations F31 and F32 
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 F33 (ES 100 1:30, PVA 1%) 
 
 F34 (ES 100 1:40, PVA 1%) 
Figure 24 q Particle size distribution curve of formulations F33 and F34 
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 F35 (ES 100 1:50, PVA 1%) 
 
 F36 (ES 100 1:10, PVA 2%) 
Figure 24 r Particle size distribution curve of formulations F35 and F36 
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F37 (ES 100 1:20, PVA 2%) 
 
 F38 (ES 100 1:30, PVA 2%) 
Figure 24 s Particle size distribution curve of formulations F37 and 38 
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 F39 (ES 100 1:40, PVA 2%) 
 
 F40 (ES 100 1:50, PVA 2%) 
Figure 24 t Particle size distribution curve of formulations F39 and F40 
. 
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Figure 25 a Entrapment Efficiencies of Rosuvastatin Calcium Loaded EL 100 
Nanoparticles 
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Figure 25 b Entrapment Efficiencies of Rosuvastatin Calcium Loaded ES 100 
Nanoparticles 
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Figure 25 c   Effect of Different Stabilizers at Different Concentrations on the Drug 
Entrapment Efficiencies of Rosuvastatin Calcium Loaded EL 100 
Nanoparticles 
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Figure 25 d Effect of Different Stabilizers at Different Concentrations on The Drug     
         Entrapment Efficiencies of Rosuvastatin Calcium Loaded ES 100              
Nanoparticles. 
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Figure 26 a Comparison of Invitro Release Profile of Rosuvastatin Calcium Loaded 
EL 100 Nanoparticles Containing Pluronic F68 1% Stabilizer 
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Figure 26 b Comparison of Invitro Release Profile of Rosuvastatin Calcium Loaded EL 100 Nanoparticles Containing  
Pluronic F68 2% as Stabilizer 
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Figure 26 c   Comparison of Invitro Release Profile of Rosuvastatin Calcium Loaded 
EL 100 Nanoparticles Containing PVA 1% as Stabilizer 
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Figure 26 d Comparison of Invitro Release Profile of Rosuvastatin Calcium Loaded EL 100 Nanoparticles Containing        
PVA 2% as Stabilizer 
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Figure 26 e   Comparison of Invitro Release Profile of Rosuvastatin Calcium Loaded 
ES 100 Nanoparticles Containing Pluronic F68 1% as Stabilizer 
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Figure 26 f Comparison of Invitro Release Profile of Rosuvastatin Calcium Loaded ES 100 Nanoparticles Containing           
Pluronic F68 2% as Stabilizer 
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Figure 26 g   Comparison of Invitro Release Profile of Rosuvastatin Calcium Loaded 
ES 100 Nanoparticles Containing PVA 1% as Stabilizer 
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Figure 26 h Comparison of Invitro Release Profile of Rosuvastatin Calcium Loaded ES 100 Nanoparticles Containing          
PVA 2% as Stabilizer 
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Figure 27 a  Comparison of Invitro Zero Order Release Kinetics of Eudragit L100 at 
 Different Ratios Containing Pluronic F68 (1%) as Stabilizer 
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Figure 27 b  Comparison of Invitro Zero Order Release Kinetics of Eudragit L100 at 
 Different Ratios Containing Pluronic F68 (2%) as Stabilizer 
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Figure 27 c  Comparison of Invitro Zero Order Release Kinetics of Eudragit L100 at 
 Different Ratios Containing PVA (1%) as Stabilizer 
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Figure 27 d  Comparison of Invitro Zero Order Release Kinetics of Eudragit L100 at 
 Different Ratios Containing PVA (2%) as Stabilizer 
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Figure 27 e  Comparison of Invitro Zero Order Release Kinetics of Eudragit S100 at 
 Different Ratios Containing Pluronic F68 (1%) as Stabilizer 
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Figure 27 f  Comparison of Invitro Zero Order Release Kinetics of Eudragit S100 at 
 Different Ratios Containing Pluronic F68 (2%) as Stabilizer 
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Figure 27 g Comparison of Invitro Zero Order Release Kinetics of Eudragit S100 at 
 Different Ratios Containing PVA (1%) as Stabilizer 
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Figure 27 h  Comparison of Invitro Zero Order Release Kinetics of Eudragit S100 at 
 Different Ratios Containing PVA (2%) as Stabilizer 
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Figure 28 a  Comparison of Invitro First Order Release Kinetics of Eudragit L100 at 
 Different Ratios Containing Pluronic F68 (1%) as Stabilizer 
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Figure 28 b  Comparison of Invitro First Order Release Kinetics of Eudragit L100 at 
 Different Ratios Containing Pluronic F68 (2%) as Stabilizer 
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Figure 28 c  Comparison of Invitro First Order Release Kinetics of Eudragit L100 at 
 Different Ratios Containing PVA (1%) as Stabilizer  
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Figure 28 d  Comparison of Invitro First Order Release Kinetics of Eudragit L100 at 
 Different Ratios Containing PVA (2%)  as Stabilizer 
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Figure 28 e  Comparison of Invitro First Order Release Kinetics of Eudragit S100 at 
 Different Ratios Containing Pluronic F68 (1%) as Stabilizer 
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Figure 28 f  Comparison of Invitro First Order Release Kinetics of Eudragit S100 at 
 Different Ratios Containing Pluronic F68 (2%) as Stabilizer 
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Figure 28 g  Comparison of Invitro First Order Release Kinetics of Eudragit S100 at 
 Different Ratios Containing PVA (1%) as Stabilizer 
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Figure 28 h Comparison of Invitro First Order Release Kinetics of Eudragit S100 at 
 Different Ratios Containing PVA (2%) as Stabilizer 
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Figure 29 a  Comparison of Invitro Higuchi Model Release Kinetics of Eudragit L100 at 
 Different Ratios Containing Pluronic F68 (1%) as Stabilizer 
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Figure 29 b  Comparison of Invitro Higuchi Model Release Kinetics of Eudragit L100 at 
 Different Ratios Containing Pluronic F68 (2%) as Stabilizer 
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Figure 29 c  Comparison of Invitro Higuchi Model Release Kinetics of Eudragit L100 at 
 Different Ratios Containing PVA (1%) as Stabilizer 
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Figure 29 d  Comparison of Invitro Higuchi Model Release Kinetics of Eudragit L100 at 
 Different Ratios Containing PVA (2%) as Stabilizer 
235 
 
SQUARE ROOT OF TIME
C
U
M
U
L
A
T
I
V
E
 %
 D
R
U
G
 R
E
L
E
A
S
E
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0
0
10
20
30
40
50
60
70
80
90
100
F21- ES 100(1:10) F23-ES 100(1:30) F24-ES 100(1:40) F25-ES 100(1:50)F22-ES 100(1:20)
 
Figure 29 e  Comparison of Invitro Higuchi Model Release Kinetics of Eudragit S100 at 
 Different Ratios Containing Pluronic F68 (1%) as Stabilizer 
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Figure 29 f  Comparison of Invitro Higuchi Model Release Kinetics of Eudragit S100 at 
 Different Ratios Containing Pluronic F68 (2%) as Stabilizer 
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Figure 29 g  Comparison of Invitro Higuchi Model Release Kinetics of Eudragit S100 at 
 Different Ratios Containing PVA (1%)  as Stabilizer 
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Figure 29 h  Comparison of Invitro Higuchi Model Release Kinetics of Eudragit S100 at 
 Different Ratios Containing PVA (2%) as Stabilizer 
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Figure 30 a  Comparison of Invitro Korsmeyer-Peppas Model Release Kinetics of 
 Eudragit L 100 at Different Ratios  Containing Pluronic F68 (1%) as 
 Stabilizer 
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Figure 30 b Comparison of Invitro Korsmeyer-Peppas Model Release Kinetics of 
 Eudragit L100 at Different Ratios  Containing Pluronic F68 (2%) as 
 Stabilizer 
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Figure 30 c  Comparison of Invitro Korsmeyer-Peppas Model Release Kinetics of 
 Eudragit L100 at Different Ratios  Containing   PVA (1%) as Stabilizer 
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Figure 30 d  Comparison of Invitro Korsmeyer-Peppas Model Release Kinetics of 
 Eudragit L100 at Different Ratios  Containing PVA (2%) as Stabilizer 
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Figure 30 e  Comparison of Invitro Korsmeyer-Peppas Model Release Kinetics of 
 Eudragit S100 at Different Ratios Containing Pluronic F68 (1%) as 
 Stabilizer 
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Figure 30 f  Comparison of Invitro Korsmeyer-Peppas Model Release Kinetics of 
 Eudragit S100 at Different Ratios Containing Pluronic F68 (2%) as 
 Stabilizer 
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Figure 30 g  Comparison of Invitro Korsmeyer-Peppas Model Release Kinetics of 
 Eudragit S100 at Different Ratios Containing PVA (1%) as Stabilizer 
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Figure 30 h  Comparison of Invitro Korsmeyer-Peppas Model Release Kinetics of 
 Eudragit S100 at Different Ratios  Containing PVA (2%) as Stabilizer 
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Figure 31 a  Comparison of Invitro Hixon-Crowell Model Release Kinetics of                 
 Eudragit L100 at Different Ratios Containing Pluronic F68 (1%) as 
 Stabilizer 
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Figure 31 b  Comparison of Invitro Hixon-Crowell Model Release Kinetics of         
 Eudragit L100 at Different Ratios  Containing Pluronic F68 (2%) as 
 Stabilizer 
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Figure 31 c Comparison of Invitro Hixon-Crowell Model Release Kinetics of             
 Eudragit L100 at Different Ratios Containing PVA (1%) as Stabilizer 
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Figure 31 d  Comparison of Invitro Hixon-Crowell Model Release Kinetics of  
 Eudragit L100 at Different Ratios Containing PVA (2%) as Stabilizer 
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Figure 31 e  Comparison of Invitro Hixon-Crowell Model Release Kinetics of             
 Eudragit S100 at Different Ratios Containing Pluronic F68 (1%) as 
 Stabilizer 
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Figure 31 f  Comparison of Invitro Hixon-Crowell Model Release kinetics of                    
 Eudragit S100 at Different Ratios Containing Pluronic F68 (2%) as 
 Stabilizer 
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Figure 31 g  Comparison of Invitro Hixon-Crowell Model Release Kinetics of           
 Eudragit S100 at Different Ratios Containing PVA (1%) as Stabilizer 
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Figure 31 h  Comparison of Invitro Hixon-Crowell Model Release Kinetics of           
 Eudragit S100 at Different Ratios  Containing PVA (2%) as Stabilizer 
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Figure 32   Comparison of Solubility of Best Formulations (F5, F25) with Pure Drug        
        Solution 
 
 
 
 
 
 
 
246 
 
 
0.0 0.5 1.0 1.5 2.0
0.0
0.2
0.4
0.6
0.8
1.0
1.2
PURE DRUG F5(EL 100 1:50,PLURONIC F68 1%) F25(ES 100 1:50,PLURONIC F68 1%)
Time in hours
C
u
m
u
la
ti
v
e
 a
m
o
u
n
t 
o
f
 d
r
u
g
 p
e
r
m
e
a
te
d
(m
g
)
 
 
Figure 33 a Comparison of Cumulative Amount of Drug Permeated across Duodenum  
          Segment. 
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Figure 33 b Comparison of Cumulative Amount of Drug Permeated across Jejunum  
         Segment 
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Figure 33 c Comparison of Cumulative Amount of Drug Permeated Across ileum Segment 
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Figure 33 d Comparison of Cumulative Amount of Drug Permeated Through Small            
          Intestinal Segments (At 2 Hour) 
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Figure 34 Transmission Electron Microscopy (TEM) Image of Best Formulation F5 
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CHAPTER-XI 
SUMMARY AND CONCLUSION 
 
• The λmax of rosuvastatin calcium was found to be 241nm performed using phosphate 
buffer pH 6.8. 
• The rosuvastatin calcium obeys the Beer’s law within the concentration range of                
2 to 20 µg/ml. 
• FT-IR and DSC investigations confirmed that there was no interaction between drug 
and polymers. 
• The rosuvastatin calcium loaded polymeric nanoparticles were successfully prepared 
by nanoprecipitation technique using Eudragit L100 and Eudragit S100 as polymers 
in the presence of stabilizers (Pluronic F68 and PVA).  
• Malvern zeta sizer used to explore the particle size of rosuvastatin calcium loaded 
polymeric nanoparticle showed a suitable particle size in the range of 100-250 nm.  
• The polydispersity index of nanoparticle formulation F1-F40 was less than 0.5, which 
indicated a relative homogenous dispersion. 
• Malvern zeta sizer used to explore the zeta potential of rosuvastatin calcium loaded 
polymeric nanoparticle showed a negative surface charge due to the presence of 
terminal carboxylic groups in the polymers. 
• The entrapment efficiency increased with increasing the concentration of polymers 
and decreased with increasing concentration of stabilizers. 
• The presence of stabilizers made the nanoparticle formulations more stable with high 
entrapment efficiency. 
252 
 
• The invitro release studies displayed a similar biphasic drug release pattern with a 
burst release within 2 hours followed by sustained release at 12 hours. 
• Invitro release kinetics showed sustained release and Fickian diffusion mechanism 
which describes that the drug release was purely diffusion controlled. 
• The solubility of rosuvastatin calcium loaded polymeric nanoparticles increased two 
fold when compared to pure drug solution. 
• The results of ex vivo intestinal permeability studies showed an increase in the 
permeation of rosuvastatin calcium loaded polymeric nanoparticles across small 
intestinal segments when compared to pure drug solution. 
• TEM studies confirmed the morphology of the nanoparticle formulation. 
• The stability studies confirmed that the developed rosuvastatin calcium polymeric 
nanoparticles are physically and chemically stable and retain their pharmaceutical 
properties at various temperature and humidity conditions over a period of 3 months. 
 
Hence, it was concluded that the nanoprecipitation was a useful method for the successful 
incorporation of rosuvastatin calcium with high entrapment efficiency. The solubility and ex 
vivo intestinal permeability studies suggested that the nanoparticle formulations can improve 
the bioavailability of the rosuvastatin calcium by improving its solubility and permeability 
across intestinal membrane. Furthermore, it could be presumed that if the nanometer range 
particles were obtained, the bioavailability might be increased. Hence, we can conclude that 
polymeric nanoparticles enhance the bioavailability of poorly water soluble and low 
lipophilic drug like rosuvastatin calcium as a drug delivery system. 
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